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Introduction
1.1 Generation of metabolic fuel
All living cells require energy to fulfil their basic biological processes necessary for 
life. This energy is (mainly) generated by the oxidation of metabolic substrates and is 
represented by the universal energy molecule, ATP. Hydrolytic cleavage of this ATP yields 
the energy for cell division, cell motility, transport of cellular constituents, and active 
transport of ions and various other cellular processes. Substrates to drive the production of 
ATP are obtained via the intake and digestion of food, distributed through the blood stream, 
and delivered to cells by specialized transport across the cellular membrane. Oxidative 
phosphorylation (OXPHOS) together with glycolysis and fatty acid oxidation are the principal 
pathways for the production of ATP. The net conversion of glucose into pyruvate through 
glycolysis, followed by the conversion of pyruvate and fatty acids into acetyl-CoA and acyl- 
CoA form the prelude to the tricarboxic acid (TCA) cycle, P-oxidation reactions, and 
OXPHOS in mitochondria (1). The TCA cycle and P-oxidation pathways produce the 
reducing equivalents NADH and FADH2 that ultimately fuel OXPHOS via the activity of 
enzymes in the complexes of the electron transport chain (Fig. 1). In this process the free 
energy in NADH and FADH2 is used to create a proton electrochemical gradient across the 
mitochondrial inner membrane. When protons move down this gradient into the matrix of the 
mitochondrion this energizes the F0F1-ATPase and ATP is formed. In parallel, water is 
produced following the reduction of molecular oxygen in the cytochrome oxidase reaction 
sequence (complex IV) of the respiratory chain. It is of note here that maintenance of the 
appropriate redox concentrations of the reducing equivalents NADH and FADH2 inside and 
outside the mitochondria is of crucial importance for efficiency in the process. These 
concentrations are regulated by numerous enzymatic steps and by exchange of electrons from 
these compounds across the mitochondrial membrane via the glycerol phosphate and malate­
aspartate shuttles (2, 3).
Under conditions of extreme workload, the supply of oxygen for OXPHOS may 
become rate limiting and a metabolic insult may result. Under such condition, the glycolytic 
machinery has the ability to supply ATP (in a process called substrate-level phosphorylation). 
This situation is characterized by the accumulation of H+ and lactate. Conley et al. have 
suggested that accumulation of H+, and subsequent decrease in intracellular pH, disturbs the 
metabolic steady-state and hence OXPHOS (4). A reduced rate of oxidation of glycolytic 
products by mitochondria activates lactate dehydrogenase (LDH), which regenerates NAD+ 
and lactate to prevent accumulation of glycolytically produced NADH and pyruvate (Fig. 1). 
However, production of lactate has been found also under well-oxygenated conditions, which 
demonstrates that glycolysis can provide a high and sustained supply of ATP irrespective of 
the oxidative status of mitochondria (5, 6). In fact, lactate seems to be an intermediate 
between glucose and complete oxidation into mitochondria: the LDH isoform within a locale 
of high ATPase activity (e.g. a myofibril) converts pyruvate to lactate
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Glucose Lactate Fatty acids
Figure 1. Schem atic representation o f general aspects o f ce llu la r energy metabolism. Glucose is 
transported into the cytosol via specific glucose transporters at the membrane and utilized by 
glycolysis to produce ATP and metabolic substrates for the tricarboxic acid (TCA) cycle and oxidative 
phosphorylation. The end product of glycolysis, pyruvate, is converted into lactate if not transported 
into the mitochondrial matrix (see text). The TCA cycle, together with the p-oxidation of fatty acids in 
the mitochondrial matrix, produce the NADH and FADH2 required for the reduction by O2 in the 
production of ATP via the reaction chain of oxidative phosphorylation reactions. ATP and ADP are 
transported in or out the mitochondrial matrix via specific adenosine nucleotide translocators, present 
at the mitochondrial inner membrane. Inorganic phosphate (Pi) is transported into the mitochondrial 
matrix by specific inorganic phosphate carriers.
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and this can be partly oxidized to pyruvate by an LDH-isoform in close vicinity of the 
mitochondrial membrane (7).
ADP and Pi, the products resulting from hydrolytic cleavage of ATP, are required as 
substrates for the formation of ATP in mitochondria and glycolysis (Fig. 1). The molecular 
mechanism of the delivery of ADP from the cytosol to the matrix of mitochondria is poorly 
understood but is likely under the control of high-energy phosphate transfer circuits. One of 
these circuits is formed by the members of the family of creatine kinases (CKs; see paragraph 
1.4.1.), which have been considered key players in the regulation and equilibration of adenine 
nucleotides between different cellular locales (8, 9). Along with CK adenylate kinase (AK) 
equilibrates and distributes high-energy phosphates among adenine nucleotides in order to 
attain adenine nucleotide homeostasis (8, 10, 11). Recent studies on AKs have suggested that 
AKs, in parallel with CKs, are active integral components of a high-energy transfer network 
that warrants effective handling and distribution of high-energy phosphates (12-15).
1.2 The AK isoenzyme family
AKs (EC 2.7.4.3) belong to the family of nucleoside monophosphate kinases (NMKs) 
that catalyze the reversible exchange of P- and y-phosphoryls among adenine nucleotides, via 
the reaction: 2ADP o  ATP + AMP (11, 16, 17). In this way, AKs equilibrate and regulate the 
pool of intracellular adenine nucleotides and contribute to homeostasis of adenine nucleotide 
metabolism (10). At present, 5 different AK isoenzymes have been identified in mammalian 
cells (18-20). These AK-isoforms are encoded by separate genes and each have their own 
distinct tissue distribution and subcellular localization.
AK1 is found highly expressed in the cytosol of cells in tissues with high and sudden 
energy demand, including brain, heart, and skeletal muscle but substantial expression is also 
found in erythrocytes and sperm flagella (18, 21, 22). Alternatively, AK1 can be found 
associated with membranes, if it bears an additional N-terminal peptide that may be 
myristoylated (AK1P). This form of AK1 has been implicated in p53-dependent cell-cycle 
arrest (23). Since AK activity is found associated with membranes, such as the pulmonary 
membranes (24, 25), sarcolemma membranes (26), synaptic membranes (27, 28), and disk 
membranes of the rod outer segment of retina (29), it is very likely that the membrane- 
associated AK activity is represented by this alternative AK1p-transcript (30).
AK1 uses ATP as the preferential high-energy phosphate donor (11, 17). Yet, 
phosphorylation of AMP to ADP is also achieved by donation of the high-energy phosphate 
from GTP (31). In addition, AK1 has been shown to efficiently synthesize thiamine 
triphosphates (ThTP) in vitro, according to the reaction: ThDP + ADP o  ThTP + AMP (32), 
a reaction normally catalysed by ThDP kinase. Makarchikov et a l. demonstrated, however, 
that skeletal muscle, heart and brain form mice completely lacking AK1 activity (33) are 
characterized by normal ThTP levels, indicating that AK1 is not responsible for the bulk of 
ThTP synthesis in these tissues in vivo (34).
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Many members of the AK-isoform family are found compartmentalized in the 
mitochondrion. The AK2-isoform is present in the innermembrane space of mitochondria in 
cells of liver, kidney, spleen and heart, and catalyses the same reaction as its cytosolic AK1 
family member (18). In liver of rats AK2 is found distributed both in the cytosol and inner­
membrane space of mitochondria (35). Alternative splicing of the AK2 gene results in a short 
AK2A and long AK2B transcript, giving rise to two different AK2 proteins that differ in their 
C-terminal end (36). Additionally, posttranslational modifications of adenylate kinase 2 result 
in two subtypes of each of the AK2A and AK2B isoforms that differ at their N-terminus and 
in specific activities (37). AK2 entry in mitochondria of yeast occurs via a rather unique 
pathway: the N-terminal segment together with an sequence in the interior of the protein form 
the signal for import into the mitochondrion (38). The mechanism by which mammalian AK2 
translocates to the mitochondrion is not known but at least requires an inner membrane 
electrochemical potential for its import (35). Perhaps that mammalian AK2 also contains an 
intrinsic signal peptide that together with the N-terminal segment forms the signal for 
mitochondrial import. This possibility is put forward since yeast and mammalian AK2 show 
52% amino acid similarity (11). The other mitochondrial AK isoenzyme, AK3 (correctly 
called GTP:AMP phosphotransferase), is expressed in a broad range of tissues. AK3 resides in 
the matrix of mitochondria and uses GTP as the principal high-energy phosphate donor (18). 
Recently, another putative matrix AK has been identified, named AK4, which is tissue- 
specifically expressed in kidney, liver, heart, and brain (19). However, its role as an adenylate 
kinase needs to be further investigated because neither ATP:AMP or GTP:AMP 
phosphotransferase activities have been detected for this protein (19, 39). Expression of a fifth 
cytosolic AK isoenzyme (AK5) has been reported for human brain and, when expressed in 
Escherichia coli, AK5 phosphorylates AMP with ATP and GTP as the high-energy phosphate 
donor. Although its subcellular localization is thought to be cytosolic it is currently unknown 
which of the cells in brain tissue express this enzyme (20).
1.3 The cell physiological role of adenylate kinase
In the last decade AKs have been studied extensively for their protein structure and 
substrate binding sites (40, 41), transition state (17), conformational forms (42-44), domain 
movement during catalysis (45, 46), and post-translational modifications (37). The classical 
view for its biological significance is based on three different modes of action. Firstly, AK is 
important for the biosynthesis of ADP from AMP, which is required for the adenylate 
nucleotide biosynthesis (47; Fig. 2). Secondly, the enzyme can equilibrate the nucleotide pool 
of ATP, ADP and AMP, and in that manner the cellular homeostasis of adenylate pools is 
ensured (10). Thirdly, AK can salvage molecules of ATP from accumulating ADP, during 
times when energy-consuming processes exceed the rate of energy providing metabolic 
processes (48 and references therein).
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AK in yeast is essential for growth, suggesting that it is an essential enzyme for life in 
this primitive eukaryote cell (49, 50). However, the physiological role of AK in a 
heterogeneous cell population with a higher metabolic complexity, such as skeletal muscle 
and brain, is less clear. In 1954, Bendall proposed that muscle type AK1 (also called 
myokinase) might act as a relaxing factor in muscle functioning (51). Indeed, Bessman and 
co-workers reported that inhibition of the AK catalysed phosphotransfer in glycerinated 
muscle fibers by the AK inhibitor, AP5A, results in a slight reduction in the rate of muscle 
contraction at physiological concentrations of ATP and increased muscle relaxation in the 
presence of AK1 catalysis. Under such condition, the skeletal muscle is also able to maintain a 
higher muscle tension (52). By that time, an AK energy shuttle model was put forward in 
parallel with the proposed function(s) for the CK/CrP system (8, 53). In this model, two AKs 
and one CK in one compartment are proposed to form a tetrahedral arrangement around 
energy producing sites (OXPHOS or glycolysis) in order to produce a common pool of ADP 
and entry-sites for ATP, Cr, and AMP. In another cellular compartment a tetrahedral structure 
of two AKs and one CK is thought to arrange around the energy-utilizing sites (e.g. myosin 
ATPase) (8, 53). Evidence for the hypothetical tetrahedral arrangement, however, is up to now 
not experimentally validated and, therefore, not fully accepted. Work of Goldberg and 
collaborators demonstrated for the first time the importance of cellular AK catalysis in 
skeletal muscle (12, 13, 54, 55). By transferring and communicating high-energy phosphoryls 
between cellular sites of energy production and energy consumption AK1 exerts its function 
as an integral component of the cellular energy network (14). Indeed, the AK-catalyzed 
phosphotransfer activity increases with metabolic demand, is functionally coupled to 
glycolysis and OXPHOS, and has the ability to substitute for the CK-catalyzed phosphoryl 
transfer (54, 55). It has been suggested that AKs, together with CKs, form an intertwined 
linear array between a cellular site of ATP generation and ATP consumption. In such an array, 
it is not the adenylate molecular moiety as a whole but rather only the high-energy phosphate 
groups that are transferred by coupled AK and CK reactions, in a wave-like manner. This 
model was put forward as the vectorial ligand conduction mechanism (12-14) and is supported 
by immunohistochemical studies showing that both CK and AK are physically arranged as 
linear arrays in the microenvironment of skeletal muscle actomyosin ATPases (56). 
Alternatively, functional compartments of AK and its substrates may exist, resulting in 
extremely rapid diffusion-based or concentration gradient driven reactions (12), ultimately 
coupling sites of energy production to sites of energy consumption.
When AK operates in the direction of ATP synthesis it provides the energy of both the 
Y- and P-phosphoryl in each molecule of ATP for utilization. This exclusive property of AK 
catalysis doubles the energetic potential of the ATP molecule (14). The significance of this 
function of AK is underscored by metabolic labelling studies in skeletal muscle that are 
genetically deprived of AK1 activity. Although deletion of AK1 activity in skeletal muscle 
does not result in contractile abnormalities the energetic costs of contraction are elevated (33).
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Figure 2. Purine nucleotide synthesis and degradation pathways. 1, 5-phosphoribosyl-1- 
pyrophosphate (PRPP) aminotransferase; 2, AMP deaminase; 3, adenylosuccinate synthetase; 4, 
adenylosuccinate lyase; 5, adenylate kinase; 6, adenosine kinase; 7 and 8, 5'-nucleotidase; 9, 
nucleosidase; 10, purine nucleoside phosphorylase; 11, adenine 5-phosphoribosyl 1-pyrophosphate 
transferase; 12, hypoxanthine/guanine 5-phosphoribosyl 1-pyrophosphate transferase; 13, adenosine 
deaminase; 14, adenine deaminase; 15, xanthine oxidase; 16, S-adenosylhomocysteine hydrolase. 
Figure adapted from (47).
Increased fluxes through other ATP generating pathways (i.e. glycolysis and the CK/CrP 
system) are necessary to overcome the lack of AK1 during muscle contraction. Interestingly, 
intense isometric contractions in these mutant muscles revealed a reduced capacity in muscle 
relaxation, which is associated with an elevated ADP level and a decrease in the levels of 
intracellular CrP and IMP (R. Terjung, personal communications). These observations suggest 
an important role for AK1 in buffering ADP, which in part can be compensated by the CK- 
catalyzed phosphotransfer, in line with previous findings (33) and emphasize the role of the 
AKl-catalyzed phosphoryl transfer in the management of cellular energy metabolism.
Interestingly, in humans few families have been reported that show homozygous 
deficiency of AK1, caused by mutations in the AK1 gene (21, 57, 58). Abnormalities in 
muscle energetics have not been reported for these patients. Instead, the reduction in or 
absence of AK1 activity in erythrocytes has been associated with hemolytic anemia and in 
some cases associated with psychomotor impairment (57, 58). The underlying mechanism by 
which AK1 deficiency may result in the hemolytic phenotype is currently, however, unknown.
The biological function of AK-catalysis in the mitochondrial compartment is only 
poorly defined. In fact, in the mitochondrial compartment AK2 is generally considered as a 
marker of the aqueous phase of the innermembrane space (59). Although the precise role of 
AK2 in the mitochondrial innermembrane space is not completely clear mitochondrial AK2 is
16
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thought to be functionally linked to mitochondrial metabolism (60), providing OXPHOS with 
preferential ADP (61). AK3, the other mitochondrial AK present in the matrix, is assumed to 
play a role as a scavenger of mitochondrial AMP at the interconversion of non-ATP 
nucleotide triphosphates and GTP hydrolysis, which are formed in the TCA cycle by substrate 
chain phosphorylation through succinate thiokinase (18, 62; Fig. 1). Interestingly, AK3 
mRNA has been found among hypoxically inducible mRNAs in HeLa cells, suggesting also a 
link between AK3 catalysis and anaerobic metabolism (63). At present, information about the 
role and function of AK4 and AK5 is completely lacking (19, 20).
From studies in several tissues or cells, it has become apparent that the role of AK is 
more than just a housekeeping role. The AK-circuit has been shown to provide energy for 
nuclear import, which in turn is required for exchange of information between the nucleus and 
cytosol (15). The compartmentalized AK-catalysis has also been demonstrated in the 
regulation of membrane-bound adenylate cyclase of the lung (25) and ATP sensitive 
potassium channels in cardiomyocytes (26, 64), HIT T15-cells (65) and Xenopus oocytes 
(66). Based on these findings it can be concluded that AK is also integral to the process of 
transduction of metabolic signals into cellular responses.
Under normal conditions, AK maintains ATP, ADP, and AMP concentrations close to 
equilibrium (10). During metabolic stress, such as muscle stimulation and hypoxia, AK 
regenerates ATP from ADP and causes the intracellular AMP concentration to rise. Because 
the cellular concentrations of AMP change relatively much more dramatically than ADP or 
ATP, AK-generated AMP is a useful signal molecule to monitor the cellular energy status (10, 
67, 68). As a result of an increase in the intracellular AMP concentration the enzyme AMP 
deaminase becomes activated.
1.3.1 AM P deaminase
AMP deaminase (AMPD; EC 3.5.4.6) is a tretrameric enzyme composed of identical 
80 kD subunits that catalyzes the irreversible deamination of AMP to IMP and ammonia, and 
is located at a branchpoint in the adenylate catabolic pathway (Fig. 2). Several isoforms have 
been reported for rat and human, and are termed skeletal muscle, isoform A (rat) or M 
(human); liver and kidney, isoform B (rat) or L (human); heart and erythrocytes, isoform C 
(rat) or E (human). Expression of the A/M isoform is restricted to adult skeletal muscle, 
whereas isoforms B/L and C/E are ubiquitously expressed (69).
In skeletal muscle, AMPD is activated during exercise when the rate of ATP 
consumption exceeds the rate of ATP production. To prevent high fluctuations in the 
ATP/ADP ratio CKs effectively buffer temporal and spatial changes in ATP concentrations 
(see paragraph 1.4.1), thereby assisted by the help of AK that prevents accumulation of ADP 
through regeneration of ATP and AMP. To avoid a large accumulation of AMP within the 
cell, AMP is deaminated to IMP and ammonia. In fact, consumption of AMP by AMPD 
drives the flux through the AK-catalyzed phosphotransfer reaction and thus indirectly helps to 
maintain proper ATP/ADP ratios under conditions of increased workload.
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The AMPD reaction is controlled by AMP concentration and allosterically activated 
by increases in ADP, and H+ and decreases in Pi (70, 71). Janssen et al. have found that 
deletion of AK1 activity in the fast-twitch gastrocnemius muscle results in reduction of AMP 
deaminase activity, suggesting that with the absence of AK1 the requirement for AMPD 
activity is limited (33). Similarly, in fast-twitch muscles of CK mutant mice the AMPD 
activity appears to be decreased (72) and rats in which creatine is depleted by chronic P- 
guanidinopropionic acid (P-GPA) feeding display similar features (73). The molecular 
mechanism that links functional changes in the CK and AK system to altered AMP deaminase 
activity is currently unknown but in CK mutant mice, the involvement of AMP deaminase 
gene regulation can be excluded (72).
1.3.2 AM P-activatedprotein kinase
When the intracellular AMP concentration reaches a certain threshold level that 
exceeds the buffering capacity of AMP deaminase the rise in intracellular AMP 
concentrations conducts a metabolic signal that allosterically affects AMP sensitive enzyme 
systems or circuits. For example glycogen phosphorylase in glycogenolysis, 
phosphofructokinase in glycolysis, and fructose 1,6-biphosphatase in gluconeogenesis are 
allosterically modified by AMP (1). Two other enzymes that become activated by increased 
intracellular AMP levels are AMP-activated protein kinase (AMPK) (74) and the upstream 
kinase AMP-activated protein kinase kinase (AMPKK) (75, 76). In fact, binding of AMP to 
AMPK increases the affinity for phosphorylation by AMPKK by 50-100-fold and antagonizes 
the activity of protein phosphatases (76, 77). Because ATP is able to counteract the AMP- 
induced properties of AMPK, the ATP/AMP ratio can be considered the determinant by 
which AMPK is metabolically regulated (74). In skeletal muscle, also creatine phosphate 
(CrP; see paragraph 1.4.1) can allosterically inhibit AMPK (78). Upon metabolic stress in 
these cells the cellular ATP/AMP and CrP/Cr ratios decrease and activate AMPK, which 
phosphorylates several enzymes in metabolic pathways (including M-CK), eventually 
preventing further ATP utilization as the phosphorylated target proteins become inactive (74, 
79). However, AMPK not only inhibits target proteins in catabolic pathways that limits further 
ATP utilization but also initiates cascades that maintain cellular ATP levels. For example, 
AMPK activation results in reduced lipid and glucose synthesis and accelerates fatty acid 
oxidation and enhances glucose uptake and, hence, glycolytic activity (80). In fact, the 
glycolytic enzyme phosphofructokinase (PFK) appears to be phosphorylated and activated by 
AMPK under ischemic conditions in the heart (81) and under hypoxic conditions in activated 
monocytes (82). Thus, AMPK can be considered a metabolic master switch, designed to 
monitor the intracellular energy charge and to initiate immediate responses that prevent high- 
energy phosphate depletion (68, 78). In addition, AMPK has also been implicated in the 
induction of long-term effects via regulation of gene expression by direct phosphorylation of 
nuclear proteins (83).
18
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AMPK is heterotrimerically formed by the binding between a , P, and y subunits (68). 
Interestingly, Mitchelhill et al. demonstrated that the P1 subunit is N-terminally myristoylated 
(84), resulting in the distinct subcellular localization of AMPK to membranes (85). Although 
it is currently unknown whether the N-terminally myristoylated AK1P isoform may provide 
the membrane localized AMPK with preferential AMP, AMPK is generally inextricably 
bound up with AK. In the activation of AMPK via AK-mediated AMP one assumes that the 
AK reaction is solely driven by available substrate concentrations (68, 78). Yet, AK can be 
inhibited by Ap5A (86), which has been shown to increase in hearts following ischemia (87). 
Regulation of AK catalysis by these so-called alarmones (88) may hereby indirectly influence 
the activation of AMPK. Whether this involves a gradual decrease, or requires complete 
inhibition of local AK activity to influence or affect the physiological regulation of AMPK is, 
at present, not known. Finally, it is interesting to mention that the a2 version of AMPK is 
found in the nucleus, and that AMPKs containing the y3 subunit were found in nucleoli (83). 
It is currently unknown whether this also could imply a nuclear role for AK or AK1p.
1.3.3 Regulation o f  ATP sensitive K  channels
The AK-catalysed phosphotransfer has been assigned a metabolic status signaling role, 
via its coupling with ATP sensitive K+channels (KATp channels) in the cellular membrane (64, 
89). Katp channels are widely expressed in a variety of tissue and cells where they couple the 
membrane electrical activity to the cellular metabolic status (90, 91). Their physiological role 
is best understood for pancreatic P-cells. In these types of cells opening of the channel sets the 
resting potential and upon closure, other channels are activated that depolarise the plasma 
membrane leading to hormone secretion (90, 92). In the myocardium and skeletal muscle 
KATP channels can be opened by hypoxic or ischemic conditions, leading to shortening of 
action potentials. Under such conditions, opening of KATP channels slows the influx of Ca2+, 
thereby decreasing the contractile force that leads to reduced ATP consumption (92). Also for 
neurons, opening of KATP channels results in shortening of action potentials and thus protects 
the cell from metabolic insult (93).
The KATP channels are heteromultimers formed by association of an inwardly 
rectifying K+ channel, Kir6, and a subunit that binds sulfonylureas and ATP that belongs to 
the ATP-binding cassette (ABC) superfamily, known as the sulfonyl urea receptor (SUR) (92­
94). The open probability of KATP channels directly depends on intracellular ATP/ADP levels. 
In fact, transition of the SUR subunit from the ATP to the ADP-liganded state promotes K+ 
permeation through Kir6 (95, 96). Because overall intracellular levels of ATP exceed the 
concentrations to inhibit the KATP channel (97), it is thought that local fluctuations in 
metabolite levels provide the signal for opening. The molecular mechanism by which channel 
activity is regulated is, however, far from completely understood. Based on currently available 
evidence a model has been proposed in which phosphotransfer reaction events determine local 
ATP/ADP ratios, in the KATP channel vicinity (30, 64, 89). Recent findings have shown that
19
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KATP channel regulation can also occur by creatine kinase, perhaps via similar mechanisms 
(98, 99), and the glycolytic muscle lactate dehydrogenase isoform, M-LDH (100).
1.4 The metabolic network for high-energy phosphoryl transfer
Cells with a high and fluctuating energy demand, such as skeletal muscle cells and 
neuronal cells, require the ability to maintain a balance between the rates of ATP utilization 
and regeneration during increased function, e.g. intense contractile activity. The observation 
that ATP concentrations are usually very constant during increased cellular activities (for 
example muscle contraction; 101) or even during an ischemic period (see for example 102) 
reflects the success of underlying mechanisms that are responsible for the preservation of 
ATP/ADP/AMP levels. Indeed, sophisticated mechanisms to regulate these ratios have 
evolved and are potential mechanisms for local and compartmentalized ATP regeneration.
1.4.1 The creatine kinase/creatine phosphate system
CKs (EC 2.7.3.2), catalyzing MgADP- + CrP2- + H+ ^  Cr + MgATP2-, belong to a 
family of enzymes that are expressed in tissues with a high peak-demand in metabolic energy, 
like brain, heart and skeletal muscle (8, 9). The enzymes and substrates involved in this 
reaction are together called the creatine kinase/creatine phosphate (CK/CrP) system. Detailed 
studies and reviews on the CK/CrP have appeared in the last 15 years, describing the 
biological and physiological relevance of this system (see for example 8, 103-105 and 
references therein). The function of the CK/CrP system is mainly in temporal and spatial 
energy buffering. During periods of intense cellular activity the rates of ATP hydrolysis 
exceeds the rate of ATP generation in OXPHOS and glycolysis. The pool of CrP then 
provides temporally the high-energy phosphate necessary to regenerate ATP and replenish 
ATPases with the necessary fuel (106). By coupling intracellular sites of energy production 
(i.e. OXPHOS and glycolysis) with intracellular sites of energy utilization the CK/CrP 
provides spatial energy buffering (8, 9; Fig. 3).
In skeletal muscle of all vertebrates, the principal CK isoform is the cytosolic MM- 
CK, a homodimeric protein, which is mainly present as a soluble protein in the cytosol, but 
also binds at the myofibrillar M- and I-bands (56), and to the sarcoplasmic reticulum (107). 
Skeletal muscle also contains an additional, mitochondrial, CK-isoform (ScCKmit), which 
amounts to 1-10% of the total CK activity depending on the fiber-type and the type of 
metabolism (i.e. glycolytic vs. oxidative) (9, 108). This CK-member is in close association 
and functionally interacts with the adenine nucleotide translocator (ANT) and voltage- 
dependent anion channel (VDAC), in the mitochondrial inner and outer membrane (109-111). 
Bessman and Carpenter were the first to propose that the CK and AK circuits are functionally 
intertwined (8). Clear evidence to support this model came from the use of non-invasive 
procedures for monitoring high-energy phosphoryl metabolism via 18O isotopic labeling of 
phosphate (12, 13, 112). Graded inhibition of CK-activity up to 98% resulted in a progressive
20
Introduction
shift in flow of phosphotransferase activity from the CK through the AK system, until the AK 
reaction accounts for nearly the total metabolic flux in skeletal muscle under these conditions 
(55). However, genetically modified muscles lacking both MM-CK and ScCKmit maintain an 
AK-catalyzed phosphotransfer activity that is changed by no more than two-fold, indicating 
that other phosphoryl transfer systems provide compensatory phosphotransfer capability (14). 
Among these, the guanylate kinase- (GK; the AK analog in guanine nucleotide metabolism), 
nucleoside diphosphate kinase-, and glycolytic-catalyzed phosphotransfer systems can rescue 
adequate high-energy phosphate transfer within the cytosolic locale of the cell (Fig. 3).
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Figure 3. Integration o f h igh-energy phosphoryl exchange reactions w ith  m itochondria l energy 
m etabolism . High-energy phosphates are distributed troughout the cytosol via CK-, AK-, NDPK-, GK- 
and glycolytic-mediated phosphotransfer reactions. These reactions form the cellular energetic 
infrastructure that balances fluctuations in high-energy phosphate concentrations at different cellular 
compartments (see text) and metabolically couple cytosolic ATPase compartment's with the 
mitochondrial compartment.
1.4.2 Guanylate kinase
Guanylate kinase (GK, EC 2.7.4.8) closely resembles the structure and enzyme 
reaction of AK (17, 113). By catalysing the reaction GMP + ATP o  GDP + ADP, it is a 
critical enzyme in the biosynthesis of GMP and recovery of the signal molecule cGMP (114,
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115). Although the function of membrane-associated forms of GK homologues have been 
studied in much detail (116), little is known about the differential role of distinct GKs in 
cellular energy metabolism. Yet, the function of GK is critically important in yeast since loss 
of function cannot be rescued by other nucleoside 5’-monophosphate kinases (117). In 
addition, in muscles that lack M-CK and ScCKmit or AK1 a significant compensatory role for 
phosphoryl transfer by GK was revealed, providing supportive evidence for the significance 
of GK in cellular energetics (14, 33).
1.4.3 The N PD K  circuit fo r  high-energy phosphoryl transfer
Nucleoside diphosphate kinases (NM23 or NDPKs; E.C. 2.7.4.6) are 17-20 kDa 
proteins that catalyze the high-energy phosphoryl exchange between nucleoside di- and 
triphosphates (NTP + XDP ^  NDP + XTP), using mainly ATP as the high-energy phosphate 
donor (see for review 118 and references therein). At present, eight NM23/NDPK isoforms 
have been described in humans, expressed by single genes in a variety of tissues and present 
at distinct subcellular locales (119, 120). Among the different NDPK isoforms the NDPK-A 
and -B (nm23-H1 and -H2) isoforms are the best studied, perhaps related to the fact that they 
are the two most abundant and closely related isoforms (119). In order to be enzymatically 
active the NDPK-catalyzed phosphotransfer activity requires its hexameric structure (118). In 
vivo and in vitro studies have demonstrated that nm23-H1 and -H2 subunits can form both 
homohexameric and heterohexameric molecules (118).
Along with AK and CK nm23/NDP kinases have been considered integral components 
of the cellular phosphoryl transfer network (14, 121). Indeed, NDPK mutant bacteria show 
abnormalities in nucleotide metabolism (122) and synthesis of ribo- and deoxyribonucleoside 
phosphates in these NDPK mutants is in part substituted by AK (31). Also, the direct physical 
interaction of NDPK with the glycolytic enzymes GAPDH and pyruvate kinase, and CK has 
been shown, supporting the view that NDPKs are integral components of the metabolic 
energy machinery (123 and references therein). Although most NDPKs have phosphotransfer 
capacity that allows synthesis of triphosphates other than ATP (124), NDPK-A was first 
identified as a tumour metastasis suppressor (125). Also NDPK-B has tumour metastasis 
suppression potential (126) and has been shown to activate transcription via c-myc promoter 
DNA elements (119). In fact, NDPK-A and -B have intrinsic DNA cleavage activities (119, 
127), for which Fan et al. have demonstrated that the intrinsic DNA cleavage activity of 
NDPK-A appears to be a DNAse that becomes activated upon cytotoxic T cell attack (128).
As NDPK determines the ratio of GTP and GDP this protein may also have an 
important role in guanine nucleotide-mediated signal transduction and regulatory pathways. In 
fact, NDPK-H1 (nm23-H1) has been shown to interact with the RAS-related GTPase member 
RAD (129) and the Rac1-specific nucleotide exchange factor, Tiam1, of Rho-related GTPases 
(130). Through reversibly converting the GDP-bound state to a GTP-bound state nm23-H1 
acts as an exchange factor and, in this way, acts as a GTPase activating protein. In this regard, 
the importance of NDPK-H1-mediated GTP supply has been shown in dynamin-dependent
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fission of coated vesicles during endocytosis (131) and demonstrates the multi-functionality of 
these types of enzymes.
1.4.4 Glycolytic ATP generation
Although glycolysis has been extensively described as a pathway that primarily 
provides the catabolic substrates for oxidative metabolism, or as a principal ATP production 
pathway under anaerobic conditions, its role in phosphotransfer within the ATPase 
microenvironment needs further explanation. The presence of glycolytic enzymes in the 
vicinity of ATPases in muscle cells has suggested the existence of functionally defined 
subcellular adenine nucleotide environments that depend on glycolytically-produced ATP (see 
for review 48 and references therein). Indeed, Huser et al. found that the efficiency of 
excitation-contraction (EC) in cardiac myocytes, achieved by Ca2+ release from the 
sarcoplasmatic reticulum (SR), is locally controlled by glycolytic enzymes that are closely 
associated with the Ca2+ release channel (132). Similar findings have been reported for the 
activation of Ca2+- and Na-K-ATPases and KATP channels (133-135). In fact, 
phosphatidylinositol metabolism is supported by glycolytic ATP synthesis as has been 
demonstrated in the muscle traid (136). It is therefore not surprising that also the intrinsic 
ATPase activity of the actomyosin complex highly depends on glycolytically produced ATP 
in fast-twitch muscles (137, 138). However, ATPases that preferentially depend on 
glycolytically produced ATP are not restricted to muscle cells only. In brain, Ikemoto et al. 
have demonstrated the importance of the GAPDH/phosphoglycerate couple in sustaining 
synaptic transmission. ATP generated via this couple is preferentially utilized by vesicular H+- 
pump ATPases, which generate an electrochemical proton across the vesicle membrane and, 
in this way, provides the driving force for glutamate transport into synaptic vesicles (139). 
Also in hippocampal astrocytes calcium load into calcium vesicles strongly depends on ATP 
delivery by glycolysis (140). Thus, localized glycolytic ATP synthesis may occur at sites 
where energy is immediately required, indicating that glycolysis is not only important for the 
production of catabolic substrates required for OXPHOS, but is also critical for the activity of 
particular ATPases. Perhaps this extremely high versatility of the glycolytic system can be 
explained by the fact that this is one of the “evolutionary oldest” metabolic systems, providing 
ample time for the development of highly specialized accessory roles.
Interestingly, Zeleznikar et al. found that the activity of AK highly correlates with 
glycolytic activity in the intact muscle cell (54). Also, functional coupling between 
glycolytically produced ATP and generation of CrP in the CK reaction has been demonstrated 
(9, 141). As coupling between ATP hydrolysis and local ATP regeneration is functionally 
important, especially during high rates of ATP turnover, the concerted action of the AK-, 
CK-, NDPK-, GK-, and glycolytic-catalyzed phosphotransfer reactions may thus be critically 
important in regulating the ATPase microenvironment and ATP/ADP sensitive subcellular 
sites.
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1.5 Bioenergetics of skeletal and cardiac muscle and brain
1.5.1 Skeletal muscle design and energetics
A skeletetal muscle cell is an extremely large, elongated cell that contains many 
nuclei. This multinucleated myotube is formed by the fusion of several mononucleated 
myoblast cells (muscle precursor cells).
Skeletal muscle cells are characterized by the highly organized striated pattern of 
myofibrils, in which contractile proteins are precisely partitioned in series of repeating units, 
the sarcomeres (Fig. 4A). Sarcomeres are the contractile units of muscle and are composed of 
highly regular, structured arrays of thick and thin filaments. Two transverse structures, the M- 
line (the center of the sarcomere) and the Z-line (the edge of the sarcomere), serve as primary 
anchor points for the thick and thin myosin filaments (Fig. 4B). The I-band consists of only 
thin filaments, whereas only thick filaments are present in the H-zone of the A-band. Both 
types of filaments are present in the other parts of the A-band, where there are six thin 
filaments associated with each thick filament in a hexagonal lattice (1). The sarcomeric 
assembly and integrity is controlled by the elastic filament system, which is composed of the 
protein titin (142). Typically, recent studies on the subcellular targeting of metabolic enzymes 
to distinct regions of the sarcomere have revealed that the DRAL/FHL-2 protein, a member of 
the four and an half LIM domain protein subfamily, may be involved in subcellular targeting 
of CK and AK to titin (143).
The sarcomeric myosin molecule is a hexamer consisting of two myosin heavy chains 
(MHCs), two essential or alkali myosin light chains (MLCs), and two regulatory or 
“phosphorylatable” MLCs (137). Each MHC is composed of a head or motor domain, which 
contains ATP- and actin-binding domains (Fig. 4B). The essential and regulatory light chains 
are associated with the neck region of myosin. Subsequent cross-bridging of myosin heads 
and actin filaments following sliding of actin filaments towards the center of the myosin 
filaments results in contraction of the muscle fiber. The activating mechanism, initiated by 
Ca2+, is the troponin-tropomyosin system that is associated with the actin filaments. Although 
the molecular composition and ultrastructural design of sarcomeres are remarkably similar 
among different types of muscle cells, there is a high degree of molecular variability between 
different muscle fibers. Based on both their tinted appearance (red vs. white) and their 
contractile speed (fast vs. slow) they can be divided into functional units of common 
metabolic and biochemical properties. Adult mice skeletal muscle fibers express 4 types of 
MHCs: MHC1, MHC2A, MHC2x/2D and MHC2B (144). The MHC composition or profile 
of muscle fibers is used to identify the fast- or slow-twitch fiber. Fast-fibers correspond to the 
2A, 2X, and 2B fibers, while slow fibers refer to type 1 fibers. Slow-twitch (type 1) myofibers 
contain a high concentration of mitochondria and use oxidative metabolism as the chief 
energy source. Fast-twitch fibers, such as type 2B fibers, generate ATP mainly through 
glycolysis (145, 146). In fact, Hamalainen et al. demonstrated that the mouse gastrocnemius
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Figure 4. Schematic architectural representation of a skeletal muscle cell (A) and muscle myofibril (B). 
Myofibrils (1) are encircled by the SR (2), an elaborate membrane system that connects to tubular 
invaginations in the sarcolemma present at the A-I band junction, the transverse tubules (T-tubules; 5, 
T). The terminal cisternae of the SR (3) together with the T-tubule membrane system are called triads 
(4), two of which are present per sarcomere. 6, sarcolemma; 7, basal lamina; 8, collagen fibrils. 
Adapted from (147) with permission.
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muscle contains 10% MHC type 2D fibers and 90% type 2B fibers, which indicate the high 
glycolytic potential of this fast-twitch muscle (148).
The implementation of the high-energy phosphate transfer network (Fig. 3) in muscle 
cells may have occurred during evolution because of its capacity to regenerate ATP and help 
to maintain ATP levels, even during periods of extremely intense physiological activity that 
can occur in muscle cells. Indeed, along with the cellular machinery for ATP production (i.e. 
glycolysis and OXPHOS) the AK, CK, NDPK, and GK pathways co-exist in muscle cells and 
warrant efficient delivery and distribution of high-energy phosphates, independent of 
oxidative metabolic pathways. The extent to which these different systems contribute to the 
cellular ATP turnover depends on the functional properties of muscle cells involved and the 
frequency by which these muscles are stimulated. For example, fast-contracting fibers have an 
intrinsic contractile speed that is about three times greater than slow-contracting muscle fibers 
(149). Moreover, the maximum power output is much higher in fast than in slow muscle fibers 
(137).
Thorstensson et al. studied the isozyme pattern of CK, AK1, and the glycolytic 
enzyme LDH and have found that the higher myosin ATPase activity observed in fast-twitch 
fibers is also associated with higher enzymatic activities of CK, AK1 and LDH compared with 
slow-twitch fibers (150). This fiber-type specific distribution pattern has been studied in more 
detail for the CK/CrP system and it has been shown that fibers with a high aerobic capacity, 
i.e. the type 1 fibers, have smaller CrP and MM-CK levels than fibers with a large glycolytic 
potential, such as type 2B fibers. Type 1 muscle fibers do however contain higher levels of 
ScCKmit, as can been expected from the higher content of mitochondria in these fibers (151, 
152). Strikingly, localization of MM-CK coincides with that of AK1 and the glycolytic 
enzyme aldolase at the muscle I-band (56), suggesting that these proteins may form large 
multi-enzyme complexes, required for the supply of energy for muscle contraction (137, 138, 
153, 154). Moreover, Kraft et al. have shown the direct interaction of MM-CK with 
phosphofructokinase (PFK) and aldolase (141), while Gerlach et a l. have shown the 
interaction of both MM-CK and AK1 to PFK, using affinity chromatography on immobilized 
PFK (155). The intertwined functional relationship of AK1 and glycolytic ADP:ATP 
phosphotransfer enzymes has also been demonstrated in AK1 deficient mice. In skeletal 
muscle of these mice lack of AK1 activity is compensated by increased activities of 
phosphoglycerate kinase and pyruvatekinase (156). In fact, the formation of glycolytic and 
associated proteins in multienzyme complexes in the I-band of skeletal muscle is thought to 
increase the efficiency of regeneration of ATP, hydrolyzed by the myofibrilar ATPase during 
contraction (56), but may also be of structural importance. The latter concept is demonstrated 
in Drosophila melangaster muscle, in which lack of glycerol phosphate dehydrogenase 
(GPDH) results in mislocation of the multi-enzyme complex proteins aldolase and GAPDH, 
and hence the ability to fly (157).
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1.5.2 Molecular factors regulating muscle design
Principal factors in regulating muscle fiber type determination are the myogenic 
members of the bHLH family (158), nuclear factor of activated T cells (NFAT) (159), 
peroxisome-proliferator-activated receptor-y coactivator-1 (PGC-1a) (160), and myocyte 
enhancer factor-2 (MEF2) (161). The molecular mechanism that drives fiber-type regulation 
and determination is not well understood but Lin et a l. have suggested that activation of the 
calcineurin/calcium-calmodulin-dependent protein kinase (CaMK) IV pathway may drive 
muscle fiber specification in a NFAT, PGC-1a and MEF2 dependent manner (162).
Major differences between type I and type II fibers are the higher mitochondrial 
content and oxidative metabolism in slow-twitch type I muscle fibers (137). In this respect, 
PGC-1a and CaMK IV are also known for their role in mitochondrial biogenesis (160, 163). 
Recently, it has been reported that AMPK may be the initial signaling step that couples the 
signal for compromised metabolic energy (i.e. low ATP/AMP ratio) to increased 
mitochondrial biogenesis by increasing the expression of PGC-1a and CaMK IV (164). In this 
regard, the observation that AK1 deficient gastrocnemius muscle are characterized by 
increased intermyofibrilar mitochondrial content is striking, since these muscles maintain a 
high overall ATP/AMP ratio (E.J.; personal observations) due to lack of ability to generate 
AMP via AK. In general, this may suggest that various pathways co-exist and stimulate 
mitochondrial biogenesis. Recently, also NO generated by eNOS has been shown to play a 
role in mitochonderial biogenesis in a cGMP- and PGC1a-dependent manner (165). Whether 
such a mechanism relates to the increase in intermyofibrilar mitochondrial content observed in 
AK1 deficient gastrocnemius muscle (156) remains, however, to be established.
1.5.3 Cardiac muscle design and energetics
The heart is a hollow organ and although it is also striated the cardiac muscle has 
many differences from skeletal muscle. A major difference between skeletal and cardiac 
muscle is that cardiac muscle does not form a syncytium but is formed by single mono- or bi- 
nuclear cardiomyocytes. The contractile cardiomyocytes are densely packed cells that are 
grouped into muscular rods or bands. These cells display a longitudinal polarity of their 
internal contents, including myofibrils, mitochondria and nuclei. The closely apposed portions 
of cells (primarily the cell tips) contain numerous junctions that collectively form intercalated 
discs, allowing them to function as an integrated whole (166; Fig. 5). Myofibrils build up the 
majority of the myocardial cell volume and these bundles of contractile protein filaments are 
flanked by many mitochondria, indicating their high dependence on aerobic metabolism. Fatty 
acids are the major oxidation fuel, while glucose and lactate provide the remaining need (Fig. 
1). In fact, the oxidation of fatty acids accounts for approximately 70-80% of the oxygen 
consumption in physiological conditions (167).
In the mammalian heart two functionally distinct MHC isoforms are expressed: 
MHCa and MHCp. Both MHCa and MHCp can form a a -  and pp-MHC homodimeric or ap-
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MHC heterodimeric structures and are developmentally and hormonally regulated (168). At 
birth, expression of MHCa is induced in a thyroid hormone-dependent fashion, while the 
expression of MHCP is downregulated. Thus, MHCa is the predominant isoform in mouse 
heart (169). Lowering the hormonal thyroid status results in hypothyroidism, a situation 
characterized by the induction of MHCP expression (169), whereas elevation of thyroid 
hormone and exercise increases MHCa (170). Because MHCa has a higher ATPase activity 
than MHCP the relative amount of each MHC determines the contractile velocity of the heart 
(169) but whether MHCa or P expression in cardiomyocytes alters the kinetic properties of 
single myocytes and activities or properties of enzymes involved in heart energy metabolism 
is, to my knowledge, unknown.
Whereas AK1 is considered to salvage ATP from ADP in the cytosol, in the inner­
membrane space of mitochondria AK2 probably uses ATP to salvage AMP generated by 
cellular metabolism (22). In this way, AK2 prevents the loss of AMP through the AMP 
deaminase pathway, as AMP cannot enter the mitochondrial matrix if not phosphorylated. 
Indeed, ADP regeneration within the inner-membrane space by AK2 results in local 
concentrations of ADP that are higher than the bulk ADP concentrations outside mitochondria 
(60, 61). Moreover, AK2 has been shown to contain a functional reserve in providing energy 
from p-phosphoryls since lack of AK1 diminished more than 94% of the total AK activity, 
while only a 36% reduction in p-phosphoryl energetics was observed (171). Despite this 
functional reserve in P-phosphoryl energetics AK1 knockout hearts display accelerated loss of 
contractile force at the onset of ischemia, pointing to reduced tolerance to ischemic stress in 
absence of AK1 (172).
Figure 5. Schem atic arch itectura l representation o f heart m uscle in the intercalated d isk  area.
A, A band;I, I band; Z, Z line. Adapted from (147) with permission
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The functional relationship of the AK-catalyzed phosphotransfer and CK- or 
glycolytic-mediated phosphotransfer has also been demonstrated for the cardiac muscle and 
are main mechanisms required for efficient communication of energetic signals (173, 174). In 
fact, deletion of AK1 catalysis in the mouse heart elevates the activity of the glycolytic 
phosphotransfer enzyme phospghoglycerate kinase (PGK) (171). Therefore, it has been 
suggested that, in analogy to skeletal muscle, the CK-, AK- and glycolytic-mediated 
phosphotransfer form part of an integrated coordinated network (175), required for efficient 
coupling between cellular sites of ATP-production and ATP-utilization (174) and optimal 
heart performance (172).
1.5.4 Brain energetics
Understanding of the energy metabolism of neurons and associated glial cells is of 
importance for understanding the normal function of the brain. However, brain energy 
metabolism is very complex, especially because of the many different cell types participating 
in brain metabolism, and goes beyond the scope of this thesis. Therefore, for a comprehensive 
review on brain energetics the reader is referred to (176, 177), and (178). What follows is a 
brief overview of our current knowledge of the expression and putative function of AKs in the 
brain, as to date, direct evidence for adenylate kinase playing an important role in energy 
transfer in the central nervous system is still lacking.
Expression of the AK1-isoform is found in rat primary cultured neurons, where it 
locates in neuronal processes as well as perinuclear regions, but not in glial-like cells (179). 
Also our group found that the expression of AK1 in the mouse brain is mainly confined to 
neurons, as demonstrated in primary co-cultures of mouse neurons and astrocytes (30). The 
gene expression of AK1 increases during neuronal differentiation in mouse embryonal 
carcinoma P19 cells and in rat brain primary cultured cells (179) and suggests a role for AK1 
in neuronal function and development. Indeed, the AK1 protein can be detected early during 
embryogenesis and increases during the course of development in the rat brain (180). During 
this process, expression of the AK1 gene is controlled by the basic helix-loop-helix 
transcription factor NeuroD in PC12 cells (181), one of the major neuronal differentiation 
factors (181).
Along with the above mentioned cytosolic distribution of AK1 in primary cultured 
neurons AK activity is found associated with the synaptic plasma membrane (presumably 
AK1P; 23, 30), suggesting that AK is also strategically located to play a role in local 
regeneration of ATP to provide the manifold activities of the synaptic membrane (27, 28). For 
example, the subcellular regulation of KATP channels by the membrane-bound AK1, AK1P, 
has been demonstrated in the neuronal-like N2a cell, where AK1P may function in translating 
cellular energetic signals to membrane metabolic sensors (30).
Expression of the fourth AK isoform, AK4, is found in the pyramidal cells in the 
hippocampus and granular cells in the cerebellum and nasal neuroepithelium. It has been 
suggested that AK4 may act in the mitochondrial matrix in analogy to AK3 in these cells (19).
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However, the precise role of AK4 in energy metabolism is still a matter of debate as Noma et 
al. were not able to detect any AK activity in the human AK4 protein (39). At present, the 
physiological role of the fifth AK-isoform, AK5, in energy metabolism of the central nerve 
system remains also unclear (20).
1.6 Experimental approaches
1.6.1 Animal models to study the function o f  gene products in vivo
By applying gene targeting to embryonic stem (ES) cells mutations can be introduced 
to a gene of interest in the mammalian lineage. This field of reverse genetics started in the 
mid-eighties after it had been demonstrated that mouse ES cells have to ability to recombine 
incoming DNA with homologous sequences in the genome (182). Since then, numerous 
reports have been published in which a classical knockout mouse model has been created to 
study the in vivo significance of various proteins and revealed clues that have led to a better 
understanding of their function (TBASE 2001; http://tbase.jax.org/). In most cases the 
classical way for generation of knockout mouse models is still based on the introduction of a 
null mutation in the gene of interest by replacing the exon carrying the ATG or an exon 
expressing a fundamental or catalytic domain of the protein of interest. A targeting vector 
carries a selection cassette inserted in the appropriate exon, flanked by regions of homology 
with the target gene. In many cases, a negative selection cassette is used to enrich for those ES 
cells that have undergone a targeted mutation event, by employing the positive and negative 
selection strategy (183). In recent years, researchers have replaced the brute-force strategy of 
introduction of null mutations by the introduction of more subtle type of mutations, such as 
point mutations and small deletions or insertions (184), or even knock-in with a gene of 
interest (185). For the latter type of knock-in mouse models, the gene of interest is targeted 
following insertion of a cDNA of interest at the targeted locus (for review see 186). A 
relatively new approach in functional genome analysis is the ability to exert conditional 
control over gene expression in the mouse, which enables investigators to switch genes on and 
off at any desired point in development or ageing (for review see 187). Knockout of genes via 
introduction of classical null mutations can result in an embryonic-lethal phenotype, which 
renders the introduced mutation useless to study. The use of a conditional knockout mouse 
model may circumvent this limitation.
Within our group mouse models have been created that completely lack M-CK, 
ScCKmit, UBCkmit, and B-CK subunits (101, 188-190). These studies have been conducted 
to study the biological importance of the CK/CrP system and have demonstrated the 
importance of brain and muscle specific CKs in behavior, muscle performance, and Ca2+ 
homeostasis (101, 190-193). More specifically, studies on CK-deficient mouse muscles have 
demonstrated the high plasticity of the myocyte in adapting to CK ablation as evidenced by 
the change in composition of cellular compartments at the ultrastructural level and change in 
RNA and protein composition at the molecular level (101, 194-196). Moreover, studies on
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these mutant muscles revealed that the AK- and CK-mediated reactions play a partly 
complementary and functionally redundant role in cellular energetics (14, 108, 197, 198).
1.6.2 How to study the adaptive response to gene inactivation?
Transcriptome analysis
Microarray technology has undergone a rapid evolution in the last decade and has 
become of widespread interest to the scientific community (see Nature Genetics supplement, 
volume 32, 2002 for comprehensive information). The basic concept behind the use of DNA 
arrays is the precise positioning of DNA fragments at high density on a solid carrier in such a 
way that they can act as molecular detectors in a nucleotide hybridization-based assay (199). 
Parameters that may differ between experimental approaches are the type of solid carrier used 
for DNA binding (glass vs. membrane filters) and the type of DNA probe spotted on the solid 
carrier (cDNA vs. oligonucleotides or genomic fragments). At present, combinations of 
parameters are used to create three types of DNA arrays: (i) filter arrays (ii) spotted glass slide 
arrays and (iii) in situ synthesized oligonucleotide arrays. Ultimately, all three types of DNA 
arrays can be used to study the expression, or rather the mRNA product levels, simultaneously 
for whole sets of transcripts as a new tool for disease diagnosis, for monitoring the outcome of 
therapeutic intervention or for studying the adaptive gene expression in response to intrinsic 
(genetic) or extrinsic (physiological) challenges.
Our group studied the changes in mRNA expression profiles between wild-type and 
AK1 deficient mice (156), using cDNAs for filter spotted arrays (200, 201). Although array- 
profiling can, in principle, be a very useful approach to determine changes at the level of 
mRNA expession we noted that at present there are also still several factors which limit its 
predictive and diagnostic potential. Firstly, the availability of useful cDNA probes is 
sometimes limiting as genes encoding different transcript isoforms and cDNAs containing the 
3’UTR and poly(A) tails may show cross-hybridization. Secondly, our current knowledge 
about alternative splice variants from the same gene is still incomplete. Also cDNA clones 
distributed by licensed vendors, such as the IMAGE Consortium (see http://image.llnl.gov/), 
may provide cDNA clones that are contaminated with T1 phage and compromised by 
incorrect sequence assignment (202) and, therefore, care has to be taken. Although not 
insuperable, one has to deal also with technical dilemmas, which may include the high- 
precision printing of the spots and reproducibility of the printed spots (199). In spite of this, 
expression profiling has been shown to be a useful technique to screen alterations in mRNA 
steady-state levels in response to altered metabolic demand or metabolic insult (156, 163, 203, 
204).
An approach in determining common regulatory principles is the use of DNA array 
analysis and the possibility to functionally cluster genes that show coordinated regulation 
(205, 206). In this way, information about expression of genes regulated by a common 
denominator can be obtained.
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Quantitative protein and activity analysis
Since a change in steady-state mRNA level for a certain gene may or may not translate 
into changes in steady-state protein levels techniques to quantitatively determine the amount 
of protein of interest are of similar importance. Proteome analysis - most commonly 
accomplished by the combination of two-dimensional gel electrophoresis for protein 
separation, visualization, and quantification and mass spectrometry for protein identification - 
is suitable for studying changes in tissue- or organelle-specific protein concentrations (207). 
Alternatively, changes in steady-state protein levels can be studied by means of quantitative 
Western blot analysis, using an antibody directed against the protein of interest to monitor the 
intracellular level of individual proteins (195). However, post-translational modifications, 
such as phosphorylation (79, 208), ADP-ribosylation (209), hydroxylation (210), etc., may 
occur in response to changes in the cellular metabolic status, which changes the properties of 
a protein and, hence, modulates the catalytic activity of most eukaryote proteins (211). In fact, 
proteins can be modified by yet unidentified metabolic response mechanisms (212). Thus, 
measuring the catalytic activity of the protein of interest provides significant information 
about the physiological adaptation. Ultimately, application of “modification-specific 
proteomics” would offer information about the actual post-translational modification (211).
M etabolic flu x  measurements by 18O metabolic labeling
In order to determine the functional integrity of the cellular energetic system in 
response to metabolic insult examination of phosphotransfer dynamics is required. 
Representative data for this kind of studies can best be obtained in the context of the intact 
skeletal muscle cell, with cytosolic compartments, protein complexes and organelles (i.e. the 
microanatomy of the cell), still in place and fully functional (see also 213). One powerful, 
useful non-invasive technique is 31P-Nuclear Magnetic Resonance Spectroscopy ((N)MRS). 
31P-NMRS allows the detection of a subset of phosphoryl containing metabolites, thereby 
providing quantitative information on the kinetics of energy metabolism in vivo (see also 
102). However, MRS does have some limitations, especially for the measurement of 
reversible phosphotransfers in metabolic conversion reactions. For example, the level of free 
ADP in the muscle cell is too low to be detected and, binding of nucleotides to proteins 
renders them undetectable with MRS. Also, MRS does not allow direct assessment of the (i.e. 
relative) contribution of the AK-catalyzed phosphotransfer to the total adenine nucleotide 
metabolism, as only pools of free y ATP, PATP, and a  ATP can be reliably detected. Yet, 31P- 
MR spectroscopy is currently the only technique available that allows direct monitoring of 
major high-energy phosphoryl metabolites in vivo during cellular activity, and thereby 
provides quantitative information about the kinetics of energy metabolism in the cellular and 
organismal context (102, 214, 215).
Another means of obtaining kinetic information can be achieved with the use of the 
18O-water labeling technique. Upon incubation of an intact tissue or suspension of cells in 
18O-water the incorporation of 18O results from hydrolytic cleavage and transfer of
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phosphoryls. Quantitative information about ATP metabolism can be obtained by measuring 
the rate of 18O appearance in phosphoryl containing metabolites of interest (112). 
Measurement of metabolic flux by 18O incorporation provides information about several 
metabolic pathways simultaneously. In addition, unique features of intracellular AK catalysis 
can be uncovered by monitoring 18O incorporation into the P-phosphoryls of ATP and ADP 
(12, 112).
During incubation, 18O-water quickly diffuses into the cell and is used to hydrolyze 
ATP, producing [18O]Pi (derived from 18O-water). Subsequently, [18O]y-ATP and [18O]y-GTP 
are being generated in the pathways that can use [18O]Pi as a substrate (see also Fig. 1). With 
each act of ATP hydrolysis 18O-labeled phosphoryls are distributed among high-energy 
phosphoryl-carrying molecules, according to the following reaction equations:
YATP + 18O H2O ^  18O Pi + ADP (ATP hydrolysis)
18O Pi + ADP ^  18O yATP (ATP synthesis)
18O Pi + GDP ^  18O yGTP (GTP synthesis)
18O yATP + Cr ^  18O CrP + ADP (CK-catalyzed phosphotransfer)
18O yATP + AMP ^  18O pADP + ADP ^  18O pATP +AMP (AK-catalyzed phosphotransfer)
18O yATP + glucose ^  18O glucose-6-P + ADP (Hexokinase-catalyzed phosphotransfer)
18O yATP + GMP ^  18O pGDP + ADP (GK-catalyzed phosphotransfer)
18O yATP + GDP ^  18O yGTP + ADP (NDPK-catalyzed phosphotransfer)
Up to three 18O-atoms can be incorporated in phosphoryls of y-ATP, p-ATP and CrP, while a 
maximum of four 18O atoms can be incorporated into Pi. Data obtained with this technique 
gives quantitative information about the turnover rate of phosphoryl containing metabolites 
under different experimental conditions (12, 112). Traditionally, 18O-labeling of cellular 
phosphoryls have been quantified using mass-spectrometry. Recently, 18O-assisted 31P NMR 
spectroscopy was developed for simultaneous measurement of metabolite levels and 
metabolic fluxes through phosphotransfer systems (171). Incorporation of 18O as a result of 
cellular metabolic activity induces an isotope shift in the 31P NMR spectrum of phosphoryl 
containing metabolites, which can be visualized and quantified using high-resolution NMR 
spectroscopy (174).
To gain information about the velocity of the AK-catalyzed phosphotransfer reaction 
Goldberg and co-workers have developed a theoretical model in which rates of ADP 
metabolism can be determined from modeling of 18O-labeling data (12, 112). The kinetic 
model represents the AK velocity (or flux) at which ADP is metabolized to generate AMP and 
ATP, taken into account the fraction of metabolically active ATP and ADP under the 
experimental conditions (see 12 for details). Information about the fraction of metabolically 
active ADP and ATP can be obtained by determining the proportion of phosphoryls in ADP 
and ATP (p or y) that become labeled when saturation is achieved. In this way, the kinetic
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model provides an estimated net flux through the AK-catalyzed phosphotransfer based on 
experimentally obtained 18O-labeling data (112).
Along with the kinetic model that can be used to determine the metabolic flux through 
the AK-catalyzed phosphotransfer a simple kinetic model has been described that can be used 
to estimate the net flux through the CK-catalyzed phosphotransfer (13). This model, put 
forward by Dzeja et al., is based on the established relationship between [18O]-CrP labeling 
and the kinetics of intracellular CrP metabolism (see for detailed information 55). The kinetic 
relationship between 18O-labeled P-ADP, P-ATP, CrP and the CK- and AK-flux is currently 
used as the working model to define the AK- and CK-catalyzed phosphotransfer in coupling 
ATP-consuming and ATP-generating processes (55; see also chapter 2, 3 and 5). In addition, 
the 18O-phosphoryl labeling technique permits assessment of phosphoryl exchange between 
different cellular compartments by monitoring changes in the [18O]Pi/[18O]y-ATP ratio (174).
1.7 Aim and outline of this thesis
“Energy is p u t into any chemical system by displacing it from  the equilibrium that will 
apply under the conditions o f  use. The adenylate energy storage system, charged by supplying 
a phosphoryl group at effectively high chemical potential to ADP, is fu lly  charged when all o f  
the adenylate present is converted to ATP, and fu lly  discharged when only AM P is presen t” 
(10). Since the cellular energy charge is usually constant and highly loaded, AMP or ADP will 
only become available to the AK reaction when energy-providing pathways become 
compromised. Therefore, assuming that the AK reaction is in equilibrium and is solely driven 
by substrate accessibility, it would follow that AK catalysis must be of minor (i.e. mostly 
“transient” or “temporal”) metabolic importance. This view appeared to be not correct. First 
indications for AK having a more pivotal and constant role in the intracellular energy network 
and the transfer of high-energy phosphoryls between sites of energy production and 
consumption, came from metabolic labeling studies on skeletal muscle (12, 13). As direct 
evidence for the biological significance of AK in intracellular energy homeostasis was still 
lacking we aimed in this thesis study to (i) unravel the biological significance of AK1 in 
cellular energetics and (ii) determine how the AK1-catalyzed phosphotransfer was coupled to 
the high-energy phosphoryl transfer network. By applying gene targeting in ES cells to delete 
the AK1 protein activity we expected to generate answers on these questions.
In order to specifically target the mouse AK1 locus, the AK1 gene was identified, 
isolated and characterized and its gene products were studied in different cells and tissues. 
Using established procedures for targeted gene inactivation (101, 192), a targeting vector was 
created and used for homologous recombination of the AK1 gene (chapter 2). The phenotypic 
characteristics of this mutant are described at the level of metabolic flux regulation (chapter 2 
and 3) and at the ultrastructural and molecular level (chapter 4).
Because M-CK fulfils an important role in energy homeostasis, AK1 deficient mice 
were cross-bred with M-CK deficient mice (101), and the physiological consequences of
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deleting both AK1 and M-CK activities in skeletal muscle were studied at the level of 
metabolic fluxes in chapter 5.
Finally, chapter 6 describes the structural and functional aspects of the mouse AK1 
gene and its gene products in detail and, in particular, provides us with more insight in the 
possible functional association between membrane-bound AK1 and the ATP sensitive 
potassium channel.
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Adenylate kinase 1 and muscle energetic economy
ABSTRACT
Efficient cellular energy homeostasis is a critical determinant of muscle performance 
providing evolutionary advantages responsible for species survival. Phosphotransfer reactions, 
which couple ATP production and utilization, are thought to play a central role in this process. 
Here, we provide evidence that genetic disruption of AK1-catalyzed ß-phosphoryl transfer in 
mice, decreases the potential of myofibers to sustain nucleotide ratios despite up-regulation of 
high-energy phosphoryl flux through glycolytic, guanylate and creatine kinase 
phosphotransfer pathways. A maintained contractile performance of AK1-deficient muscles 
was associated with higher ATP-turnover rate, and larger amounts of ATP consumed per 
contraction. Metabolic stress further aggravated the energetic cost in AK1- - muscles. Thus, 
AK1-catalyzed phosphotransfer is essential in the maintenance of cellular energetic economy, 
enabling skeletal muscle to perform at the lowest metabolic cost.
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INTRODUCTION
Adenine nucleotides are the primary high-energy phosphoryl-carrying molecules in a 
living cell. Along with their energetic role, ATP, ADP and AMP are major regulators of 
essential cellular processes, including gene expression, ion channel gating, and receptor- or 
protein kinase-mediated signal transduction (1-3). Although the energetic and regulatory 
functions of adenine nucleotides are dependent on nucleotide ratios and rates of nucleotide 
exchange between cellular compartments (4-8), the molecular mechanisms governing the 
dynamics of adenine nucleotide metabolism remain poorly understood.
Adenylate kinase (AK, EC 2.7.4.3), by virtue of its ability to catalyze the reaction ATP 
+ AMP o  2ADP, has been considered a key enzyme in the synthesis, equilibration, and 
regulation of adenine nucleotides (9, 10). Through its unique property of transferring and 
providing for utilization both p and y phosphoryls of ATP, AK doubles the energetic potential 
of the ATP molecule (11, 12). By regulating ADP and AMP levels, AK renders these 
nucleotides active components in metabolic signaling determining the cellular response to 
stress (2, 3, 8, 13, 14). Several AK isoforms have been cloned, and exhibit different levels of 
tissue expression with distinct intracellular distribution (15). Tissues with high-energy 
demand, such as skeletal muscle, are particularly rich in AK1, the major enzyme isoform. 
AK1 is localized in the cytosol, clustered within myofibrils or bound to membranes (13, 15, 
16). Other isoforms, such as AK2 and AK3, are less abundant in muscle, and are generally 
confined to the mitochondrial intermembrane space or mitochondrial matrix (9, 17). The 
presence of AK in different compartments implicates this enzyme in promoting intracellular 
energy transfer, and communication between ATP-consuming and ATP-producing cellular 
sites (11, 12, 18). The AK system has, in fact, been found to facilitate high-energy phosphoryl 
transfer from mitochondria to myofibrils (19). Moreover, evidence is accumulating in support 
of an integrated intracellular high-energy phosphoryl transfer network comprised from AK, 
creatine kinase and glycolytic phosphotransfer enzymes (12, 20, 21). Although AK appears to 
be essential in cellular energetics, the significance of this enzyme in maintaining intracellular 
energy flow has not been determined.
To obtain direct information on mechanisms regulating the economy of cellular 
energetics we generated knockout-mice lacking the major AK isoform, AK1. Lack of AK1 
disrupted muscle energetic economy and induced remodeling in pathways for ATP 
production, high-energy phosphotransfer and ATP utilization, underscoring the significance of 
AK in sustaining efficient cellular energetics. The observed metabolic rearrangement in 
glycolytic, creatine kinase and guanine nucleotide phosphotransfer systems in the AK1- 
deficient mice demonstrates a high plasticity of muscle energetics, and may provide a 
mechanism for the maintenance of energetic homeostasis under metabolic stress.
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MATERIALS AND METHODS 
AK1 targeting vector
Genomic DNA fragments of the AK1 gene were obtained by screening an EMBL3 
phage library of partially digested genomic DNA of the mouse strain 129/Sv using as a probe 
rat AK1 cDNA spanning exons 5-7 (provided by Dr. N.D. Goldberg and A. Nakazawa). 
Phages from positive plaques were purified to homogeneity and characterized using standard 
procedures (5). Exons were identified using Southern blot hybridization with exon specific 
oligonucleotides and positioned by restriction mapping followed by partial sequence analysis 
of genomic DNA fragments. Appropriate segments that covered the entire exon 1-7 region of 
the AK1 gene were subcloned into plasmid pGEM3 (Promega). The 2.6 and 4.1 kb 
SalI/BamHI and HindIII/BamHI fragments were used as left and right arms of homology to 
generate the targeting vector (Fig. 1). In the construct the exon 3-5 area, encoding the ATP 
binding site, was replaced by a BamHI/Hindlll hygromycin B resistance (hygroBr) cassette 
(22). To enable selection for homologous targeting a negative selection cassette, containing 
the 2.0 kb herpes simplex virus thymidine kinase gene (HSV-tk; 22) was inserted at the 3’ 
BamHI site. The AK1 targeting vector was linearized at the Xbal site located at the vector’s 
multiple cloning site upstream of the 5’ AK1 insert.
AK1_/" embryonic stem cells
Wild-type E14 embryonic stem (ES) cells were grown on a layer of irradiated SNLH9 
feeder cells, cultured and electroporated (5, 22). 24 hours after electroporation, cells were 
grown in the presence of 300 ^g/ml hygromycin B (Life Technologies) and 0.2 ^M Fiau 
(Bristol-Meyer), and allowed to grow for another 8-10 days before resistant colonies were 
isolated. For detection of the desired AK1 mutation, genomic DNAs from individual ES 
clones were prepared according to established procedures (5). DNA was digested with either 
BamHI or KpnI/Xhol restriction enzymes for the identification of targeted homologous 
recombination events at both sides of the replacement cassette (5). The homologous 
recombination event at the 5’ side of the AK1 locus was determined using a unique 800 bp 
Sall/Kpnl fragment as probe (probe a, Fig. 1). For identification of the 3’-event, a 1700 bp 
BamHI/XhoI fragment (probe b, Fig. 1) was used.
AK1_/" knockout mice
Targeted embryonic stem cells (AK1+-) were injected into blastocysts derived from 
C57BL/6 mice to obtain chimeric, heterozygous, and homozygous offspring (4, 5). AK1-- 
mice were kept on a mixed 50%-50% C57BL/6-129/Ola inbred background during breeding. 
Southern analysis was performed on DNA from tail biopsies used for genotyping. A PCR 
assay was designed where three primers were used to discriminate between wild-type, 
heterozygous, and homozygous mutant mice. Forward primer was AK1M1 located in intron 1 
(5’GGAGCCTGACACTTATTGCTG). Reverse primers were AK1M2
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(5 ’ GAATT GCT GTCC GGT AT AGC) and H1 (5’GGCTGGCACTCTGTCGATACCC) 
located in intron 2 and the hygromycin B resistance gene, respectively. PCR reactions were 
carried out in 50 ^l containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.01% 
gelatin, 100 ng of each primer, 100 ng DNA template and 1 U Taq polymerase. Amplified 
products, generated from the wild-type and AK1 mutant locus, were 384 and 626 bp in length, 
respectively. Gastrocnemius-plantaris-soleus (GPS) muscles from age matched homozygous 
AK1-deficient and wild-type control animals, also having a 50%-50% C57BL/6x129/Ola 
mixed inbred background, were used throughout experiments. Under standard housing 
conditions, we saw no abnormalities in birth weight, weight-gain during growth into 
adulthood, or daily food-intake in 1th and 2nd -generation 
AK1- - animals. Also fiber-type distribution was normal in AK1 mice. Mice were anesthetized 
with 2,2,2-tribromoethanol (350 mg/kg i.p.) or pentobarbital (100 mg/kg i.p.). All procedures 
conformed to the Guidelines fo r  the Care and Use o f  Laboratory Animals of the Dutch 
Council and the National Institutes of Health, and were approved by the Institutional Animal 
Care and Use Committee at the University of Nijmegen, the Mayo Clinic and the Vrije 
University Amsterdam.
N orthern blot analysis
Total RNA from freshly isolated skeletal GPS muscle, as well heart and brain, were 
extracted using the lithium chloride-urea method (5) and analyzed by Northern blot (5). RNA 
blots were hybridized with a fragment of rat AK1 cDNA, spanning exon 5-7, and a 1.3 kb rat 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe. Hybridization was 
carried out overnight at 65°C in 0,5 M NaPO4-buffer pH 7.2, 7% (w/v) SDS, 1 mM EDTA, 
and blots were washed to a final stringency of 1SSC/1% (w/v) SDS at 65°C and exposed on 
Kodak X-Omat films.
Zymogram analysis
Homogenates from freshly excised GPS muscles (10% w/v) were prepared in SETH 
buffer (in mM: 250 sucrose, 2 EDTA, 10 Tris-HCl; pH 7.4) at 4°C. GPS extracts were diluted 
1:1 in 30 mM Na3PO4 buffer (pH 7.4), containing 0.05% v/v Triton X-100, 0.3 mM DTT and 
a protease inhibitor cocktail (1 mM PMSF, 10 ^g/ml leupeptin and 1 ^g/ml aprotinin; 
Boehringer Mannheim #1697498). Muscle extracts were incubated for 30 min at room 
temperature, centrifuged for 20 min at 11,000 g  and an aliquot (1-5 ^l) applied to agarose gels 
(Alameda, CA). AK1 and creatine kinase isoenzymes were separated electrophoretically, and 
stained for enzyme activity (5).
Adenylate kinase and nucleoside diphosphate kinase activity
AK activity was measured spectrophotometrically in GPS muscle extracts (8). In 
addition, AK activity was measured by a luciferase-based ATP bioluminescence assay 
(Sigma) in the presence of 2 mM ADP using a BioOrbit 1253 luminometer. The nucleoside
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diphosphate kinase (NDPK) activity, expressed in relative light units (RLU)min-1mg 
protein"1, was determined with the same bioluminescence assay in the presence of the AK 
inhibitor, diadenosine pentaphosphate (Ap5A; 200 ^M), and the reaction started with dGTP (2 
mM).
AMP deaminase
AMP deaminase (AMPD) activity was measured using GPS muscle extracts (23). 
AMPD activity was measured in a reaction buffer containing 15 mM AMP and formation of 
the reaction product, IMP, monitored by HPLC. Western blot analysis of AMPD was 
performed on muscle extracts probed with a polyclonal antiserum raised against purified rat 
skeletal muscle AMPD. Developed nitrocellulose membranes were digitized and analyzed 
using NIH Image (24).
High-energy phosphoryl transfer
ATP turnover and phosphoryl flux through AK, creatine kinase (CK) and glycolytic 
systems were measured in intact GPS muscle complex using the 18O-phosphoryl labeling 
technique (19, 25-27). Isolated mouse GPS muscle was preincubated for 15-20 min at room 
temperature in media containing (in mM) 137 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 1 NaH2PO4, 20 
HEPES, 0.05 EDTA, 5 glucose and 24 NaHCO3 (pH 7.4). The muscle complex was then 
rapidly transferred into media enriched with 20% of 18O-water (Isotec Inc.), and paced at 2 
Hz. In separate experiments, hypoxia was simulated by pre-incubating muscles in 2 mM KCN 
(for 3 min), and then transferring muscles into 18O-enriched media with 2 mM KCN for an 
additional 3 min (at continuous 2 Hz pacing). Cellular ATP, ADP, GTP, GDP, inorganic 
phosphate, creatine phosphate (CrP) and glucose-6-phosphate (G-6-P) were purified and 
quantified using high-performance liquid chromatography (25, 27). Samples containing 
phosphoryls of y-ATP, P-ATP, P-ADP, y-GTP, P-GTP, P-GDP, inorganic phosphate and CrP, 
as glycerol 3-phosphate, were converted to trimethylsilyl derivatives. 18O-enrichment of 
phosphoryls in glycerol 3-phosphates was determined with a Hewlett-Packard 5980B gas 
chromatograph-mass spectrometer. Total cellular ATP turnover along with net AK- and CK- 
catalyzed phosphotransfer were determined from the rate of appearance of 18O-containing 
phosphoryls (11, 25, 27). The rate of net phosphoryl flux through the glycolytic system was 
measured by the appearance of 18O-labeled phosphoryls in glucose-6-phosphate (G-6-P), 
which was purified by HPLC (27).
Metabolite levels
ATP, ADP, AMP, GTP, and GDP levels were quantified in perchloric muscle extracts 
by HPLC (19, 25). CrP, muscle lactate and glucose-6-phosphate levels were determined using 
coupled enzyme assays (4, 19). Muscle inorganic phosphate level was determined using the 
EnzChek Phosphate Assay kit (Molecular Probes).
47
Chapter 2
31In  vivo P-NMR spectroscopy
In mice anaesthetized with 1.5% enflurane, 31P-NMR spectra were determined in vivo 
in hind limb muscles using a 7T S.M.I.S. spectrometer. Recordings were performed prior, 
during 25-min of ischemia and following 16-min of reperfusion. Ischemia was induced by 
occluding hind limb circulation. Spectra were analyzed using time domain fitting, and 
normalized to the mean value of the B-ATP intensity of the first four spectra.
Contractile muscle properties
Peak force, maximal rate of force rise and half-relaxation time were obtained under 
isometric conditions in medial gastrocnemius muscles (at 35°C) from wild-type and AK1- 
deficient mice (n=20) as described (28). Maximal shortening velocity was obtained in a 
subgroup by extrapolation of the force-velocity relationship. Fatigability was investigated by 
applying a series of 20 isometric contractions (150 ms duration; 150 Hz) within 10 s.
Statistics
Data are presented as mean ± S.E., unless otherwise indicated. Student’s t test for 
unpaired samples was used for statistical analysis, and P<0.05 was considered significant.
RESULTS 
Cloning of the genomic AK1 gene and generation of AK1-/- m utant mice
By screening a genomic mouse 129/Sv phage library, several phages were isolated that 
contained the entire AK1 gene, including upstream and downstream flanking segments. The 
structural organization of the AK1 gene in these phages (Fig. 1A), which spans a total of 12 
kbp and comprises 7 exons, has an exon-intron distribution that appears highly conserved 
when compared to other species, including man (29). For disruption of the AK1 gene a 
targeting vector (Fig. 1A) was constructed in which the left and right arms of homology 
spanned 2.6 and 4.1 kbp, respectively. Exons 3-5 (encoding the ATP-binding site) plus 
adjacent intron segments were deleted from the vector and replaced by a hygromycin B 
resistance cassette, inserted in antiparallel orientation. By gene targeting, applied to mouse 
E14 ES cells (4, 5, 22), 5 cell clones with the desired genotypic modification were obtained. 
All ES clones had undergone correct homologous recombination events, downstream as well 
as upstream of the replacement mutation, as confirmed by Southern blot analysis (Fig. 1B and 
1C). Successful disruption of the AK1 gene was confirmed at the RNA level by Northern blot 
analysis (Fig. 1D), and at protein level by zymogram analysis of protein extracts (Fig. 1E-G). 
No residual mRNA was detected upon hybridization with an AK1 cDNA probe spanning exon
5-7, suggesting that a true null mutation was generated with respect to RNA and protein 
production. It is of note here that lack of AK1 in animals kept under normal housing 
conditions did not induce overt developmental or physiological abnormalities (not illustrated).
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Absence of AK-catalyzed phosphotransfer in skeletal muscle from AK1-/- mice
Genetic deletion of AK1 produced loss of 18O incorporation into P-phosphoryls of 
ATP indicating lack of AK-catalyzed phosphotransfer in AKl-knockout skeletal muscle (Fig. 
2). The percentage of P-ATP 18O labeling was 4.43 ± 0.33 in wild-type («=6), and 0.04 ± 0.02 
in AKl-knockout (n=6, p<0.001; Fig. 2). AK-phosphotransfer flux in wild-type was 4.25 ± 
0.31 nmol ADP min-1mg protein-1 or 20% of total ATP turnover in contracting (2 Hz) 
muscle. In AK1-knockout, AK-phosphotransfer flux was 0.05 ± 0.01 nmol ADPm in-1mg 
protein-1 or below 0.2% of total ATP turnover. Adenine nucleotide-dependent AK activity 
was 3621 ± 218 nmol ATP min-1mg protein-1 in the wild-type, but only 11 ± 3  nmol 
ATP min-1mg protein-1 in the AK1-knockout (p<0.001). Total AK activity in the AK1- 
knockout muscle was diminished by 99.7% when compared to wild-type. The remaining 0.3% 
of AK activity could be attributed to minor AK isoforms still present in AK1-knockout 
muscle. Thus, the AK1-knockout GPS muscle is characterized by absence of AK-catalyzed P- 
phosphoryl transfer, which remains uncompensated by remaining AK isoforms.
Adenine nucleotide levels and metabolism in A K l-knockout skeletal muscle
AK1 has been implicated in adenine nucleotide synthesis and metabolism (9, 10). 
AK1- - knockout skeletal muscle demonstrated maintained ATP levels, 28.3 ± 1.5 nmol mg 
protein-1, compared to 26.4 ± 0.8 nm olm g protein-1 in the wild-type (n=6). The total sum of 
adenine nucleotides (ATP, ADP and AMP) was also preserved in AK1-deficient muscle, 33.9 
± 1.8 nm olm g protein-1, compared to 31.2 ± 0.9 nm olm g protein-1 for the wild-type (n=6). 
Adenine nucleotide de novo synthesis is a rather slow process (30), and thus could be 
supported by minor AK isoforms present in AK1-knockout muscle. However, in non­
contracting AK1- - gastrocnemius muscle the ATP/ADP ratio was higher than in the wild-type,
8.8 ± 0.2 versus 8.0 ± 0.2, respectively (p<0.03; n=5). Moreover, in GPS muscle contracting
Figure 1. (A) Targeted mutagenesis of AK1 with wild-type (top) and mutant (bottom) AK1 genes 
shown after homologous recombination. Exons: shaded or black. Introns or extragenic regions: white. 
In the targeting vector (middle) a selectable HygroB cassette replaces the 5.5 kb BamHI/HindIII gene 
fragment (exons 3-5) that encodes the ATP-binding domain of AK1. A HSV-tk cassette was fused to 
the right arm of homology to facilitate selection of properly targeted ES clones. Length of restriction 
fragments (arrowed lines) from wild-type and mutant alleles are indicated. (B and C) Southern blot of 
genomic DNAs from wild-type and mutated E14 ES clones. DNAs were cleaved with KpnI/XhoI or 
BamHI restriction enzymes, resolved by agar gel electrophoresis, and blot-analyzed by hybridization 
with probes (indicated in A) that discriminate between recombination events at the 3'- (B) and 5'- (C) 
segments of homology. Diagnostic KpnI/XhoI digestion yields 11.5 and 5.6 kb fragments, whereas 
BamHI digestion results in 4 and 7 kb fragments for wild-type and mutant alleles. (D) Northern blot 
analysis of RNAs from wild-type and AK1-/- tissues. Blots with equivalent amounts of total RNA (10 |ig) 
from skeletal muscle (SK), heart (H), and brain (B) probed with AK1 cDNA. Note the absence of AK1 
mRNA in homozygous mutants. (E, F and G) Zymogram analysis of homogenates from brain (B), 
heart (H), and gastrocnemius (G)-plantaris (P)-soleus (S)-muscle of wild-type, AK1-/- (homozygous) 
and AK1+/- (heterozygous) mice. AK1 and creatine kinase (CK) isoenzymes were separated by
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at 2 Hz, the ATP/ADP and ADP/AMP ratios were 5.6 ± 0.2 versus 6.7 ± 0.4 (p<0.05; «=6), 
and 9.3 ± 0.8 versus 5.4 ± 0.2 (p<0.001; n=6) in AK1-- deficient and wild-type, respectively 
(Fig. 3). This suggests that AKl-deficient muscle has a lower potential to sustain nucleotide 
ratios during functional load.
B-ATP
WT AK1-KO
Figure 2 . Absence o f AK -phosphotransfer in AK1-knockout skeletal muscle. p-ATP phosphoryl 
oxygens replaced with 18O, as an indicator of AK-catalyzed phosphotransfer, in wild-type (WT, n=6) 
and AK1-knockout (AK1-KO, n=6) GPS muscle.
AK-produced AMP is metabolized to IMP by AMP deaminase (AMPD), a critical 
enzyme in the adenine nucleotide cycle (24). The maximal activity of AMPD was lower in 
AK1-- gastrocnemius compared to wild-type (214 ± 23 versus 330 ± 30 ^mol-min-1-g-1 
muscle, respectively; p<0.02; n=5). Western blot analysis of the AK1- - gastrocnemius showed 
a 50% reduction in the expression of the 80 kDa AMPD protein (p<0.01) compared to wild­
type (not illustrated). Thus, although adenine nucleotide levels are maintained in AK1- 
deficient muscle, the dynamics of adenine nucleotide metabolism catalyzed by nucleotide 
metabolizing and/or phosphotransfer enzymes may be altered upon deletion of AK1.
d D  WT 
^ A K l-K O
ATP/ADP ADP/AMP
Figure 3 . Adenine nucleotide ratios in AK 1-knockout skeletal muscle. ATP/ADP and ADP/AMP 
ratios measured in wild-type (n=6) and AK1-knockout (n=6) GPS muscle paced for 3 min at 2 Hz.
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Creatine kinase in AK1-knockout skeletal muscle
Along with AK, creatine kinase (CK) provides a major pathway for regulation of 
nucleotide ratios and energy transfer (4, 20, 31, 32). Wild-type and AK1-deficient GPS 
muscle extracts contained essentially equal levels of creatine phosphate (CrP), 50.4 ± 3.0 
(«=6) and 47.8 ± 3.2 (n=6) nmol CrPm g protein-1, respectively. Moreover, in vivo changes in 
CrP levels, measured by 31P NMR spectroscopy, during metabolic transitions exhibited 
similar profiles in wild-type and AK1-/- hind leg muscles (Fig. 4A). However, in AK1- 
knockout GPS, the percentage of CrP 18O labeling was 21.9 ± 1.7 (n=6) compared to 15.8 ±
1.3 (n=6) in the wild-type (p<0.05; Fig. 4B) indicating increased turnover of substrates in the 
CK catalyzed reaction. This translated into moderate increase in net CK-catalyzed 
phosphotransfer flux (13.9 ± 1.4 and 16.5 ± 1.1 nmol CrPm in-1mg protein-1 in wild-type and 
AK1-knockout, respectively). Thus, while CrP is maintained at wild-type level in the AK1- 
knockout skeletal muscle, the relative CK-catalyzed CrP turnover appears increased upon 
deletion of AK1.
0 10 20 30 40 50 60 WT AK1-KO
Time (min)
Figure 4. Creatine phosphate levels and creatine kinase phosphotransfer in AK1-knockout 
skeletal muscle. A. Levels of creatine phosphate (CrP) in wild-type and AK1-/- mice analyzed by 31P 
NMR, and expressed as resonance peak heights normalized to the mean value of the p-ATP intensity 
of the first four spectra. Series were recorded every 108 seconds (90° pulses) before, during and after 
ischemia of the lower hind limb muscles in wild-type (dashed line, open squares) and AKI-deficient 
(solid line, closed triangles) mice. After four reference spectra, an ischemic period of 25 min (shaded 
area) was introduced following 16 min-recovery. B. Increased creatine kinase-catalyzed CrP turnover 
in AKI-knockout muscle. Percentage of CrP-phosphoryl oxygens replaced with 18O, as an indicator of 
creatine kinase-catalyzed phosphotransfer, in wild-type (n=6) and AK1-knockout (n=6) GPS muscle 
determined by mass spectrometry.
Glycolytic phosphotransfer and glycolytic intermediates in AK1-knockout muscle
AK phosphotransfer is coupled to glycolysis and regulates the activity of ATP- and 
AMP-sensitive glycolytic enzymes (26, 33). In turn, glycolysis also serves a high-energy
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phosphoryl transfer function in parallel with AK and CK (32). Here, deletion of AK1 affected 
glycolyticphosphotransfer, as well as levels of glycolytic intermediates.
Time (min)
c. PME
Time (min)
Figure 5. A. Increased hexokinase-catalyzed glucose-6-phosphate turnover in AK1-knockout muscle. 
Glucose-6-phosphate phosphoryl oxygens replaced with 18O, as an indicator of glycolytic 
phosphotransfer, in wild-type (n=6) and AK1-knockout (n=6) GPS muscle. B-C. Intracellular pH (B) 
and phosphomonoester (PME) levels (C) in wild-type (WT) and AK1-/" mice analyzed by 31P NMR, and 
expressed in pH units or as resonance peak heights normalized to the mean value of the p-ATP 
intensity of the first four spectra. Series were recorded before, during and after ischemia of the lower 
hind limb muscles in wild-type (dashed line, open squares) and AK1-deficient (solid line, closed 
triangles) mice. After four reference spectra, an ischemic period of 25 min was introduced following 16 
min-recovery. Note a faster pH drop and increased PME levels during the ischemic period in AK1'/_ 
compared to wild-type mice.
Glycolytic phosphotransfer was assessed by hexokinase-catalyzed incorporation of 18O 
into glucose-6-phosphate (G-6-P), which increased from 8.4 ± 0.3 («=6) in wild-type to 11.2 ± 
0.6 (n=6) in AK1-knockout muscle (p<0.05) at a labeling rate of respectively 6.6 ± 0.3 and 
15.1 ± 0.5 nm olm in-1mg protein-110-1 (p<0.01; Fig 5A). The estimated net glycolytic flux 
was increased from 1.31 ± 0.06 to 3.00 ± 0.09 nmol G-6-Pmin-1mg protein-1 in wild-type and 
AK1-knockout muscle, respectively (p<0.01). Increased glycolytic flux was accompanied by
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higher muscle levels of G-6-P (7.8 ± 1.0 and 13.6 ± 1.6 nmol-mg protein"1 in wild-type and 
AKl-knockout, n=6; p<0.001) and lactate (8.3 ± 0.7 and 12.6 ± 2.1 nm olm g protein-1 in wild­
type and AK1-knockout, n=6; p<0.001). Alterations in glycolytic metabolism were further 
assessed in vivo by monitoring phosphomonoester (PME) containing glycolytic intermediates 
and intracellular pH by 31P NMR spectroscopy. Ischemia induced a faster muscle acidification 
in AK1-mutant mice (Fig. 5B), suggesting that the block in B-phosphoryl exchange between 
ADP and ATP is associated with accelerated anaerobic glycolysis and production of lactate. 
Moreover, the increase in PME levels was significantly more pronounced in AK1-deficient 
mutant mice (Fig. 5C). This increase in the intracellular concentration of glycolytic 
intermediates, along with increased G-6-P turnover, indicates elevated glycolytic metabolism 
in AK1-knockout muscle.
Guanine nucleotide metabolism in A K l-knockout skeletal muscle
Adenine nucleotide metabolism is coupled to guanine nucleotide metabolism through 
the nucleoside diphosphate kinase (NDPK) catalyzed phosphotransfer (34). There is an 
important link between GTP production by substrate level phosphorylation in the Krebs cycle 
and ATP production in mitochondria. AK1-deficient muscle had a 50% higher intracellular 
GTP concentration compared to wild-type, 0.75 ± 0.06 versus 0.43 ± 0.02 nmol mg protein-1, 
respectively (p<0.001; n=6). Also, the GDP concentration was 17% higher in AK1- - muscle 
compared to wild-type, 0.20 ± 0.02 nm olm g protein-1 and 0.16 ± 0.004 nm olm g protein-1, 
respectively (p<0.03; n=6). This resulted in higher muscle levels of guanine nucleotides (GTP 
plus GDP) in AK1- - compared to wild-type, 0.95 ± 0.07 versus 0.59 ± 0.02 nmol mg protein-1, 
respectively. Also, the GTP/GDP ratio was elevated in AK1-knockout muscle compared to 
wild-type, 3.7 ± 0.2 versus 2.7 ± 0.1, respectively (p<0.003; n=6, Fig. 6A). Concomitantly, the 
ATP/GTP ratio was lower in AK1-- muscle compared to wild-type (38 ± 1 and 61 ± 2; 
p<0.001; n=6), indicating increased guanine nucleotide contribution to muscle energetics (Fig. 
6A). The NDPK activity, however, was unaltered in AK1- - gastrocnemius (19.9 ± 1.5 -103 
RLU min-1mg protein-1; n=3) compared to wild-type (21.4 ± 1.7 -103 RLU-min-1-mg-1 protein; 
n=3). To assess the dynamics of guanine nucleotide metabolism, the rate of 18O phosphoryl 
labeling of y and P-GTP/GDP were determined (Fig. 6B). In AK1- - GPS, the percentage of y- 
GTP 18O labeling was 26.4 ± 1.6 (n=6), significantly higher than 18.5 ± 0.5 (n=6) measured in 
the wild-type (p<0.05; Fig. 6B). Such increase in y-GTP turnover indicates that phosphoryl 
flux through enzymes catalyzing GTP production, such as succinyl-CoA synthase of the 
Krebs cycle and/or NDPK, is elevated following deletion of the AK1 gene. NAD+ levels were 
significantly higher in freshly isolated AK1-- muscle (n=5) compared to wild-type (n=5), 3.4 
± 0.2 versus 2.8 ± 0.6 nmol-mg protein-1, respectively (p<0.02). Moreover, the NAD/NADH 
ratio was higher in in vitro incubated AK1-deficient muscle, 1.1 ± 0.1 versus 0.7 ± 0.1 for the 
wild-type (p<0.01; n=6), suggesting elevated aerobic Krebs cycle metabolism. The AK analog 
in guanine nucleotide metabolism, guanylate kinase catalyzes P-GTP/GDP turnover providing 
energy from P-phosphoryls. The percentage of combined P-GTP/GDP 18O labeling was 2.5 ±
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0.1 (n=6) and 4.6 ± 0.2 (n=6) in wild-type and AK1-knockout GPS, respectively (p<0.001; 
Fig. 6C). This indicates that guanylate kinase-catalyzed phosphotransfer is up-regulated in the 
AK1-knockout muscle. Thus, production and utilization of guanine nucleotides is increased 
following disruption of AK1-catalyzed phosphotransfer.
GTP/GDP ATP/GTP WT AK1-KO
WT AK1-KO
Figure 6 . Guanine nucleotide m etabolism  in AK 1-knockout skeletal muscle. A. The GTP/GDP 
and ATP/GTP ratios were measured in wild-type (n=6) and AKl-knockout (n=6) GPS muscle paced for 
3 min at 2 Hz. B. Increased y-GTP phosphate turnover in AKl-knockout skeletal muscle. Percentage 
of y-GTP phosphoryl oxygens replaced with 18O, as an indicator of enzyme activity catalyzing GTP 
production, in wild-type (n=6) and AKl-knockout (n=6) GPS muscle. C. Increased guanylate kinase- 
catalyzed phosphotransfer in AKl-knockout skeletal muscle. Percentage of p-GTP/GDP phosphoryl 
oxygens replaced with 18O, as an indicator of guanylate kinase phosphotransfer, in wild-type (n=6) and 
AKl-knockout (n=6) GPS muscle.
Reduced energetic efficiency of contractile perform ance in A K l-knockout muscle
During evolution muscles have developed an efficient energy transduction, transfer 
and utilization system in order to consume a minimum amount of ATP per contraction (1, 35­
37). AK, by its ability to transfer and provide the energy of both p and y phosphoryls of ATP, 
has been considered an important enzyme in maintaining cellular energetic economy (9, 12). 
To assess whether AK1 gene deletion affected muscle energetic efficiency, muscle 
performance and ATP turnover rate were determined. AK1-deficient gastrocnemius had an 
isometric (twitch and tetanic) force production equivalent to that of the wild-type (Table I).
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Also, muscle speed was not different between groups, as indicated by a similar maximal rate 
of force development, half-relaxation time and maximal shortening velocity (Table I). 
Repeated isometric contractions resulted in a similar decrease in the rate and amplitude of 
force generation in wild-type and mutant muscle (Table I). Thus, the overall contractile 
performance of an AK1-deficient muscle appears rather normal.
Table 1. Contractile properties of medial gastrocnemius muscles from wild-type and AK1'/_ mice.
Control AK1--
(n=11) (n=9)
Twitch Force (N) 0.29 ± 0.06 0.30 ± 0.07
Tetanic Force (N) 1.49 ± 0.23 1.47 ± 0.32
Tetanic/twitch ratio 5.10 ± 0.94 4.78 ± 0.94
Maximal rate of force rise 
(%F max/ms)
3.32 ± 0.69 3.54 ± 0.79
Half-relaxation time (ms) 8.4 ± 2.1 8.7 ± 2.1
Maximal shortening velocity 97.2 ± 1.8 95.6 ± 18.5
(mm/s) (n=5) (n=5)
Fatigue index (%)
68.3 ± 6.6 
(n=7)
67.8 ± 10.0 
(n=8)
Data are mean ± S.D. for the number (n) of muscles indicated. Fatigue index: force at the end of 
exercise as percentage of initial force.
However, y-ATP 18O-labeling, reflecting muscle energy transduction rate, was significantly 
increased from 14.1 ± 0.9% («=6) in the wild-type to 18.4 ± 0.5% in AK1-mutant muscle 
(n=6; p<0.002; Fig. 7A). Furthermore, the total cellular ATP turnover, determined from 18O 
incorporation into major high-energy phosphoryls, including y/p-ATP, creatine phosphate 
(CrP), inorganic phosphate, glucose-6-phosphate, and y/p-GTP/GDP, was significantly 
increased from 21.6 ± 0.9 nm olm in-1mg protein-1 in wild-type (n=6) to 26.3 ± 1.2 nm olm in-1 
mg protein-1 in AK1-knockout (n=6) GPS, respectively (p<0.02; Fig. 7B). Thus, the overall 
ATP production and utilization was elevated in AK1-knockout muscle. This translates into an 
increased ATP consumption per  contraction from 180 ± 2 pmol ATP mg protein-1 in the wild­
type to 219 ± 1 pmol ATP mg protein-1 in AK1-knockout muscles contracting at 2 Hz 
(p<0.02; n=6). Such rise in the energetic cost of contraction, by 22%, indicates reduced 
efficiency of cellular energetics in the absence of AK1-catalyzed phosphotransfer.
A berran t redistribution of phosphotransfer flux and increased energy expenditure in 
A K l-knockout muscle during hypoxic stress
Metabolic stress induces redistribution of phosphotransfer in skeletal muscle (26). AK 
function is believed to increase under stress to regenerate ATP and maintain muscle energetic
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A. B.
Figure 7 . Increased ATP turnover in AK1-knockout skeletal muscle. A. Increased y-ATP 
phosphate turnover in AK1-knockout GPS. Percentage of y-ATP phosphoryl oxygens replaced with 
18O, as an indicator of ATP synthesis rate, in wild-type (n=6) and AK1-knockout (n=6) GPS muscle. B. 
Increased ATP turnover in AK1-knockout skeletal muscle. Total ATP turnover, obtained from 18O 
incorporation into major high-energy phosphoryls, in wild-type (n=6) and AK1-knockout (n=6) GPS 
muscle.
efficiency (8, 27). Here, the contribution of AK-mediated phosphotransfer to total cellular 
ATP turnover increased from 20 ± 2% to 52 ± 5% in response to hypoxia (2 mM KCN 
treatment) in wild-type GPS (Fig. 8A). In AK1-knockout muscle, AK phosphotransfer was 
modestly increased during hypoxia, and contributed 2 ± 1% to total cellular ATP turnover 
(Fig. 8A). With hypoxia, the contribution of CK-catalyzed phosphotransfer to 
intracellularenergetics decreased from 64 ± 7% to 34 ± 4% in wild-type, and from 63 ± 5% to 
47 ± 4% in AK1-knockout GPS (Fig. 8B). Thus, wild-type GPS responds to hypoxic stress by 
a decrease in CK-mediated phosphotransfer associated with increased AK-flux. Deletion of 
AK1 produces aberrant redistribution of phosphotransfer flux in hypoxic muscle, with a 
blunted AK response and an apparently higher contribution of CK. In wild-type skeletal 
muscle the sum of AK- and CK-catalyzed phosphotransfers was essentially not changed in 
normoxia versus hypoxia, at 84 ± 7% and 86 ± 4% of total cellular ATP turnover, respectively 
(Fig. 8C). However, in AK1-knockout GPS the contribution of AK- and CK-catalyzed 
phosphotransfer to total ATP turnover was significantly lower than in normoxic wild-type 
muscle (63 ± 5%; p<0.001; «=6), and was even further reduced under hypoxia (49 ± 5%; 
p<0.001; n=6; Fig. 8C). This aberrant redistribution of phosphotransfer in AK1-- muscle 
translated into a more pronounced difference in total ATP turnover compared to the wild-type, 
22.0 ± 1.2 versus 16.8 ± 1.2 nm olm in-1mg protein-1, respectively (p<0,02; n=6; Fig. 8D). 
Thus, in response to hypoxia, in the wild-type muscle total ATP turnover was reduced by 19% 
while only by 10% in the AK1-knockout. Therefore, under hypoxia, the AK1-deficient muscle 
had a higher energy expenditure, by 31%, compared to normal muscle.
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DISCUSSION
Efficient cellular energetics is a critical determinant of muscle performance, and thus 
an evolutionary necessity for species survival (35, 36). Here, we provide first evidence that 
disruption of AK-catalyzed phosphotransfer by gene deletion leads to overt reduction in 
energetic efficiency of contractile performance associated with metabolic remodeling in 
glycolytic, creatine kinase and guanine nucleotide phosphotransfer systems. Thus, 
phosphotransfer reactions are an integral component of cellular energetics required for 
nucleotide homeostasis, optimal high-energy phosphoryl transfer and efficient ATP 
utilization.
Although the molecular structure and kinetic properties of the AK protein have been 
established (10, 38), the biological significance of AK catalysis in a living cell has remained 
poorly understood. Here, deletion of AK1 was associated with dramatic reduction in total 
muscle AK activity and lack of P-phosphoryl turnover, providing definite evidence that P- 
phosphoryl transfer is an exclusive property of AK catalysis, which cannot be supported by 
other phosphotransfer reactions.
Throughout evolution, AK has been highly conserved and implicated in de novo 
adenine nucleotide synthesis and equilibration (9). In yeast, absence of mitochondrial AK 
activity compromises export of ATP from mitochondria (39), and generalized AK mutation 
can be lethal due to uncompensated disruptions in P-phosphoryl energetics and adenine 
nucleotide synthesis (40). Here, in AK1-knockout muscle, ATP and total adenine nucleotide 
levels were rather preserved. Thus, the marginal AK-like activity that remains in AK1- 
knockout muscle is probably sufficient to support adenine nucleotide synthesis (30). However, 
AK1-deficient muscle was unable to sustain ATP/ADP and ADP/AMP ratios underscoring the 
importance of AK in regulating adenine nucleotide metabolism.
Through NDPK and guanylate kinase, adenine nucleotide metabolism is coupled to 
guanine nucleotide metabolism, which in turn serves a critical role in signal transduction (34). 
In fact, metabolic consequences induced by NDPK deficiency can be in part compensated 
through AK (41). Although NDPK activity was not notably changed, guanylate levels as well 
as guanine nucleotide P- and y-phosphoryl turnover were significantly increased in AK1-- 
muscle. This increase in guanine nucleotide turnover could compensate for about 10% of lost 
adenine nucleotide P-turnover, indicating that metabolic flux through guanine nucleotide- 
dependent Krebs cycle reactions and guanylate kinase are altered following deletion of the 
AK1 gene. In fact, increased y18O GTP labeling in AK1-knockout muscle was associated with 
increased activity of succinyl CoA synthetase, a Krebs cycle enzyme that couples cleavage of 
succinyl CoA to phosphorylation of GDP and contributes to labeling at the y-phosphoryl 
position in GTP (25). Also, altered mitochondrial NAD+/NADH ratios suggest elevated Krebs 
cycle activity and increased mitochondrial involvement in AK1- - muscle. EM-ultrastructural 
analysis of fast-twitch fibers confirmed that these metabolic changes are paralleled by an 
increase in mitochondrial volume (not shown). Taken together, the observed increase in
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steady-state levels of guanine nucleotides and their metabolic dynamics upon disruption of 
adenine nucleotide homeostasis suggest an increased contribution of guanine nucleotides in 
AK1-knockout muscle.
Figure 8 . Aberran t red is tribu tion  o f phosphotransfer flu x  in AK 1-knockout skeletal m uscle in 
response to  hypoxia. A. Hypoxia markedly elevates AK-catalyzed flux in wild-type, but not in AK1- 
knockout GPS. AK-catalyzed phosphotransfer, expressed as percentage of total cellular ATP turnover, 
in wild-type (n=6) and AK1-knockout (n=6) GPS muscle. B. Increased contribution of creatine kinase- 
catalyzed phosphotransfer in hypoxic AK1-deficient compared to hypoxic wild-type GPS. Creatine 
kinase-catalyzed phosphotransfer, expressed as percentage of total ATP turnover, in wild-type (n=6) 
and AK1-knockout (n=6) GPS muscle. C. Contribution of combined AK-and creatine kinase-catalyzed 
phosphotransfer to cellular ATP turnover is reduced in normoxic and hypoxic AK1-knockout GPS. Sum 
of AK- and creatine kinase-catalyzed phosphotransfer is expressed as percentage of total ATP 
turnover measured by the 18O-phosphoryl labeling technique. D. ATP turnover rates in wild-type and 
AK1-knockout GPS under hypoxia. Hypoxia was induced by KCN (2 mM), an inhibitor of mitochondrial 
respiration.
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In many cell types, AK-catalyzed phosphotransfer is interrelated with CK and 
glycolytic phosphotransfer systems (12, 21). In insulin-secreting pancreatic P-cells, increased 
glycolytic and CK flux, which occurs in response to elevated extracellular glucose, results in 
suppression of AK-catalyzed phosphotransfer (3, 14). Conversely, in skeletal muscle, 
inhibition of CK and/or glycolysis results in marked increase in AK-catalyzed 
phosphotransfer (27). Here, deletion of AK1 induced adaptive changes in CK-catalyzed 
phosphotransfer and up-regulation of high-energy phosphoryl flux through glycolytic 
metabolism. Specifically, the glycolytic flux rate more than doubled, and was accompanied by 
a similar increase in the concentrations of glycolytic intermediates, such as glucose-6-P and 
lactate. Similarly, levels of phosphomonoester compounds (glycerol phosphate, G-1-P and G-
6-P), measured in vivo in ischemic AK1- - muscle, were twice as high as in the wild-type, and 
were accompanied by faster accumulation of lactate and faster drop in intracellular pH. 
Although CrP levels were maintained, CK-catalyzed phosphotransfer was moderately 
increased in AK1-- muscle compared to the wild-type. Thus, the AK1-knockout muscle adapts 
to the lack of AK1-catalyzed phosphotransfer through up-regulation of glycolytic, along with 
CK and guanine nucleotide phosphotransfer systems.
This in accord with previous studies with CK-knockout mice which also indicate a 
high plasticity of muscle energetic systems in adapting to genetic disruption of an energy 
supply pathway (4, 27, 31, 42). However, despite metabolic and cytoarchitectural adaptation, 
deletion of the M-CK and/or ScCKmit CK isoforms resulted in abnormal muscle contractile 
response, intracellular Ca2+-handling, and mitochondrial respiration (4, 43). Moreover, in 
heart muscle deletion of CK genes reduced the ability to sustain adenine nucleotide ratios, and 
rendered cardiac work more 'energetically costly' in terms of high-energy phosphate use, and 
decreases in free energy released from ATP hydrolysis (7). Here, we demonstrate that AK1- 
deficient muscles exhibit a higher rate of 18O y-phosphoryl labeling and total ATP turnover. 
As the overall level of phosphoryl containing metabolites was not significantly changed upon 
deletion of AK1, this indicates that the energetic efficiency of AK1-knockout muscle is lower 
than that of wild-type.
AK1-deficient muscles did not exhibit any apparent deviation in contractile and 
fatigue performance compared to control muscle suggesting that the same work output can be 
generated in both muscles. However, the AK1-knockout muscle did consume a larger amount 
of ATP per  contraction indicating lower energetic efficiency of muscle performance following 
AK1 deletion. Metabolic stress, which is associated with aberrant redistribution of 
phosphotransfer flux, further aggravated the energetic cost in an AK-deficient muscle, 
providing evidence for the crucial role of AK in optimal cellular energy allocation.
In conclusion, loss of AK-supported P-phosphoryl energetics disrupts adenine and 
guanine nucleotide homeostasis and associated metabolic circuits (i.e. the AMP deaminase 
reaction) and results in redistribution of energy flow, through alternative glycolytic and CK 
phosphotransfer systems. Such metabolic plasticity of myocytes provides an apparent 
compensatory potential that limits cellular energetic failure and preserves muscle contractile
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performance. However, intracellular metabolic rearrangement is not sufficient to sustain 
energetic economy in AKl-deficient muscle, in particular under metabolic stress, suggesting a 
specific energetic function for AK. Thus, this study provides new evidence that 
phosphotransfer reactions in general, and adenylate kinase in particular, are essential for 
cellular energetic economy, enabling skeletal muscle to perform with high thermodynamic 
efficiency under physiological and pathophysiological conditions.
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AK1 deficient heart under metabolic stress
ABSTRACT
Rapid exchange of high-energy carrying molecules between different intracellular 
compartments is essential in sustaining cellular energetic homeostasis. Adenylate kinase (AK) 
catalyzes transfer of adenine nucleotideß- and y-phosphoryls, and has been implicated in 
facilitating intracellular energy communication and regulating nucleotide metabolism. 
However, direct evidence demonstrating the biological significance of this phosphotransfer 
enzyme is still lacking. Here, the AK1 gene encoding the major AK isoform was disrupted by 
a targeted replacement mutation, and energetic dynamics in AK1-knockout hearts determined 
by 18O-phosphoryl oxygen analysis using 31P NMR and mass spectrometry. In AK1-knockout 
hearts, total AK activity and ß-phosphoryl transfer was reduced by 94% and 36%, 
respectively which was associated with an apparent compensatory up-regulation of 
phosphoryl flux through remaining minor AK isoforms and the glycolytic phosphotransfer 
enzyme, 3-phosphoglycerate kinase. In the absence of metabolic stress, deletion of AK1 did 
not translate into gross abnormalities in nucleotide levels, y-ATP turnover rate or creatine 
kinase-catalyzed phosphotransfer. However, under hypoxia AK1-deficient hearts, compared 
to the wild-type, had a blunted AK-catalyzed phosphotransfer response, lowered intracellular 
ATP levels, increased Pi/ATP ratio and suppressed generation of adenosine. Thus, although 
lack of AK1-phosphotransfer can be compensated in the absence of metabolic challenge, 
under hypoxia AK1-knockout hearts display compromised energetics and impaired 
cardioprotective signaling. This study, therefore, provides first direct evidence that AK1 is 
essential in maintaining myocardial energetic homeostasis, in particular under metabolic 
stress.
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INTRODUCTION
Adenylate kinase (AK) catalyzes reversible phosphotransfer, 2 ADP o  AMP + ATP, 
and participates in de novo synthesis, regeneration and salvage of adenine nucleotides (1-5). 
AK is particularly abundant in tissues with high-energy turnover, where it facilitates transfer 
of energy-rich P- and y-phosphoryls and regulates vital ATP-dependent cellular processes (6­
10). In fact, AK may serve as an integral component of phosphotransfer networks, along with 
creatine kinase (CK) and glycolysis, effectively coupling ATP-generating with ATP- 
consuming or ATP-sensing intracellular sites (11-15).
In the heart, CK-catalyzed phosphotransfer is the major pathway that can transfer 
high-energy phosphoryls derived from the y-phosphoryl of ATP (10, 16-18). Although less 
active than CK, AK catalysis provides a unique mechanism for transfer and utilization of both 
Y- and P-phosphoryls in the ATP molecule (10, 15). In this way, AK-catalyzed 
phosphotransfer doubles the energetic potential of ATP, and could provide an additional 
energetic source under conditions of increased energy demand (10, 19). However, due to lack 
of membrane permeant and selective AK inhibitors, the biological importance of AK in heart 
muscle and its role in sustaining myocardial energetics under conditions of metabolic stress 
have not been established.
We have recently demonstrated that deletion of the AK1 gene, which encodes the 
major AK isoform, produces a phenotype with reduced skeletal muscle energetic economy 
despite multiple metabolic adaptations (20). Here, the contribution of AK1-catalyzed 
phosphotransfer to cardiac energetics was determined using AK1-deficient hearts. Cellular 
energetics and phosphotransfer kinetics, under normal and hypoxic conditions, were 
monitored using a newly developed technique based on 18O-phosphoryl labeling in 
conjunction with 31P NMR and mass spectrometry. In AK1-knockout hearts, we report a 
significantly compromised adenine nucleotide P-phosphoryl transfer. While lack of AK1 
appears to be compensated under normal conditions, under hypoxic stress AK1-deficient 
hearts have a reduced ability to sustain intracellular energetics and cardioprotective signaling. 
This study demonstrates that AK1-catalyzed phosphotransfer is essential in the maintenance 
of myocardial energetic homeostasis.
MATERIALS AND METHODS 
AK1-knockout mice
Gene-targeted mice were derived from mouse ES cells carrying a replacement 
mutation in the AK1 gene using established procedures (12, 13). Complete inactivation of 
AK1 expression was achieved by homologous DNA recombination, with a HygroB-cassette 
vector used to replace the entire exon 3-5 region in the AK1 gene (Fig. 1A) as described in 
detail elsewhere (20). In this way, homozygous AK1-deficient (AK1--) mice were generated 
and their hearts compared with those of age-matched wild-type controls (50%-50%
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C57BL/6x129/Ola mixed inbred background mice). The investigation conformed to the 
Guidelines fo r  the Care and Use o f  Laboratory Animals of the Dutch Council and the 
National Institutes of Health, and was approved by the Institutional Animal Care and Use 
Committee at the Mayo Clinic and the University of Nijmegen.
Heart isolation
Wild-type and AK1-knockout mice (40-50 g) were heparinized (250 U ip), and 
anesthetized with pentobarbital (100 mg/kg ip). Hearts were rapidly excised, washed from 
blood and used immediately for 18O-phosphoryl-labeling or freeze-clamped in liquid N2 for 
enzymatic analysis.
Western blot and zymogram analysis
Homogenates from freshly excised hearts (10% w/v) were prepared in SETH buffer 
(250 mM sucrose, 2 mM EDTA, 10 mM Tris-HCl, pH 7.4) at 4°C. Heart extracts were diluted 
1:1 in 30 mM Na3PO4 buffer (pH 7.4), containing 0.05% v/v Triton X-100, 0.3 mM 
dithiothreitol and a complete protease inhibitor cocktail (Boehringer Mannheim). For Western 
blot analysis, extracted proteins were separated on 10% SDS-polyacrylamide gels and 
proteins electrophoretically transferred onto nitrocellulose membranes. AK1 and CK-M 
proteins were detected using anti-mouse AK1 and CK-M antibodies raised in rabbit against 
synthetic peptides of corresponding proteins. Immunocomplexes were visualized by 
chemiluminescence using goat anti-rabbit immunoglobulin G coupled to horse raddish 
peroxidase. For zymogram analysis, extracts were centrifuged for 20 min at 11,000 g, and 
aliquots (1-5 .^l) applied to agarose gels. AK1 and CK isoenzymes were separated 
electrophoretically and stained for enzyme activity (13).
Phosphotransfer rates
AK and CK catalyzed phosphotransfers were measured in intact cardiac muscle using 
the 18O-phosphoryl-labeling technique (10). This procedure is based on the incorporation of 
one 18O atom, provided from 18O-water, into inorganic phosphate (Pi) with each act of ATP 
hydrolysis and the distribution of 18O-labeled phosphoryls among high-energy phosphoryl- 
carrying molecules depending on the following reactions: 
yATP + 18O H2O ^  18O Pi + ADP (ATP hydrolysis)
18O Pi + ADP ^  18O yATP (ATP synthesis)
18O yATP + Cr ^  18O CrP + ADP (CK-catalyzed phosphotransfer)
18O yATP + AMP ^  18O pADP + ADP ^  18O pATP +AMP (AK-catalyzed phosphotransfer) 
Up to three 18O atoms can be incorporated in phosphoryls of yATP, pATP and creatine 
phosphate (CrP), while a maximum of four 18O atoms can be incorporated into Pi.
I8O-phosphoryl-labeling. Isolated hearts were superfused with Krebs-Henseleit (KH) 
buffer (in mM: NaCl 137; KCl 5; CaCl2 2; MgCh 1; EDTA 0.05; NaH2PO4 1; HEPES 20; 
glucose 5; NaHCO3 24; pH 7.45) saturated with 95% O2/5% CO2, and paced at a constant rate
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of 2 Hz using platinum electrodes. Under this condition, due to a small size and thin walls, 
hearts continuously beat and preserve intracellular adenine nucleotide ratios throughout the 
duration of experiments (21; see also Fig. 2A). In control protocols, hearts were incubated for 
3 min in KH buffer then transferred for an additional 3 min to a KH buffer supplemented with 
20% of 18O-containing water. In hypoxia-simulated protocols, the mitochondrial cytochrome c 
oxidase inhibitor KCN (2 mM) was added to buffers. At the 6 min-point, hearts were freeze- 
clamped, pulverized in mortar with liquid N2, and extracted in a solution containing 600 mM 
HClO4 and 1 mM EDTA. Proteins were pelleted by centrifugation (15.000 g, 10 min) and 
protein content determined with a DC Protein Assay kit (Bio-Rad). Extracts were neutralized 
with 2 M KHCO3, and used for determination of 18O labeling by 31P NMR spectroscopy and 
mass spectrometry.
31P  NM R spectroscopy. 18O incorporation in y-phosphoryl of ATP or phosphoryls of 
CrP was measured by 31P NMR spectroscopy. 18O incorporation induces an isotope shift in the 
31P NMR spectrum, and is used to study enzymatic reactions in vitro (22). Based on this 
principle, we here developed a novel approach to monitor phosphotransfer kinetics in intact 
heart muscle. Perchloric-acid extracts were pre-cleaned with Chelex 100 resin (Sigma), 
supplemented with 2 mM EDTA and methylene diphosphonate (MDP). Samples, 
concentrated by vacuum-centrifugation to obtain higher NMR signals, were supplemented 
with deuterium water (10%). 31P NMR spectra were recorded at 202.5 MHz on a Bruker 11 T 
spectrometer (Avance) in 5 mm tubes at 5°C. In hearts superfused with regular, 16O- 
containing, media CrP appears as a single peak in the NMR spectrum (Fig. 1B, left panel). In 
18O-containing media, CK-catalyzed incorporation of 18O into CrP results in the appearance of 
18O1 and 18O2 phosphoryl species (Fig. 1B, right panel). As a consequence, the CrP 31P NMR 
signal is split into 3 peaks corresponding to 16O, 18O1 and 18O2 phosphoryl species (Fig. 1B, 
right panel). At 20% of 18O-containing water, a fourth peak, corresponding to 18O3 phosphoryl 
species, was usually at the limit of detection. Isotope shifts were also observed following 
incorporation of 18O into phosphoryls of yATP. Percentages of 16O, 18O1, 18O2 and 18O3 
phosphoryl species in yATP and CrP were proportional to the integrals of respective lines in 
the NMR spectrum. The cumulative percentage of phosphoryl oxygens replaced by 18O in 
yATP and CrP was calculated as [%18O 1 + 2(%18O2) + 3(%18O3)]/[3(% 18O x H2O)] (8). In 
addition to 18O-incorporation into CrP, ß-ATP or y-ATP, 31P NMR 18O-phosphoryl-labeling 
permits simultaneous measurements of tissue levels of Pi, CrP and ATP. 18O-phosphoryl- 
labeling values for y-ATP obtained by 31P NMR correlated well (r=0.94) with those obtained 
by mass spectrometry. Although the 31P NMR 18O-phosphoryl-labeling technique is faster 
than mass spectrometry, its lower sensitivity precludes reliable monitoring of relatively slower 
18O-labeling of ß-ATP under our experimental conditions. Therefore, 18O-phosphoryl-labeling 
of ß-ATP was determined by mass spectrometry.
M ass spectrometry. Incorporation of 18O into ß-phosphoryls of ATP was determined 
by mass spectrometry using established procedures (10, 19). ATP from heart extracts was 
purified and quantified by high-performance liquid chromatography (HPLC System Gold,
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Beckman) using a Mono Q HR 5/5 ion-exchange column (Pharmacia). Elution was 
accomplished using a linear gradient of triethylammonium bicarbonate (TEAB) buffer (pH 
8.8) from 1 to 950 mM. The ß-phosphoryl of ATP was transferred to glycerol by a combined 
catalytic action of AK and glycerokinase. Samples that contained phosphoryls of ß-ATP, as 
glycerol 3-phosphate, were converted to a respective trimethylsilyl derivative using TRI- 
SIL/BSA (Pierce) as the derivatization agent. 18O-enrichment of phosphoryls in glycerol 3- 
phosphates was determined with a Hewlett-Packard 5973 gas chromatograph-mass 
spectrometer operated in the select ion-monitoring mode. Specifically, mass ions (m/z) of 357, 
359, 361 and 363 that correspond to phosphoryl species of 18O0, 18O1, 18O2 and 18O3 were 
determined. The cumulative percentages of phosphoryl oxygens replaced by 18O in ß-ATP 
were calculated as described above.
Metabolite levels. Adenosine, AMP, ADP and ATP were purified and quantified with 
HPLC (10). The levels of ATP, CrP and Pi were determined using 31P NMR spectroscopy 
comparing respective peak areas with peak area of 250 nmol MDP used as an internal 
standard (23).
Enzyme activity
Frozen samples were powdered in liquid N2 with mortar and pestle and extracted with 
150 mM NaCl, 60 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.2% Triton X-100, 1 mM PMSF, 
10 ^g/ml leupeptin and 1 ^g/ml aprotinin. Extracts were centrifuged (10 min, 8,000 g, 4°C), 
and enzyme activities measured using coupled enzyme assays with a Beckman DU 7400 
spectrophotometer at 340 nm. The activity of CK was measured with a commercial kit (47-20, 
Sigma). The activity of AK was measured in 100 mM potassium acetate, 10 mM HEPES (pH 
7.5), 20 mM glucose, 4 mM MgCl2 , 2 mM NADP+, 2 mM ADP, 2 mM EDTA, 2 mM 
dithiothreitol, 4.5 U/ml hexokinase, and 2 U/mL glucose-6-phosphate dehydrogenase (10, 15). 
The activity of 3-phosphoglycerate kinase (PGK) was measured using a reaction mixture 
containing 50 mM imidazole buffer (pH 7.6), 2 mM MgCl2, 0.1 mM EDTA, 1 mM ATP, 5 
mM 3-phosphoglycerate, 0.2 mM NADH and 5 U/ml of glyceraldehyde-3-phosphate 
dehydrogenase. The reaction was started by addition of 40 ^l of heart extract. Changes in 
absorbance were recorded at 340 nm.
Statistical analysis
Data are expressed as mean ± S.E. The Student's t test for unpaired samples was used 
for statistical analysis, and a difference at P<0.05 was considered significant.
RESULTS 
AK1-knockout heart energetics under control conditions
A targeted replacement mutation in the AK1 gene was engineered (20) by positioning 
the HygroB selection-cassette in lieu of the exon 3-5 segment of the AK1 gene, which
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normally encodes the ATP-binding domain of the protein (Fig. 1A). That the mutant AK1 
allele was rendered dysfunctional was confirmed in heart muscle extracts from wild-type and 
mutant animals which demonstrate lack of AK1 mRNA (20), absence of AK1 protein (Fig. 
2A left panel), and loss of AK1-related enzymatic activity (Fig. 2A right panel) in AK1-- 
homozygotes. No apparent up-regulation of CK isoforms and related enzymatic activities was 
detected following deletion of AK1 (Fig. 2A).
Figure 1A. Structural organization of the mutant AK1 gene. Gene-targeting with a HygroB cassette- 
bearing vector was used to replace the ATP binding site-coding exons 3, 4 and 5 and mutate the AK1 
gene (see ref. 20). A schematic drawing of the exon-inton organization and positioning of the HygroB 
cassette in the mutant locus is provided. Exons are shown as black boxes, while white boxes 
represent 5' and 3' untranslated regions. In addition, restriction sites for the endonuclease BamH1 is 
provided. B. Incorporation of 18O into high-energy phosphoryls induces an isotopic shift in 31P NMR 
spectrum - a novel approach in assessing phosphotransfer rates in intact heart muscle. 18O induces an 
isotopic shift in cellular phosphoryl-containing metabolites, including those of Pi, CrP, and y- and p- 
ATP. As an example, the 31P NMR spectra of creatine phosphate (CrP) are presented from extracts of 
hearts superfused with buffer containing either regular H216O (B left panel) or 20% H218O-enriched 
water (B right panel). Creatine kinase phosphotransfer rate can be monitored through the appearance 
of phosphoryl species of CrP containing 18O1 and 18O2.
In the wild-type mouse heart, total AK activity was 1180 ± 220 nmol ATP min-1 mg 
protein-1 (Fig. 2B). In the AK1-knockout, total cardiac AK activity was dramatically reduced 
to 65 ± 2 nmol A TPm in-1mg protein-1 (Fig. 2B). Thus, total AK activity in AK1-knockout
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hearts was diminished by more than 94% when compared to the wild-type. The remaining 6% 
of AK activity could be attributed to minor AK isoforms, such as AK2, still present in AK1- 
knockout hearts (20). In fact, we observed a reduction in P-phosphoryl transfer by only 36% 
(see Fig. 4B) suggesting a marked compensatory up-regulation of phosphoryl flux through 
remaining minor AK isoforms.
Figure 2 . AK1-knockout hearts lack AK1 and have reduced tota l AK activ ity. A. Western blot (left 
panel) indicates lack of AK1 protein in AK1'/_ homozygous heart muscle. As a control, Western blot of 
the CK-M isoform is also shown. Zymogram analysis (right panel) of heart homogenates shows 
abundant AK1, along with mitochondrial (CK-MIT), muscle-type (CK-MM) and muscle/brain-type (CK- 
MB) creatine kinase isoenzyme activity. The brain-type (CK-BB) is marginally expressed. The AK1-/" 
heart tissue lacks AK1 activity, but retains the creatine kinase isoenzyme activities. B. Total AK activity 
in extracts from wild-type (n=4) and AK1-knockout (n=3) hearts. AK activity was measured 
spectrophotometrically in the direction of ATP formation. Star indicates significant difference between 
the two groups.
Nucleotide levels in wild-type («=5) and AK1-knockout (n=5) hearts were not 
significantly different (Fig. 3A). AMP was 4.9 ± 0.8 and 5.7 ± 0.7 nm olm g protein-1, ADP 
was 11.1 ± 0.8 and 10.9 ± 0.5 nm olm g protein-1, while ATP was 29.3 ± 1.6 and 26.2 ± 2.8 
nm olm g protein-1, in the wild-type and AK1-knockout hearts, respectively. Moreover, the 
percentage of phosphoryl oxygens replaced by 18O in yATP, an indicator of the ATP synthetic 
activity in the myocardium, was similar between wild-type (n=4) and AK1-knockout (n=4) 
hearts (48 ± 5% to. 50 ± 3%, P>0.05; Fig. 3B). In addition, total CK activity in wild-type and 
AK1-knockout hearts was not significantly different, 4770 ± 490 (n=4) and 5050 ± 410 (n=3) 
nmol ATP min-1mg protein-1, respectively (P>0.05; Fig. 3C). In fact, CK-catalyzed 
phosphotransfer, expressed as the percentage of phosphoryl oxygens replaced by 18O in CrP, 
was essentially the same in wild-type (77 ± 3%; n=4) and AK1-knockout (77 ± 4%; n=4)
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hearts (Fig. 4A). However, the activity of the glycolytic phosphotransfer enzyme, 3- 
phosphoglycerate kinase (PGK), was significantly increased from 370 ± 20 to 560 ± 60 nmol 
1,3-diphosphoglyceratemin-1mg protein-1, in wild-type (n=4) and AK1-knockout (n=3) 
hearts, respectively (P<0.05; Fig. 3D). Thus, under control conditions, deletion of the AK1 
gene, which produces marked reduction in total myocardial AK activity, did not translate into 
abnormal nucleotide levels or ATP production. Moreover, in AK1-deficient hearts, there was 
no change in CK-activity and CK-catalyzed phosphotransfer, but rather a compensatory 
increase in the activity of PGK, a key phosphotransfer enzyme in the glycolytic pathway (14).
Figure 3. AK 1-knockout hearts have preserved nucleotide levels, ATP turnover and creatine 
kinase (CK) activ ity, but increased 3-phosphoglycerate kinase (PGK) activity. A: HPLC 
chromatograms of nucleotide profiles in wild-type (WT; left panel) and AK1-knockout (AK1-KO; right 
panel) heart extracts under control conditions. B. Percentage of y-ATP phosphoryl oxygens replaced 
with 18O in wild-type (n=4) and AK1-KO hearts (n=4) as an indicator of total ATP production. C. CK 
activity in WT (n=4) and AK1-KO (n=3) hearts. CK activity was measured spectrophotometrically in the 
direction of ATP formation. D. PGK activity in WT (n=4) and AK1-KO (n=3) hearts. PGK activity was 
measured spectrophotometrically in the direction of 1,3-diphosphoglycerate formation. Star indicates 
significant difference between groups.
Deficient energetics in the AK1-knockout heart under hypoxic stress
Available evidence indicate that AK-catalyzed phosphotransfer increases under 
metabolic stress (14, 19). Therefore, the absence of AK1, the major AK isoform in heart 
muscle (4, 24), may impose an energetic disadvantage under stress conditions.
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Down-regulation of the CK/CrP system is a sensitive marker of the myocardial 
response to hypoxic stress (25). In hypoxia, induced with the mitochondrial poison KCN (2 
mM), CK-catalyzed phosphotransfer was markedly suppressed in both wild-type and AK1- 
knockout hearts (Fig. 4A). In contrast, in hypoxia AK-catalyzed phosphotransfer was 
increased in both wild-type and AK1-knockout hearts (Fig. 4B), from 10 ± 0.4% to 25 ± 3.3% 
(p<0.01; «=4), and from 6.5 ± 0.2% to 11 ± 1.5% (p<0.05; n=4), respectively. Although AK- 
catalyzed phosphotransfer was activated by hypoxia, the increase was markedly lower in the 
AK1-knockout than wild-type, 67% and 147% respectively (Fig. 4B). In addition, under 
hypoxia, ATP levels dropped to 22.1 ± 1.3 in the wild-type (n=5), and even further, to 16.6 ±
1.9 nm olm g protein-1, in AK1-knockout hearts («=5; Fig. 4C). Thus, under hypoxic stress, 
ATP levels are significantly lower in AK1-deficient compared to wild-type hearts (p<0.05; 
Fig.4 C).
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Figure 4. Reduced ability of AK1-knockout hearts to maintain cellular energetics in hypoxia.
Hypoxia was induced by 2 mM KCN. A. Percentage of creatine phosphate phosphoryl oxygens 
replaced with 18O, as an indicator of CK-catalyzed phosphotransfer, in wild-type (n=4) and AK1- 
knockout (AK1-KO; n=4) hearts under control (open) and hypoxic (filled) conditions. B. Percentage of 
p-ATP phosphoryl oxygens replaced with 18O, as an indicator of AK-catalyzed phosphotransfer, in 
wild-type (n=4) and AK1-knockout (n=4) hearts under control (open) and hypoxic (filled) conditions. 
CK- and AK- catalyzed phosphotransfers were assessed by the 18O-phosphoryl labeling technique. C. 
ATP levels in wild-type (n=5) and AK1-knockout (n=5) hearts measured by 31P NMR under control 
(open) and hypoxic (filled) conditions. D. Pi/ATP ratio, an index of the energetic status, in wild-type 
(n=5) and AK1-knockout (n=5) hearts measured by 31P NMR under control (open) and hypoxic (filled) 
conditions. In hypoxia, ATP was significantly reduced while Pi/ATP ratio increased in AK1-KO 
compared to wild-type.
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Moreover, the Pi/ATP ratio, an index of cardiac energetic deficit, was significantly higher (4.0 
± 0.6 vs. 2.6 ± 0.3; P<0.05) in AK1-knockout («=5) compared to wild-type (n=5) hearts. 
Thus, under hypoxic stress, a null mutation in the AK1 gene translates into a blunted increase 
in AK-catalyzed phosphotransfer, and is associated with lower ATP levels and higher Pi/ATP 
ratio. Adenosine is a potent trigger of cardioprotective processes in the heart under metabolic 
stress (26-29). Although adenosine significantly increased in wild-type hearts under hypoxia 
(from 3.2 ± 1.4 to 7.7 ± 1.5 nm olm g protein-1; P<0.05), it remained essentially at baseline 
levels in AK1-knockout hearts exposed to the same hypoxic stress (from 4.2 ± 0.8 to 3.3 ± 0.6 
nm olm g protein-1; P>0.05). Thus, deletion of the AK1 gene compromises the ability of 
cardiac muscle to generate a cardioprotective mediator under hypoxia.
Figure 5. B lunted adenosine production  in AK 1-knockout hearts in hypoxia. Adenosine levels in 
wild-type (n=5) and AK1-knockout (n=5) heart extracts measured by HPLC.
DISCUSSION
Although AK was discovered half-a-century ago and implicated in the regulation of 
energy metabolism (2, 14, 30), the significance of this phosphotransfer enzyme in myocardial 
energetic homeostasis has not been established (10). Here, using the knockout approach to 
delete the AK1 gene, along with the 18O-phosphoryl oxygen exchange analysis to monitor 
cellular phosphotransfer dynamics, we provide direct evidence for a critical role of AK in 
sustaining cardiac energetics and promoting a cardioprotective response under hypoxic 
conditions.
Hearts from gene-targeted mice with a null mutation of the AK1 gene lacked AK1 
protein expression, which was associated with a dramatic reduction in total cardiac AK 
activity. This corroborates the observed absence of AK1-gene products and AK1 activity in 
other tissues from AK1-knockout mice (20). In the heart, under control conditions, AK1 
deficiency did not translate into gross abnormalities in nucleotide levels or y-ATP turnover
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rate. Thus, energy metabolism in AK1-deficient hearts, under normal conditions, is apparently 
well compensated. In this regard, the mammalian myocardium appears to adapt better than 
lower organisms, such as yeast, where the AK gene is essential for mitochondrial energetics 
and cell survival (31).
Previous studies with CK-knockout mice have uncovered a high plasticity of muscle 
energetic systems in adapting to genetic disruptions in energy-supply pathways (12, 13, 16). 
Although AK1 is the main AK isoform, heart muscle also expresses minor isoforms, in 
particular AK2 and AK3 (24). In fact, AK-catalyzed phosphoryl flux in AK1-knockout hearts 
was reduced by 36% compared to the wild-type, a decrease less pronounced than that in total 
AK enzymatic activity which was reduced by 94%. This may indicate that in AK1-- hearts, 
there is a compensatory increase in AK2- and AK3-catalyzed phosphotransfer suggesting 
significant functional reserve in remaining AK isoforms. AK2/AK3-processed phosphoryls in 
mitochondria could be handed to cytosolic CK and glycolytic systems, securing delivery of 
high-energy phosphoryls to cellular ATP-consuming sites. This is supported by data 
indicating a close functional interaction of AK phosphotransfer with both the CK and/or 
glycolytic systems (32, 33). In the present study, AK1-deficient hearts displayed no 
significant compensatory increase in CK-catalyzed phosphotransfer, but the activity of 3- 
phosphoglycerate kinase, a critical enzyme in the glycolytic phosphotransfer pathway, was 
significantly augmented by 51% following deletion of AK1. Thus, under control conditions, 
the AK1-knockout heart could maintain an apparent energetic homeostasis by adaptive up- 
regulation of metabolic flux through remaining AK isoforms and glycolysis. In addition, 
cytoarchitectural and possibly other metabolic adaptations in the AK1-- heart could contribute 
to an overall compensation for the loss of the AK1 gene (20).
The extent of adaptations was, however, insufficient to sustain cardiac energetics in 
the AK1-- myocardium exposed to hypoxic stress. Under hypoxic conditions, ATP levels were 
significantly more depressed and the Pi/ATP ratio significantly increased in AK1-deficient 
hearts when compared to the wild-type. Observed lower ATP levels and higher Pi/ATP ratio 
indicate a more pronounced energetic deficit (34) in the hypoxic myocardium of AK1- 
deficient when compared to wild-type hearts. This may suggest a unique feature of AK- 
catalysis, essential in sustaining optimal myocardial energetics under stress.
Indeed, AK-catalyzed phosphotransfer has the exclusive ability to transfer and make 
available the energy of both P- and y-phosphoryls in the ATP molecule (10, 14). This property 
of AK catalysis, not shared by other phosphotransfer enzymes, could sustain cellular 
energetics under hypoxia, when the major energy delivery pathway catalyzed by CK is 
compromised (10). Moreover, in the wild-type, AK flux increases in response to hypoxia, 
thereby preventing a rapid decline in myocardial ATP levels. In AK1-deficient hearts, 
however, the AK response to hypoxia is blunted creating a significant deficit in energy 
transfer and reducing the ATP-regeneration potential of the hypoxic myocardium. In this 
regard, hearts with genetically disrupted AK1-catalysis bear similarities with failing hearts in 
which the disease-compromised phosphotransfer capacity, including down-regulation in AK
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as well as CK and glycolytic enzyme activities, precipitates ventricular dysfunction (15, 35­
37).
In addition to an energetic function, AK has a distinct signaling role through 
generation of AMP and activation of AMP-dependent processes (9, 38, 39), including opening 
of ATP-sensitive potassium (KATP) channels (7) and adenosine production (40, 41). This is of 
significance in view of the role that these AK-catalysis dependent events play in protecting 
the myocardium under hypoxic insult (37). In fact, AK gene expression is induced by hypoxia 
(47), and agents that increase AK activity are beneficial in preserving tissue functions under 
hypoxic conditions (48). Therefore, the absence of hypoxia-induced adenosine production 
observed here in AKl-knockout hearts may reduce the ability of AK1-deficient heart muscle 
to withstand hypoxic injury. Moreover, reduced AK-phosphotransfer in AKl-deficient hearts 
may further alter the behavior of KATP channels which sense changes in cellular metabolism, 
and contribute to cellular protection (28, 42-46). In this way, the energetic disbalance of AKl- 
deficient hearts would be further aggravated by compromised cardioprotective signaling under 
metabolic stress.
In summary, this study demonstrates that AK1 is an integral component of cardiac 
energetic homeostasis facilitating transduction of adenine nucleotide-associated signals into 
cellular response to metabolic stress. While lack of AK1 is apparently compensated under 
normal conditions, absence of AK1 under hypoxic stress translates into pronounced energetic 
deficit associated with lowered ATP levels and depressed generation of adenosine, a major 
endogenous cardioprotective mediator. Thus, AK-catalyzed phosphotransfer could provide a 
previously unrecognized target in promoting cardiac tolerance to metabolic stress.
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Metabolic response to AK1 deficiency in muscle
ABSTRACT
Genetic ablation of adenylate kinase 1 (AK1), a member of the AK family of 
phosphotransfer enzymes, disturbs muscle energetic economy and decreases tolerance to 
metabolic stress, despite re-arrangements in alternative high-energy-phosphoryl transfer 
pathways. To define the mechanisms of this adaptive response, soleus and gastrocnemius 
muscles from AK1-- mice were characterized by cDNA-array profiling, Western blot and 
ultrastructural analysis. We demonstrate that AK1 deficiency induces fiber-type specific 
variation in groups of transcripts involved in glycolysis and mitochondrial metabolism, and in 
gene products defining structural and myogenic events. This was associated with increased 
phosphotransfer capacities of the glycolytic enzymes pyruvate kinase and 3-phosphoglycerate 
kinase. Moreover, in AK1- - mice, fast-twitch gastrocnemius, but not slow-twitch soleus, had 
an increase in adenine nucleotide translocator (ANT) and mitochondrial creatine kinase 
protein, along with a doubling of the intermyofibrillar mitochondrial volume. These results 
provide molecular evidence for wide-scale remodeling in AK1 deficient muscles aimed at 
preservation of efficient energetic communication between ATP producing and utilizing 
cellular sites.
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INTRODUCTION
The metabolic status of skeletal muscle is reciprocally linked to fiber-type composition 
and functional demand. This implies that myocytes must undergo constant reprogramming of 
their gene expression in response to fluctuations in intrinsic or extrinsic physiological signals 
such as intracellular Ca2+ concentrations, hormonal stimulation, or altered workload (1-3). 
Moreover, disturbance of cellular energetics by metabolic inhibitors or genetic mutation may 
also induce alterations in the muscle phenotype via changes in the gene program for fiber-type 
specification (4-6). The high plasticity in the responsiveness of muscle is exemplified by 
myosin isoform transitions, mitochondrial division, and alterations in gene expression of 
enzymes involved in oxidative and glycolytic pathways (3, 7-10). Although many other 
aspects of myocyte infrastructure may change in concert, the molecular mechanisms 
regulating reprogramming of muscle energetics are still unknown.
Indeed, an important unresolved issue is the relationship between muscle design and 
metabolic pathways maintaining cellular energy homeostasis. Adenylate kinases (AK, EC 
2.7.4.3) are evolutionary strongly conserved enzymes which catalyze the reaction ATP + 
AMP o  2 ADP. This reaction is one of the principal steps in adenine nucleotide metabolism 
and high-energy phosphoryl (~P) transfer in the cellular bioenergetic network (11-13). Among 
several AK isoenzymes found in mammals skeletal muscle is particularly rich in AK1, the 
major cytosolic isoform (14).
Along with the AK circuit, the creatine kinase (CK, EC 2.7.3.2)/creatine phosphate 
(CrP), nucleoside diphosphokinase (NDPK or nm23, EC 2.7.4.6) and glycolytic 
phosphotransfer systems coexist in skeletal muscle and serve to balance adenylates at ATP- 
consuming and ATP-generating intracellular sites (4, 13, 15-17). The relative importance of 
the AK, CK, and glycolytic phosphotransfer system is muscle fiber-type dependent (3, 18, 
19). For example, the CK/CrP phosphotransfer circuit is most active in fast-twitch fibers as 
demonstrated by a high content of CrP and high levels of cytosolic M-CK. Slow-twitch fibers 
exhibit lower amounts of CrP and M-CK, but -  due to the high mitochondrial content -  
possess relatively large amounts of ScCKmit (20). Expression of glycolytic proteins is most 
abundant in fast fibers and the mechanisms by which glycolytic genes are collectively or 
individually activated have in part been identified (21). In fact, the redox cofactors NAD(P)H 
and NAD(P)+, which couple glycolysis or the pentose-phosphate cycle to the Krebs cycle and 
oxidative phosphorylation in mitochondria, are important regulators of glycolytic gene 
transcription (22). Other coupling exists with calcium-calcineurin (1), calcium/calmodulin- 
dependent protein kinase (9, 10), and AMP-activated kinase (AMPK) signaling (6), which 
regulate myocyte programs for mitochondrial biogenesis and glycolytic machinery. The 
mechanism underlying the regulation and distribution of AK and NDPK gene products in 
specific fiber-types of muscle is less clear.
We have recently demonstrated that inactivation of the AK-circuit induces flux 
redistribution in the cellular phosphotransfer network, associated with an elevated glycolytic
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metabolism (23). Preserved muscle function, albeit with lower efficiency, in these animals 
suggests metabolic and cellular adaptations induced by genetic stress associated with AK 
deficiency. Indeed, we here uncovered a coherent reprogramming in the genetic and 
molecular profile of soleus and gastrocnemius muscles from mice lacking AK1. These 
adaptations occur at the mRNA and/or protein level, and could support energy metabolism 
and performance in muscles compromised by AK1 deficiency.
MATERIALS AND METHODS 
AK1 knockout mice
Gene-targeted mice carrying a HygroBR replacement mutation in the exon 3-5 region 
of the AK1 gene were derived as described in detail elsewhere (23). Age and sex matched (3­
5 months old; born at identical data) homozygous AKl-deficient and wild-type control 
animals (both with 50%-50% C57BL/6x129/Ola mixed inbred background) were used 
throughout experiments. Housing conditions were kept exactly identical to exclude effects of 
variations in (steroid) hormone levels, or food supply. Growth rates of wild-type and AK1 
knockout mice were similar, resulting in body weights varying between 26-28 g and 22-24 g 
for 3-5 months old males and females, respectively. The investigation conformed to the 
Guidelines fo r  the Care and Use o f  Laboratory Animals of the Dutch Council, and was 
approved by the Institutional Animal Care and Use Committee at the University of Nijmegen.
M acroarray hybridization.
Total RNA from freshly isolated skeletal gastrocnemius and soleus muscles was 
extracted using the lithium chloride-urea method (23). Macroarrays were prepared by spotting 
individual plasmids with cDNA insert (134 different mouse sequences for glycolytic enzymes, 
mitochondrial enzymes and transporters, fatty acid metabolism enzymes, muscle regulatory 
factors, proteins active in Ca2+ signaling, glucose transport, tissue oxygenation as well as 
cytoskeletal components and transcription factors (see www.ncmls.kun.nl/celbio/data.htm for 
detailed information)) onto Hybond N+ membranes using a gridding robot (24). 32P labeled 
single-stranded cDNA was used as probe to hybridize membranes with gridded cDNA arrays 
as previously described in detail elsewhere (24). Four AK1 knockout and control mice were 
analysed and statistically compared.
D ata analysis
Acquisition of radioactive signals from the gridded arrays was performed on a Bio­
Rad GS 363 phosphorimager (Bio-Rad, Hercules, CA, USA) using the Molecular Analyst 
software from Bio-rad. Because the signal intensity varied widely, membranes were exposed 
for 30 minutes (detection of abundant RNA) and 16 hours (non-abundant RNA) and 
hybridization levels for individual cDNAs expressed as the mean Arbitrary Units (A.U.) of
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duplicate spots. Signals were divided by the value for the sum of detectable signals, resulting 
in the identification of an unaffected subset of genes that were used for final normalization.
W estern blot analysis
Gastrocnemius and soleus muscles excised from the hind legs of 3 mice were pooled. 
Protein extracts were prepared and analysed as described (25). For Western blot analysis, 
extracted proteins were separated on 10% SDS-polyacrylamide gels and proteins 
electrophoretically transferred onto nitrocellulose membranes. Specific proteins were detected 
using antibodies raised against species-specific protein or synthetic peptides of corresponding 
proteins as described elsewhere (25). After image acquisition with a densitometer (Bio-Rad 
GS-690), proteins were quantified using the Molecular Analyst software from Bio-rad. For 
correlation, intensities of signals were compared with intensities of signals in the C57BL/6 
calibration series. To confirm equal loading of protein a representative gel was stained with 
Coomassie Brilliant Blue (R-250) and, after immunodetection, blots were stained with 
Ponceau S.
N orthern blot analysis
RNA blots were prepared as described (23) and hybridized with 32P-labeled cDNAs 
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), muscle pyruvate kinase (PK-M), 
P-enolase, MLC-2s, ScCKmit, GLUT4, and a-actin as probe (probe lengths 0.5-2 kbp). 
Hybridization was carried out overnight at 68°C in 0.5 M NaPO4-buffer pH 7.2, 7% (w/v) 
SDS, 1 mM EDTA, and blots were washed to a final stringency of 0.1xSSC/1% (w/v) SDS at 
68°C and exposed to Kodak X-Omat films. Signals were quantified by phosphorimager 
analysis as described above. Per genotype, 4 animals were analysed (independently from 
macroarray experiments) and statistically compared.
Enzyme activity
Protein extracts were prepared from frozen powdered muscles as described in detail 
elsewhere (26). AK activity in supernatant, expressed as relative light units (RLU)min-1mg 
protein-1, was measured by a luciferase-based ATP bioluminescence assay (Sigma) in the 
presence of 2 mM ADP using a BioOrbit 1253 luminometer. Nucleoside diphosphate kinase 
(NDPK) activity, expressed as RLU min-1mg protein-1, was determined with the same 
bioluminescence assay in the presence of the AK inhibitor, diadenosine pentaphosphate 
(Ap5A; 200 ^M), and the reaction started with dGTP (2 mM). Three animals per genotype 
were analysed and statistically compared. The activity of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), pyruvate kinase (PK) and 3-phosphoglycerate kinase (PGK) were 
measured using coupled enzyme assays (27). Reactions were started by the addition of 10 ^l 
(GAPDH and PGK) or 20 ^l (PK) of muscle extract and activities spectrophotometrically 
recorded at 340 nm with a Beckman DU 7400 spectrophotometer. Per genotype, five animals 
were analysed and statistically compared.
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Electron microscopy and morphom etric analysis
Mice were anesthetized with 2,2,2,-tribromorthanol (350 mg/Kg i.p.) and the GPS 
muscle complex was fixed using a clamp and dissected during immersion fixation with 2% 
glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. Subsequently, muscles were prepared and 
examined on a JEOL JEM1010 electron microscope (4, 15). Intermyofibrillar mitochondrial 
volumes in superficial gastrocnemius muscle were estimated from electron micrographs at a 
magnification of 8000x by point counting. For each individual muscle, at least three randomly 
taken micrographs were analyzed. Per genotype, six animals were measured and statistically 
compared.
Statistics
Data are presented as mean ± S.E. Student’s t test for unpaired samples was used for 
statistical analysis, and P<0.05 was considered significant.
RESULTS 
mRNA profiles of fast-twitch and slow-twitch fibers
Prior to typing the cellular and molecular adaptations that are evoked as a response to 
AK1 deficiency we established the normal gene expression characteristics of two distinctly 
different skeletal muscle types, gastrocnemius and soleus muscles. These muscles can be 
considered the archetypes of fast and slow skeletal muscle in the mouse hind leg (19), for 
which differences in contractile performance and metabolic design are mirrored in their 
transcription profiles (1, 3). Using a customized cDNA macroarray assay and experimental 
conditions that avoid mRNA amplification (24) a selective subset of mouse-muscle cDNAs 
was probed for their potential to discriminate between gastrocnemius and soleus. Ultimately, 
86 candidate cDNAs were chosen that belonged to different functional clusters, gave good 
signal to noise ratio, and were considered suitable indicators for inter- and intra-muscular 
comparison. About 65% of the signals (56 signals) represented mRNAs with similar 
expression levels in soleus and gastrocnemius muscles. The remaining signals (30 signals) 
represented mRNAs with expression levels that were significantly different (p<0.05; n=4). 
Transcripts with expression levels that differed by a magnitude 2 or more (p<0.01; n=4) 
between these two muscles are shown in Table I and Fig. 1. Quantitative data for the 
remaining 10 mRNAs, which differed by a magnitude less than 2 can be found at 
www.ncmls.kun.nl/celbio/data.htm.
Differential regulation of energy generation, consumption and distribution pathways is 
central to the determination of the nature and function of the muscle fiber (1-3). We therefore 
assessed the expression level of mRNAs for several key enzymes in these pathways. The 
relative abundance of AK1 mRNA was 2.2-fold higher in the gastrocnemius muscle compared 
with the soleus muscle (Fig. 2A). This result was confirmed by the observation that AK- 
catalyzed phosphotransfer activity was approximately 3-fold higher in gastrocnemius muscle
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Figure 1. Fiber-type specific mRNA expression. A. Scatter graph representation of array data from 
gastrocnemius (x-axis) compared with soleus (y-axis). Each data point represents the mean of signals 
obtained for an individual gene. Transcript levels are represented by the (x,y) positions in the scatter 
graph. Data points marked with gray boxes represent differences by a magnitude 2 or more. The solid 
line indicates maintained steady-state mRNA levels whereas the dotted lines indicate mRNA levels 
that differ 2-fold. B. Net differences in mRNA expression level between the gastrocnemius and soleus 
muscle. Note the relative higher mRNA expression of AK1 in the gastrocnemius muscle (#9). Data are 
expressed as the mean ± S.E. from four determinations.
86
Metabolic response to AK1 deficiency in muscle
than in soleus muscle (Fig. 2A). Also the composition and function of the CK phosphotransfer 
system depends on the specific muscle type (20). Our macroarray analysis showed that M-CK 
mRNA is 3.7-fold higher expressed in gastrocnemius compared with the soleus muscle. In 
contrast, the ScCKmit gene expression level is 2.1-fold higher in soleus muscle (Fig. 2B). Still, 
the ScCKmit mRNA level was only 3% and 23% of that of M-CK mRNA in gastrocnemius 
and soleus muscle, respectively. Subsequent comparison of M-CK and ScCKmit protein levels 
in soleus and gastrocnemius muscle by means of quantitative blot analysis, using specific 
antibodies directed against ScCKmit and CK-MM (Fig. 2B; inset), indicated that mRNA and 
protein product levels were well correlated. When normalized to total protein content, the M- 
CK protein level appeared 1.8-fold higher in gastrocnemius than in soleus, while the ScCKmit 
protein level was 2.7-fold higher in soleus than in gastrocnemius muscle.
Table I. Differential mRNA expression in gastrocnemius and soleus skeletal muscle.
EST/cDNA Gastrocnemius Soleus
GDH 0.23 ± 0.02 0.07 ± 0.02
Tfam 0.31 ± 0.04 0.08 ± 0.04
Glut. synt. 0.54 ± 0.05 0.17 ± 0.03
GPDH 0.97 ± 0.07 0.21 ± 0.03
B-CK 1.0 ± 0.2 0.36 ± 0.08
PGK 1.08 ± 0.09 0.40 ± 0.07
GAPDH 1.3 ± 0.2 0.4 ± 0.1
LDH-A 2.4 ± 0.4 0.91 ± 0.06
AK1 3.0 ± 0.3 1.4 ± 0.2
Glycogen phos.B 3.3 ± 0.2 1.06 ± 0.09
Aldolase A 14.1 ± 0.5 4.5 ± 0.4
ß-enolase 13.4 ± 1.1 4.7 ± 0.2
M-CK 73 ± 8 20 ± 1
Serca2 0.4 ± 0.1 2.3 ± 0.1
MLC-2s; partial cDNA 0.55 ± 0.04 3.7 ± 0.7
MLC-1s/v 0.8 ± 0.2 6.6 ± 1.0
MLC-2s 1.1 ± 0.1 6.9 ± 1.0
Myoglobin 0.9 ± 0.1 3.5 ± 1.0
PiC 1.06 ± 0.06 2.1 ± 0.3
ScCKmit 2.1 ± 0.2 4.5 ± 0.5
Data are expressed in arbitrary units as mean ± S.E. (n=4); P<0.01.
Abbreviations: GDH, glutamate dehydrogenase; Tfam, mitochondrial transcription factor A; Glut. synt., 
glutamine synthetase; GPDH, glycerol phosphate dehydrogenase; B-CK, creatine kinase B; PGK, 
phosphoglycerate kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LDH-A, lactate 
dehydrogenase; AK1, adenylate kinase 1; Glycogen phos.B, glycogen phosphorylase B; M-CK, 
creatine kinase M; Serca2, sarcoplasmatic reticulum Ca2+ ATPase; MLC-2s, myosin light chain 2 slow; 
MLC-1s/v, essential myosin light chain 1 slow/ventricular; PiC, inorganic phosphate carrier; ScCKmit, 
mitochondrial creatine kinase.
87
Chapter 4
Figure 2. Fiber-type distribution of AK, CK, and NDPK. A. Relative abundance of AK1 transcript and 
total AK enzymatic activity in soleus and gastrocnemius muscles. B. Relative abundance of ScCKmit 
and M-CK in soleus and gastrocnemius muscles. The inset shows a Western blot of immuno-reactive 
ScCKmit and M-CK from soleus (S) and gastrocnemius (G) muscles. C. Relative abundance of NDPK- 
M2 transcript and total NDPK enzymatic activity in soleus and gastrocnemius muscles. Data are 
expressed as the mean ± S.E. from three or four determinations.
Along with the AK- and CK-catalyzed high-energy phosphoryl transfer, the NDPK 
phosphotransfer pathway warrants transport and distribution of ~P over nucleotide di- and 
triphosphates (13, 16, 17). The expression level of different NDPK isoforms present on the
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gridded membranes (nm23-M1, nm23-M2, nm23-M4 and the human homologue of mouse 
nm23-M3, DR-nm23), did not differ more than 1.2-fold between gastrocnemius and soleus 
muscles. Taken into account that the expression of the nm23-M2 isoform was the highest in 
skeletal muscle (data not shown), this finding was corroborated by the observation that there 
was a good correlation between the transcript level for nm23-M2, and the accompanying total 
NDPK activity (Fig. 2C). The total NDPK activity was not significantly different between 
soleus and gastrocnemius. Thus, whereas NDPK gene-product and activity levels are equally 
maintained in soleus and gastrocnemius muscle, AK- and CK-mediated phosphoryl transfer 
activity is clearly dependent on muscle phenotype.
The sarcomeric myosin molecule is a hexamer consisting of two myosin heavy chains 
(MHCs), two essential myosin light chains (ELCs), and two regulatory myosin light chains 
(RLCs). Because myofibrillar protein isoforms generally show tissue-specific distribution these 
proteins may serve as useful markers for skeletal muscle fiber typing. As anticipated on the 
basis of a slow or fast-twitch muscle fiber (3), the expression level of genes encoding the 
MLC-1s/v and MLC-2s mRNAs differed 6 to 8-fold between gastrocnemius and soleus muscle 
(Table I; Fig. 1). Also the signals for the mRNAs for mitochondrial inorganic phosphate carrier 
(PiC), Ca2 -ATPase isoform Serca2, and myoglobin, of which the translation products are 
associated with oxidative metabolism, were 2.0-, 3.8-, and 5.2-fold higher in the soleus 
muscle, respectively (Table I; Fig. 1). Strikingly, the steady-state transcript level for the nuclear 
encoded mitochondrial transcriptionfactor Tfam (or mtTFA) was 3.9-fold higher in the 
glycolytic gastrocnemius muscle compared with the oxidative soleus muscle. This observation 
was surprising because the gastrocnemius is a mitochondria-poor muscle, but may be explained 
by the fact that cooperation of more than one factor is needed to regulate mitochondrial 
biogenesis (9, 10). Unexpectedly, relatively high steady-state B-CK transcript levels were 
detected in soleus and gastrocnemius muscle. This observation is most easily explained by the 
fact that immature muscle cells (i.e. satellite cells) actively transcribe the B-CK gene (15). As 
expected, signal intensities for mRNAs related to glycolysis (P-enolase, Aldolase A, GAPDH, 
and PGK) or coupled pathways (glycogen phosphorylase B, LDH-A, and GPDH) were higher 
in gastrocnemius than in soleus muscle (Table I; Fig. 1). Thus, we may conclude that the 
cDNA macroarray has sufficient discriminating power to distinguish mRNA profiles of fast 
and slow-type muscles.
Differences in gene products for high energy phosphoryl transfer in the absence and 
presence of AK1
Changes at the molecular level may occur when the muscle genotype or the integrity 
of various intrinsic or extrinsic physiological control mechanisms are disturbed (6, 9, 25, 28). 
To determine the spectrum of molecular changes related to the absence of AK1 we compared 
mRNA profiles of gastrocnemius and soleus, between wild-type and AK1-- animals. 
Altogether, fourteen genes were identified for which the expression levels differed 
significantly between AK1 proficient and deficient muscles (Table II; Fig. 3).
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Table II. Transcript profiling in wild-type and AK1-/" gastrocnemius muscle
EST/cDNA Wild-type AK1KO
GASTROCNEMIUS
Glycolytic metabolism
*
ß-enolase 100 ± 11 143 ± 5
• * Pyruvate kinase M 100 ± 2 134 ± 7
GPDH* 100 ± 6 147 ± 4
❖GAPDH* 100 ± 11 187 ± 7
Mitochondrial metabolism
Glutamate dehydrogenase 100 ± 6 46 ± 19
Acyl CoA dehydrogenase 100 ± 6 65 ± 11
M ono- or diphosphate kinases
Adenylate kinase I 100 ± 9 4 ± 1
DR-NM23 (NDPK-M3) 100 ± 17 214 ± 32
Structural
Myosin Light Chain 2s 100 ± 10 63 ± 5
Myosin Light Chain 2s (partial) 100 ± 11 61 ± 8
Myogenesis
MYF5 100 ± 35 327 ± 56
SOLEUS
Glycolytic metabolism
a-enolase 100 ± 18 181 ± 13
Lactate dehydrogenase A 100 ± 6 77 ± 2
Monophosphate kinase
Adenylate kinase 1 100 ± 12 5 ± 1
Data are expressed as mean ± S.E. (n=4); P<0.05. Values for wild-type were set to 100%.
* Data acquisition after 30 minutes exposure in phosphorimager.
Knockout of AK1 produced a dramatic 96% decrease in the AK1 mRNA signal (Table 
II; Fig. 3A-B) for gastrocnemius muscle. Likewise, soleus muscle of AK1- - animals showed a 
95% reduction in AK1 mRNA content (Table II; Fig. 3C). We surmised that transcript 
profiles of other enzymes involved in energy transfer pathways might be among the principal 
targets for adaptation to AK1 deficiency. Yet, M-CK transcript levels on the arrays of AK1 
knockout gastrocnemius and soleus were not significantly different from wild-type. The 
steady-state M-CK transcript level was respectively 88 ± 8 A.U. and 85 ± 12 A.U. in the
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wild-type and AK1 knockout gastrocnemius muscle («=4, p>0.05) and 16 ± 1 A.U. and 16 ± 2 
A.U. in the wild-type and AK1 knockout soleus muscle (n=4, p>0.05), respectively. Also the 
level of the mRNA for the mitochondrial CK isoform, ScCKmit, was unaffected (2.6 ± 0.1 vs.
2.3 ± 0.1 A.U. in the gastrocnemius and 3.5 ± 0.2 vs. 3.5 ± 0.6 A.U. in the soleus of wild-type 
and AK1 deficient mice, respectively; n=4, p>0.05). Thus, in response to AK1 gene deletion, 
the levels of transcripts encoding the ScCKmit and M-CK isoforms are not changed. We 
observed, however, a two-fold increase in the signal level for DR-nm23 mRNA in the absence 
of AK1 in gastrocnemius muscle (Table II; Fig. 3B). DR-nm23 mRNA level in soleus muscle 
did not differ by genotype. Total NDPK-catalyzed phosphoryl transfer capacity in the 
gastrocnemius and soleus muscles was not affected by AK1 gene deletion (21 ± 2 vs. 20 ± 2 
103 RLU m in-1mg protein-1 and 23 ± 2 vs. 27 ± 2 103 RLU m in-1mg protein-1 in wild-type 
and AK1 knockout, respectively; p>0.05, n=3).
A daptation in glycolytic, m itochondrial and structural gene product levels
Several studies support the functional interaction of the AK circuit with the glycolytic 
machinery for energy production (13, 29-32). Previous studies showed that AK1-- muscles 
have upregulated glycolytic flux. In keeping with this finding, we observed that four of the 
affected signals in gastrocnemius represented mRNAs that encode enzymes acting in the 
glycolytic pathway. For muscle enolase, consisting of two subunits encoded by two distinct 
genes (enolase a  and P), there was a significant increase in the steady state level of the P- 
enolase mRNA in the gastrocnemius knockout muscle (Table II; Fig. 3B). In soleus muscle a 
similar increase, but now for the a-enolase mRNA was seen (Table II; Fig. 3C). As the P- 
enolase level is dependent on muscle energetic demand (33, 34), this result suggests a similar 
role for the a-enolase subunit in skeletal muscle. Similarly, the levels of mRNAs for PK-M, 
GAPDH, and GPDH were approximately 1.5 fold increased in mutant gastrocnemius 
compared with wild-type (Table II; Fig. 3B). Also the PGK mRNA level tended to be greater 
(30%) in the AK1 deficient gastrocnemius muscle (p<0.08). Conversely, there was a 23% 
decrease in the level of the mRNA for the tetrameric glycolytic enzyme lactate dehydrogenase 
(LDH), LDH-A, in soleus muscle in AK1-- compared with wild-type (Table II; Fig. 3C). 
Levels of mRNAs for PK-M, GAPDH and GPDH in soleus and LDH-A in gastrocnemius did 
not significantly differ between knockout and wild-type muscles. Because the flux through 
glycolysis was increased in gastrocnemius-plantaris-soleus (GPS) muscle complex of AK1 
knockout mice (23) we next raised the question whether the mRNA level for the insulin and 
AMPK dependent glucose importer, GLUT4, was possibly altered. The steady-state GLUT4 
transcript level appeared unaffected by AK1 absence in both gastrocnemius (1.8 ± 0.4 and 2.9 
± 0.7 A.U. in wild-type and AK1 knockout, respectively; p>0.05, n=4) and soleus (1.4 ± 0.3 
and 1.4 ± 0.4 A.U. in wild-type and AK1 knockout, p>0.05; n=4) muscle.
In addition to glycolytic mRNAs also transcripts encoding enzymes in other related 
catabolic pathways were analyzed. In the glycolytic gastrocnemius muscle of AK1 knockouts 
we observed lower mRNA levels for long chain acyl CoA dehydrogenase and glutamate
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Figure 3 . Expression profiling of skeletal muscles from AK1"'" and wild-type mice. A.
Autoradiograms of cDNA array profiles from wild-type and AK1 knockout gastrocnemius muscle. Total 
RNA was isolated and first strand cDNA product was 32P labeled and used as hybridization probe.
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dehydrogenase (35% and 54% reduction, respectively; Table II; Fig. 3B). Both messengers 
encode proteins that reside in the mitochondrial matrix and are involved in the oxidation of 
glutamate and fatty acids. In the oxidative soleus muscle these messenger signals were 
unaffected by the absence of AK1 (data not shown).
Based on the intramuscular comparison (Table I and Fig. 1) the regulatory cardiac/slow-twitch 
myosin light chain 2 (MLC-2s) may be considered a marker for oxidativefiber-types. In AK1 
animals, signals representing the MLC-2s mRNA (full length and partial) were downregulated 
by approximately 40% in the gastrocnemius muscle, but not affected in soleus muscles (Table 
II; Fig. 3B). This observation suggests that downregulation of MLC-2s gene transcription is 
essential in evoking changes in isoenzyme composition for the regulatory MLCs. 
Interestingly, also the essential cardiac/slow-twitch MLC-1s/v transcript in gastrocnemius 
muscle inclined to a decrease in concentration (50% reduction; p<0.07; n=4).
Among the key factors involved in transcriptional control of myofibers are the 
myogenic basic helix-loop-helix (bHLH) transcription factors. Expression levels of MyoD and 
Myf5 strongly correlate with the fast muscle phenotype (35, 36), while myogenin has been 
shown to be associated with the slow muscle phenotype (37). In fast-twitch gastrocnemius 
muscles lacking AK1 the MYF5 transcript level was increased by more than 200% (Table II; 
Fig. 3B). Whereas signals of myogenin transcripts could not be reliably detected, the MyoD 
mRNA level tended to be upregulated (73% with low significance p<0.09; n=4). In the soleus 
muscle no differences were observed for the bHLH transcription factors.
Northern blot analysis of newly isolated mRNA samples from gastrocnemius muscles 
independently confirmed the results from our macroarray experiments (Fig. 3D). Signals 
obtained with probes specific for ScCKmit and GLUT4 were at similar strength for wild-type 
and AK1 deficient muscles (0.68 ± 0.05 vs. 0.68 ± 0.04 and 0.37 ± 0.02 vs. 0.36 ± 0.02 A.U. 
in AK1KO and wild-type, respectively; p>0.05; n=4). The intensities of mRNA bands for P- 
enolase and PK-M were 1.3- and 1.4-fold upregulated in mutant gastrocnemius muscle (2.1 ± 
0.1 vs. 1.6 ± 0.1 and 1.01 ± 0.02 vs. 0.71 ± 0.04 A.U. in AK1KO and wild-type, respectively; 
p<0.03; n=4). Also the GAPDH mRNA signal was increased 1.4-fold in mutant
Signal intensities of individual spots were quantified by phosphorimager analysis and normalized to the 
sum of detectable signals. Note the absence of AK1 mRNA in AK1 knockout muscle (position B15). B. 
Scatter graph for the comparison of transcript profiles between AK1-mutant and wild-type 
gastrocnemius muscles. Each data point represents the mean ± S.E. of signals obtained for an 
individual gene from four determinations. Transcript levels are represented by the (x,y) positions in the 
scatter graph. X-axis and y-axis represent wild-type and AK1 knockout RNA profiles, respectively. The 
solid line indicates maintained steady-state mRNA levels. Significant different mRNA levels are 
marked with gray boxes C. Scatter graph for comparison of transcript profiles between AK1-mutant 
and wild-type soleus muscles. D. Northern blots of total RNAs isolated from wild-type (n=4) and AK1 
knockout (n=4) gastrocnemius muscles. Specific probes for ScCKmit, GLUT4, GAPDH, PK-M, p- 
enolase, and a-actin were used for hybridization. RNA levels were quantified by phosphorimager 
analysis and normalized to the a-actin signal (see text).
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gastrocnemius (0.46 ± 0.03 vs. 0.34 ± 0.02 A.U. in AK1KO and wild-type, respectively; 
p<0.02; n=4), but less pronounced than in the macroarray data set (1.8-fold increase). Use of 
the MLC-2s cDNA probe confirmed the earlier observed decrease in MLC-2s transcript level 
(signal intensity 0.8 ± 0.2 vs. 1.5 ± 0.2 A.U. in AK1KO and wild-type, respectively; p=0.05; 
n=4). Independent confirmation of the mRNA array data for soleus muscle was not achieved 
because the RNA yield from this muscle was too low for use in the Northern blot assay.
Increased glycolytic phosphotransfer capacity in AK1 knockout skeletal muscle
We next used protein-chemical and functional assays to establish the relationship 
between mRNA and protein levels and enzymatic activities, focusing on key phosphoryl 
transfer enzymes in the glycolytic pathway, PK, GAPDH and PGK. Semi quantitative blot 
and enzymatic analysis of GAPDH showed maintained protein levels and activities for 
GAPDH in mutant skeletal muscle (Fig. 4A). The protein level for PK was increased 2-fold in 
absence of AK1 and was paralleled by 2-fold increase in PK-catalyzed phosphotransfer 
capacity (Fig. 4B-D). Thus, the increase in GAPDH mRNA level is not followed by an 
increase in GAPDH protein quantity and enzymatic activity. For the adaptive PK upregulation 
in AK1- - gastrocnemius muscle mRNA level, protein content as well as enzymatic activity 
appeared linearly coupled.
In addition to PK, PGK is the other principal phosphoryl transfer enzyme that 
produces ATP in the glycolytic pathway. PGK catalyzed phosphotransfer activity was 
increased 2-fold (Fig. 4E). Together, the increased steady-state levels for several glycolytic 
mRNA species and the more direct observation of increased enzymatic activity of PK and 
PGK, indicate that glycolysis-driven phosphoryl-exchange between ADP and ATP may be 
one of the principal targets for adaptation in fast-twitch muscles of AK1- - mice.
AK1 deficient muscle show increased m itochondrial content
Based on theoretical considerations and experimental evidence it is now commonly 
accepted that the AK, CK and glycolytic circuits may be intertwined with mitochondrial 
activity and together form integrated networks for high-energy phosphoryl transfer at different 
subcellular locales (13, 16, 23, 32). As shown in Fig. 5A and inset 4C, the level of the 
cytosolic M-CK protein was not affected in skeletal muscle. We did, however, observe a 40% 
increase in the level of mitochondrial ScCKmit in the gastrocnemius muscle of AK1 deficient 
mice. Also, the signal for the mitochondrial adenine nucleotide transporter (ANT) was 
similarly increased. Similar results were obtained for another fast-twitch muscle, the psoas 
major muscle (data not shown). Intriguingly, the increase in steady-state protein levels of 
ANT and ScCKmit in AK1 knockout gastrocnemius muscle was not accompanied by a 
corresponding increase in mRNA level. The level of two other mitochondrial proteins, the 
inorganic phosphate carrier (PiC) and voltage dependent anion channel (VDAC; porin), were 
not changed in AK1-deficient gastrocnemius muscle (data not shown). In mutant soleus 
muscle no significant alterations in the level of ANT and ScCKmit protein were detected.
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Figure 4. Increased glycolytic phosphotransfer capacity in AK1-/- gastrocnemius skeletal 
muscle. A. GAPDH activity in wild-type and AK1 knockout gastrocnemius muscles (n=5 each). The 
inset illustrates a Western blot image of immuno-reactive GAPDH in wild-type and AK1 knockout 
gastrocnemius muscle. B. Densitometric analysis of Western blot image (inset) for PK-M. Protein 
extracts were pooled from 3 mice, electrophoretically separated on 10% SDS-polyacrylamide gels and 
subjected to Western blot analysis. WT (o) and AK1KO (•) PK-M protein levels are indicated on the 
linear calibration plot. This plot serves to correlate signal intensities with known quantities of immuno- 
reactive PK-M protein. Note the 2-fold increased PK-M protein level in AK1KO (1.6) compared with 
wild-type (0.8) gastrocnemius protein extracts. C. Densitometric analysis of Western blot image for M- 
CK (inset). The blot shown in (B) was reprobed with the M-CK antibody. Note equal M-CK protein 
levels in wild-type (1.2) and AK1KO (1.2) gastrocnemius protein extracts. D. PK activity in wild-type 
and AK1 knockout gastrocnemius muscles (n=5). E. PGK activity in wild-type and AK1 knockout 
gastrocnemius muscles (n=5). Asterisk indicates significant difference between groups.
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To analyze whether the changes in mitochondrial marker proteins were also reflected 
in variation of mitochondrial density or appearance we applied EM-morphometric analysis. 
Indeed, a 2-fold increase in mitochondrial volume was detected in AK1 deficient 
gastrocnemius muscles (Fig. 5B and C). Taken together, these findings indicate that in 
response to AK1 gene deletion cell-type dependent adaptations occur to maintain cellular 
energetic homeostasis.
A  C57BL/6 WT AK1KO
%*C 1*C 2*c
WT AK1KO
Figure 5. Increased mitochondrial content in AK1 deficient skeletal muscle. A. Western blot 
images for ScCKmit, ANT, and M-CK. Protein extracts were pooled from 3 mice, electrophoretically 
separated on 10% SDS-polyacrylamide gels and subjected to Western blot analysis. Images were 
analyzed as described in Methods. B. Ultrastructural changes in gastrocnemius skeletal muscle from 
AK1 deficient mice. Electron micrographs of longitudinal sections through myofibers of the 
gastrocnemius muscle. Fast-twitch fibers of AK1 deficient mice display an increased intermyofibrillar 
mitochondrial volume. C. Increased mitochondrial density in AK1 deficient gastrocnemius muscle. 
Mitochondrial volume density was assessed by point counting for six AK1-/" and control animals. 
Asterisk indicates significant difference between groups.
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DISCUSSION
Previously we had demonstrated that inactivation of the AK1 gene compromises 
economic efficiency of the cellular energetic network despite the fact that there is rewiring of 
fluxes through other pathways for metabolic energy transfer. These adaptive responses 
apparently ameliorate - but do not entirely obscure - the effects of loss of the AK1 
phosphotransfer activity (23, 26, 38). Here we provide a detailed analysis of the molecular 
events underlying compensatory responses to muscle AK1 deficiency, demonstrating that 
regulation at the level of gene transcript abundance, enzymatic activity, as well as 
(re)organization of the cellular ultrastructure is involved, with a signature to sustain cellular 
high-energy phosphoryl generation and transfer capacity.
Although regulation of the AK1 gene and its products has been described in several 
reports (23, 39), not much attention has been paid to the relevance for metabolic context or 
cell-type requirements of AK-mediated phosphoryl exchange. We demonstrate here by 
mRNA-profiling and biochemical activity measurement that AK1 transcript level is well 
correlated to enzymatic capacity (when normalized to total RNA or protein content) and is 2-3 
fold higher in fast-twitch gastrocnemius compared to slow-twitch soleus muscle. This 
underscores the relative importance of AK catalysis for muscle that is relatively poor in 
mitochondria and highly dependent on glycolytic ATP production. Similar fiber-type 
specificity was noted for mRNA and protein products of the gene for muscle-type cytosolic 
creatine kinase, M-CK. Although we still do not fully understand how cytosolic AK and CK 
enzymes are integrated in the cellular energy network (13, 32), predominance in fast-twitch 
myocytes would fit to their role in protecting the cell from threshold effects of abnormal 
ATP/ADP/AMP ratios during transient periods of sudden and profound energy demand. No 
correlation to fiber-type was found for expression of members of the NDPK family of genes 
(nm23-M1, nm23-M2, nm23-M3/DR-nm23, and nm23-M4). Based on this finding it is 
tempting to speculate that NDPK-mediated phosphotransfer may feed high-energy 
phosphoryls into other metabolic pathways, not directly involved in energy homeostasis 
associated with muscle contraction.
Our array profiling demonstrated that AK1 absence caused a parallel, 1.5- to 2-fold, 
increase in the level of PK-M, P-enolase, GAPDH, PGK and GPDH mRNAs in 
gastrocnemius. Northern blot quantification supported this finding for the first three mRNAs 
mentioned. This strongly points to concerted transcriptional regulation of these glycolytic 
genes. In concordance with our earlier findings (23) we surmise that upregulation of mRNAs 
encoding glycolytic enzymes in gastrocnemius serves a general need for larger capacity of the 
glycolytic pathway in AK1- - mutants. It is of note, therefore, that the contents of mRNAs for 
long chain acyl CoA dehydrogenase and glutamate dehydrogenase were decreased. This could 
suggest that the production of Krebs cycle intermediates from metabolic pathways other than 
glycolysis may be downregulated. Again this could be viewed as a direct adaptational effect 
that fits the general drift towards a more glycolytic profile.
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Various regulatory circuits like the myogenic bHLH transcription factor family, 
calcineurin/CaMK/PGC-1/NFAT/MEF2-, myogenic regulatory factor (MRF) activity, or 
NPAS2/BMAL-pathways have now been identified that, together, may be implemented in the 
transcriptional regulation of cellular carbohydrate metabolism and ultrastructural design of 
myofibers (and other cell types as well) (1, 9, 10, 22, 35-37, 40). We found no change in 
abundance of mRNA for calcineurin in AK1- - gastrocnemius and soleus, but this does not 
exclude a regulatory role for this enzyme, as the calcineurin pathway is mainly regulated at 
the level of factor relocation. We did observe, however, that the concentration of MYF5, a 
member of the bHLH family of myogenic transcription factors (TFs), was increased 3-fold. 
Also the level of another member, MyoD, was increased. Allen and co-workers (36) reported 
that MYF5 and MyoD preferentially activate the skeletal MHC Ilb gene, specifying the 
myosin isoform that is highest expressed in the glycolytic fast-type fiber IIB. In parallel, a role 
for MyoD has been proposed in the maintenance of fast-fiber characteristics (35). Against this 
background, these TFs might be considered good candidates for being involved in the 
transition in glycolytic versus oxidative phenotype and the accompanying contractile 
properties of muscle design in our AK1- - mice.
It is of note that different pathways for matching muscle infrastructure to conditions of 
metabolic stress might be effective in slow and fast type myofibers. In the highly oxidative 
soleus muscle, lack of AK1 produced an 80% increase in steady state level of a-enolase 
mRNA and down regulated LDH-A mRNA levels with no changes in PK-M, GAPDH and 
GPDH mRNAs levels. Intriguingly, recent findings indicate that the a-enolase mRNA 
encodes two distinct proteins, a-enolase and Myc-binding protein (MBP)-1 protein, due to 
alternative usage of translation initiation sites (41). P-Enolase is involved in glycolysis, 
whereas the MBP-1 protein downregulates c-Myc oncoprotein expression. Activation by c- 
Myc, in turn, can promote lactate dehydrogenase (LDH-A) gene transcription (42, 43). 
Increased production of the MBP-1 protein from the a-enolase mRNA would therefore be 
expected to result in downregulation of c-Myc, and subsequent reduction in LDH-A gene 
activity. Although this is exactly what was observed in our array measurements, clearly more 
detailed study is necessary to see whether this explains our findings. Another hypothetical 
possibility would be that the redox state of NAD cofactors and its effect on the 
NPAS2/BMAL1 transcription machinery (22) is involved in the metabolic signaling and 
suppression of the LDH-A transcript level. We put this possibility forward because 
gastrocnemius muscles of AK1- - mice show significant higher NAD+ levels (20% increase; 
E.J., unpublished observation).
In validating our array quantification data with Northern and Western blot analyses we 
noticed that there was discordance between mRNA and protein levels for some genes. Most 
striking was that the almost 2-fold increase in GAPDH mRNA was not paralleled in GAPDH 
activity in muscle extract. Conversely, a relatively modest increase in PK-M mRNA level was 
accompanied by a 2-fold increase in PK-M content and activity. This suggest that the 
mechanism(s) of adaptive response may also include regulation at the rate of translation or
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protein turnover (44). Ultimately, shifts in isoenzyme composition, phosphorylation or protein 
complexation should therefore be taken into account. For example, skeletal muscle PK- 
catalyzed phosphotransfer activity can be increased upon binding with MM-CK resulting in 
an increased flux through PK, independently of its substrate concentrations (45). Interestingly, 
an up-regulation of GAPDH and/or PK mRNA, as we found here, has also been reported for 
heart and skeletal muscle in response to muscle disuse and ischemic stress (46, 47).
The adaptations in the glycolytic pathway, especially the phosphotransfer enzymes PK 
and PGK, should also be discussed in the context of a possible direct structural and functional 
association between AK1 and glycolytic enzymes. Indeed, AK1 can physically interact with 
phosphofructokinase and participate in the formation of a larger glycolytic enzyme complex 
or cluster (30, 31, 48). Whether this complex only serves to provide localized glycolytic 
ADP:ATP phosphotransfer capacity, presumably important for sustaining actomyosin sliding 
and force-production, or also has any other structural-organisational function is currently 
unknown. Immunostaining experiments have indicated that AK1 is present in distinct 
subcellular locales of skeletal muscle that coincide with localization of enzymes of the 
glycolytic apparatus (49). Adaptations, instead of serving a general role in cellular energetics, 
may therefore also have a role in guarding structural integrity of the glycolytic infrastructure 
of muscle.
Finally, it is important to note that AK1 is involved in the communication between 
myofibrillar ATPases and mitochondria (13, 27, 32, 50), thereby maintaining efficient 
intracellular energy flow (23). Translocation of ADP into mitochondria or release of ATP in 
the cytosol is achieved via translocator complexes composed of ANT, porin (VDAC) and 
octameric mitochondrial creatine kinase (51). Because diffusion of ADP is very limited in 
muscle cells (52) and the AK pathway for ADP (re)phosphorylation is depleted in AK1-- 
gastrocnemius muscle, the observed 2-fold increase in mitochondrial volume, and 
concomitant increase in ANT and ScCKmit protein may serve to match the mitochondrial 
ADP import capacity with the increase in glycolytic flux. Apparently, post-translational 
regulation may be involved in this phenomenon, as the mRNA levels for ANT and ScCKmit 
were not accordingly adapted. Intriguingly, other mitochondrial import proteins like the PiC 
and VDAC were not increased. In this regard muscles of M-CK knockout mice have a similar 
pattern in molecular and cytoarchitectural adaptations (24, 25). In these mutants, ScCKmit 
and ANT1 mRNA levels were maintained whereas ScCKmit and ANT protein levels were 
dramatically increased. This was also paralleled by an increase in pyruvate kinase protein 
level and intermyofibrillar mitochondrial volume (24, 25). When combined, this suggests that 
the AK1- and M-CK-catalyzed phosphotransfer circuit may have functional redundancy as the 
deficiency for both circuits is sensed and counteracted in a highly similar manner.
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Phosphotransfer deficiency and muscle energetics
ABSTRACT
Previously we demonstrated that efficient coupling between cellular sites of ATP- 
production and ATP-utilization, required for optimal muscle performance, is mainly mediated 
by the combined activities of creatine kinase (CK)- and adenylate kinase (AK)-catalyzed 
phosphotransfer reactions. Herein, we show that simultaneous disruption of the genes for the 
cytosolic M-CK- and AK1 isoenzymes compromises intracellular energetic communication 
and severely reduces the cellular capability to maintain total ATP turnover under muscle 
functional load. M-CK/AK1 (MAK_/_) mutant skeletal muscle displayed aberrant ATP/ADP, 
ADP/AMP and ATP/GTP ratios, reduced intracellular phosphotransfer communication, and 
increased ATP supply capacity, as assessed by 18O-labeling of [Pi] and [ATP]. Analysis of 
actomyosin complexes in vitro demonstrated that one of the consequences of M-CK and AK1 
deficiency is hampered phosphoryl delivery to the actomyosin ATPase, resulting in loss of 
contractile performance. These results suggest that MAK == muscles are energetically less 
efficient than wild-type muscles, but an apparent compensatory redistribution of high-energy 
phosphoryl flux through glycolytic and guanylate phosphotransfer pathways limited the 
overall energetic deficit. Thus, the present study suggests a coordinated network of 
complementary enzymatic pathways that serve in the maintenance of energetic homeostasis 
and physiological efficiency.
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INTRODUCTION
In tissues with high and sudden energy demand, creatine kinase (CK)- and adenylate 
kinase (AK)-catalyzed reactions form the principal pathways securing efficient 
communication between the subcellular compartments responsible for production and 
utilization of metabolic energy (1-6).
Adenylate kinases (AK, EC 2.7.4.3), an evolutionary conserved family of enzymes 
which catalyzes the reaction ATP + AMP o  2 ADP (7), have been implicated in cellular 
adenine nucleotide homeostasis (8). cDNAs for five isoforms of AK (AK1-AK5) along with 
the variant of AK1 (AK1P, a membrane-bound form with a presumed role in cell cycle 
regulation) have been cloned from metabolically active tissues (9-12). Mammalian skeletal 
muscle is particularly rich in AK1, the major isoform of the family (9), present in the 
sarcoplasm, and clustered along the myofibrillar I-band or bound as AK1p to membranes (13­
15). By donating the energy of the P-phosphoryl group of ATP/ADP to the cellular energetic 
pool, AK isoenzymes protect cells against energy deprivation in periods of high metabolic 
demand (6, 16-20). The different intracellular localizations and distinct kinetic properties of 
AK isoforms permit the formation of a coordinated enzymatic network for nucleotide- 
mediated metabolic signaling, coupling myofibrillar, nuclear or sarcolemmal energy- 
dependent processes with mitochondrial energetics (21-23).
Creatine kinases (CK, EC 2.7.3.2), catalyzing the reaction MgADP- + CrP2- + H+ o  
Cr + MgATP2-, belong to a smaller and evolutionary younger family of enzymes with a role in 
high-energy phosphoryl transfer and cellular energy buffering (1, 5, 24). Creatine kinases are 
foremost found in cells with high peak-demands in metabolic energy, such as the brain, heart 
or skeletal muscle (1, 5). In skeletal muscle, the principal CK isoform is the cytosolic isoform 
(MM-CK), a homodimer mainly present as a soluble protein in the cytosol and bound to the 
myofibrillar M- and I-bands (13), as well as to the sarcoplasmic reticulum membranes (25). 
Skeletal muscle also contains an additional, mitochondrial, CK-isoform (ScCKmit) which 
amounts to 1-10% of the total CK activity, depending on the type of muscle fiber (26, 27). 
This CK-member associates and functionally interacts with the adenine nucleotide 
translocator (ANT) and voltage-dependent anion channel (VDAC) in the mitochondrial inner 
and outer membrane (28-30), providing an efficient ATP export and metabolic signal- 
reception pathway (31).
AK and CK in concert with nucleoside diphosphokinase (NDPK) and the enzymes that 
function in the glycolytic phosphotransfer pathway, form the cellular energetic infrastructure 
responsible for effective handling and distribution of high-energy phosphoryl (~P) groups 
throughout the structured muscle environment (5, 6, 24, 32-34). In this network, AK- and CK- 
mediated reactions play a complementary and functionally alternate role (18, 27, 35, 36). By 
pharmacological inhibition of the CK-circuit it has been demonstrated that an increase in AK- 
mediated phosphotransfer may compensate for loss of CK-activity (17). Likewise, in skeletal 
muscles carrying a null mutation in either the M -C K  or AK1 gene, leading to complete lack of
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corresponding protein expression and activity, an adaptive rewiring of flux through the 
remaining intact phosphotransfer circuit occurs (6, 18, 19). In addition, M -C K  and AK1 
mutant muscles respond with similar but not identical ultrastructural and molecular 
adaptations, suggesting an inherent plasticity of the bioenergetic network (6, 24, 37-39).
While progress has been made in our understanding of individual phosphotransfer 
reactions, the consequences of combined deletion of major AK and CK isoforms remain 
unknown. Here, we report on the effects deleting both the AK1 and M-CK proteins in a single 
cell-type, skeletal muscle fiber of a double-knockout mouse. Use of this model provides us 
with a unique opportunity to assess the significance of the activities of mitochondrial CK, 
glycolytic enzymes and NDPK-mediated phosphotransfer reactions in muscle physiology and 
metabolism. Monitoring intracellular phosphotransfer kinetics by 18O-phosphoryl labeling 
revealed that lack of AK1 and M-CK resulted in a serious impairment of communication 
between ATP-generating and ATP-consuming cellular sites. As a consequence, AK1/M-CK- 
deficient muscles had a reduced ability to sustain the dynamic fluctuations in ATP/ADP/AMP 
nucleotide metabolism and overall cellular ATP turnover during functional load, despite 
increased high-energy phosphoryl flux through alternative glycolytic and guanylate 
phosphotransfer pathways. These data provide further evidence for the existence of a fully 
integrated high-energy phosphoryl transfer system with a high degree of functional plasticity 
required for optimal muscle energetics.
MATERIALS AND METHODS 
Generation of M-CK/AK1 deficient mice
Gene-targeted AK1 deficient mice were derived from mouse embryonic stem cells 
carrying a replacement mutation in the AK1 gene. Creatine kinase knockout mice were 
derived from embryonic stem cells carrying a replacement mutation in the M -C K  gene. 
Cohorts of AK1'-' and M -C K 1' animals were generated and maintained as previously described 
(24, 39). AK1 and M -C K  knockout mice were crossbred to obtain animals that were 
heterozygous for both AK1 and M -C K  alleles, and these animals were subsequently mated to 
obtain homozygous double mutants. Genotyping for wild-type and mutant AK1 and M -C K  
alleles was performed using a PCR assay as described previously (6, 40). Lack of AK1 and 
M-CK protein activity was confirmed by Western blot and zymogram analysis. 
Gastrocnemius and soleus muscles from age matched homozygous M-CK/AK1-deficient 
(MAK==) and wild-type control animals, also having a 50%-50% C57BL/6x129/Ola mixed 
inbred background, were used for all studies. The investigation conformed to the Guidelines 
for the Care and Use of Laboratory Animals of the Dutch Council and the National Institutes 
of Health, and were approved by the Institutional Animal Care and Use Committee at the 
University of Nijmegen and the Mayo Clinic.
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High-energy phosphoryl transfer
ATP turnover and phosphoryl flux through AK, CK and glycolytic systems were 
measured in intact gastrocnemius-plantaris-soleus (GPS) muscle complex using the 18O- 
phosphoryl labeling technique (16, 17, 21, 41). Mice were anaesthetized with pentobarbital 
(Beuthanasia D) (100 mg/kg i.p.) and injected with heparin (50 U i.p.) prior to muscle 
dissection. Isolated mouse GPS muscle was preincubated for 12 min at room temperature in a 
medium containing (in mM) 137 NaCl, 5 KCl, 2 CaCl2 , 1 MgCl2 , 1 NaH2PO4, 20 HEPES, 
0.05 EDTA, 5 glucose and 24 NaHCO3 (pH 7.4). The muscle complex was then rapidly 
transferred into a medium enriched with 30% of 18O-water (Isotec Inc.), and paced at 2 Hz 
exactly as described (6). After 3 min of 18O-labeling muscles were freeze-clamped, using 
liquid N2, and extracted in a solution containing 0.6 M HClO4 and 1 mM EDTA. Protein 
content was determined using a Protein Assay kit (BIO-Rad). Cellular ATP, ADP, GTP, GDP, 
inorganic phosphate, creatine phosphate (CrP) and glucose-6-phosphate (G-6-P) were purified 
and quantified using high-performance liquid chromatography (17, 41). To obtain information 
on basal levels and turnover rates of phosphoryl-containing metabolites, isolated mouse GPS 
muscle was treated identically, but without pacing. Samples containing phosphoryls of y-ATP, 
P-ATP, P-ADP, y-GTP, P-GTP, P-GDP, inorganic phosphate and CrP, as glycerol 3- 
phosphate, were converted to trimethylsilyl derivatives. 18O-enrichment of phosphoryls in 
glycerol 3-phosphates was determined with a Hewlett-Packard 5980B gas chromatograph- 
mass spectrometer (6).
High-energy phosphoryl transfer rates
Total cellular ATP turnover was estimated from the total number of 18O atoms that 
appeared in phosphoryls of Pi, CrP, y-ATP, P-ATP, P-ADP, y-GTP, P-GTP/GDP and G-6-P. 
Net AK-, CK-, and hexokinase-catalyzed phosphotransfers were determined from the rate of 
appearance of 18O-containing phosphoryls in P-ATP and ADP, CrP and G-6-P, respectively 
(6, 17, 41, 42).
Metabolite levels
ATP, ADP, GTP, and GDP levels were quantified in muscle perchloric extracts by use 
of HPLC (21, 41). AMP, ADP, CrP, muscle lactate and glucose-6-phosphate levels were 
determined using coupled enzyme assays (21, 24). Muscle inorganic phosphate level was 
determined using the EnzChek Phosphate Assay kit (Molecular Probes).
Zymogram analysis and enzyme activity
Homogenates from freshly excised GPS muscles (10% W/V) were prepared in SETH 
buffer (in mM: 250 sucrose, 2 EDTA, 10 Tris-HCl; pH 7.4) at 4°C. GPS extracts were diluted 
1:1 in 30 mM Na3PO4 buffer (pH 7.4), containing 0.05% v/v Triton X-100, 0.3 mM DTT, and 
a complete protease inhibitor cocktail (Boehringer Mannheim). Muscle extracts were 
incubated for 30 min at room temperature, centrifuged for 20 min at 11,000 g and an aliquot
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(1-5 ^l) applied to agarose gels (Alameda, CA). AK1 and creatine kinase isoenzymes were 
separated electrophoretically, and stained for enzyme activity (6, 43). CK and AK activities 
were measured from whole hindlimb muscle extracts (6) using a CK NAC activated kit 
(Boehringer Mannheim) and a coupled enzyme system, respectively (21).
Western blot analysis
Skeletal muscles were excised, pulverized with a mortar and pestle using liquid N2 and 
extracted in a buffer containing 50 mM NaCl, 60 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.2% 
Triton X-100, to which a complete protease inhibitor cocktail (Boehringer Mannheim) was 
added. Extracts were centrifuged (10 min, 8000 g, 4°C) and proteins separated on 10% SDS- 
polyacrylamide gels, before being electrophoretically transferred onto nitrocellulose 
membranes. M-CK and AK1 proteins were detected using antibodies raised against chicken 
muscle M-CK (44) and mouse AK1-GST fusion proteins (15). Aldolase antibody (Rockland, 
Gilbertsville, PA) was used as a control. Immunocomplexes were visualized by 
chemiluminescence using a secondary antibody coupled to horse raddish peroxidase and 
exposure to Kodak X-omat AR films.
Actomyosin contraction
Actomyosin contraction was measured using an established superprecipitation method 
(45, 46). Excised femoral quadriceps muscles (muscles from 2 mice combined) were 
pulverized with mortar and pestle using liquid N 2, and extracted in a buffer containing 0.6 M 
KCl, 0.04 M NaHCO3, 0.01 M Na2CO3, 4 mM DTT and a complete protease inhibitor 
cocktail (Boehringer Mannheim). Extracts were homogenized (3 x 5 s) with a blender 
(Polytron), maintained at 4°C for 10-15 min, and centrifuged (30 min, 9500 g, 4°C). The 
supernatant was gently diluted with 10 volumes ice-cold water, containing 0.5 mM DTT and 
maintained at 4°C for 30 min. The solution was centrifuged (15 min, 7000 g, 4°C) and the 
precipitate dissolved in a buffer containing 0.6 M KCl, 20 mM Tris-HCl (pH 7.4) and the 
complete protease inhibitor cocktail (Boehringer Mannheim). Skeletal muscle actomyosin was 
stored at -20°C after mixing with an equal volume of glycerol. Superprecipitation was 
measured in a buffer containing 0.8 mg/ml skeletal muscle actomyosin, 0.8 mM CaCl2, 2 mM 
MgCl2 , 50 mM KCl, 1 mM EGTA, 20 mM Tris-HCl, at pH 6.8 and 25°C. The change in 
absorbance at 660 nm was followed after addition of ADP (0.2 or 2 mM), 
phosphoenolpyruvate (PEP; 2 mM), CrP (2.0 mM) or ATP (2 mM). Three measurements for 
each genotype (muscles from 2 mice per sample combined) were performed and statistically 
compared.
Statistics
Data are presented as mean ± S.E. Student’s t test for unpaired samples was used for 
statistical analysis, and P<0.05 considered significant.
109
Chapter 5
RESULTS
Generation of M-CK/AK1 double knockout mice
To generate a mouse model lacking cytosolic AK1 and M-CK isoforms single-mutant 
animals carrying a homozygous null mutation in the AK1 gene (6) or the M -C K  gene (24) 
were mated. Subsequent crossbreeding of the F1-males and females with the heterozygous M - 
CK+I'/AK1+I' genotype gave litter with normal size. Among an offspring of 175 pups analyzed, 
9 animals were M -C K -' and AK1'-' (further referred to as MAK_/_), indicating normal 
Mendelian segregation (1 in 16 expected). Zymogram and Western blot analysis confirmed 
complete absence of M-CK and AK1 protein and enzymatic activity in these animals (Fig. 1). 
MAK= = mice showed no overt abnormalities, bred normally when maintained as a separate 
lineage over multiple (now > 6) generations and had normal life expectancy.
Figure 1. Lack o f AK1 and M-CK in skeletal m uscle o f double  m utant M-CK/AK1 mice. A.
Zymogram analysis of homogenates from the gastrocnemius-plantaris-soleus (GPS) muscle complex 
from wild-type and MAK=/= mice. Native proteins were electrophoretically separated on agarose gels 
and stained for AK and CK activity. Note absence of AK1 and M-CK activities but preserved ScCKmit 
activity in MAK=/= muscles. B. Western blot using anti-M-CK and AK antibodies demonstrating absence 
of M-CK and AK1 proteins in gastrocnemius homogenates from MAK=/= mice. A (weak) band, 
migrating at slightly higher Mw than M-CK, represents the cross-reactive mitochondrial ScCKmit 
isoform. Aldolase signals are shown as controls. C. Mutations in the AK1 and M-CK gene revealed by 
PCR genotype analysis. PCR analysis was designed to specifically distinguish between wild-type and 
mutant alleles. Genomic DNA from tail biopsies was used as template.
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Cellular energetics in resting and contracting MAK=/_ muscle
Genetic deletion of M-CK and AK1 produced a dramatic reduction in the amount of 
18O labeling of the pools of CrP, P-ATP and P-ADP in skeletal muscle. Compared with wild­
type, 18O metabolic labeling of CrP was decreased from 8.8 ± 0.4 to 5.4 ± 0.2% in MAK = = 
resting, non-contracting muscle, a reduction of 39% (p<0.05, n=6; Fig. 2A). Stimulation of 
contractile activity further aggravated the difference in metabolic labeling of CrP between 
wild-type and mutant muscles, changing from 17.2 ± 1.2% in wild-type to 8.0 ± 0.5% in 
knockout muscle (p<0.05, n=6), a reduction of 54% (Fig. 2A). On average, muscle 
stimulation at 2 Hz increased 18O labeling of CrP by 95% in wild-type, but gave only a 49% 
elevation in MAK= = mutant muscle. This increase in [18O]CrP labeling despite the absence of 
M-CK could be attributed to metabolic flux through the mitochondrial ScCKmit reaction, 
which is still functionally active in MAK = = mutant muscles. Indeed, MAK = = muscles had a 
residual CK activity of 1.5 ± 0.1 ^mol CrP-min-1-mg protein-1 (n=3) due to the presence of 
ScCKmit, which is at 8% of total CK activity in wild-type controls. AK-catalyzed 
phosphotransfer activity, assessed by 18O incorporation in the P-phosphoryl group of ATP, 
was 1.8 ± 0.2% in non-contracting wild-type muscle and increased to 6.3 ± 0.5% in 
contracting muscle (Fig. 2B). However, AK-catalyzed P-phosphoryl labeling was 
dramatically reduced in MAK= = muscles when compared to wild-type (by 68% and 85% in 
resting and contractile state, respectively), with values of 0.6 ± 0.06% in non-contracting 
muscle and 0.9 ± 0.1% in 2 Hz paced muscle (p<0.05, n=6; Fig. 2B). These results indicate 
that both CK- and AK-mediated phosphoryl exchange rates increase with metabolic demand, 
but absolute and relative capacities for up-regulation are severely impaired when M-CK and 
AK1 are both lacking.
Moreover, a prominent difference in total ATP levels was seen in non-contracting 
muscles, with 27.5 ± 0.9 nmol ATP-mg protein-1 in wild-type and only 21.9 ± 1.2 nmol 
ATP-mg protein-1 in MAK == muscle (p<0.05, n=6 each). Conspicuously, in contracting 
double knockout MAK == muscles total ATP levels were well maintained compared with 
wild-type (26.8 ± 0.3 nmol ATP-mg protein-1 vs. 25.2 ± 1.6 nmol ATP-mg protein-1, 
respectively; p>0.05, n=6 each). These results suggest that coupling between metabolic 
energy salvage systems in MAK = = muscles may be less tight under resting conditions, but 
becomes partly restored under conditions of increased energy demand. It is conceivable that 
different thresholds in ATP/ADP/AMP ratios are necessary to switch-on alternative pathways 
for energy homeostasis. Indeed, the ATP/ADP ratio, a kinetic index of ~P utilization and 
replenishment, was decreased from 8.4 ± 0.2 to 5.9 ± 0.1 in non-contracting and from 6.5 ± 
0.2 to 5.6 ± 0.1 in contracting MAK = = muscles when compared with wild-type controls, 
respectively (p<0.05, n=6). Moreover, the ADP/AMP ratio was significantly higher in non­
contracting MAK= = muscle and MAK= = muscle under work-load when compared with wild­
type: 9.4 ± 0.4 vs. 8.0 ± 0.3 (p<0.05, n=6) and 8.3 ± 0.3 (n=6) vs. 6.7 ± 0.4 (n=5; p<0.05), 
respectively. The ATP/AMP ratio in resting muscle was lower in MAK == muscle than in 
wild-type (54 ± 3 vs. 63 ± 5, respectively; n=6, p<0.02), whereas in the contracting wild-type
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(n=5) and mutant muscle (n=6) the ATP/AMP ratio was equally maintained (42 ± 4 vs. 42 ± 
2). These results indicate that in the absence of AK1 and M-CK the dynamics of adenine 
nucleotide metabolism is affected with an apparently less efficient ~P trafficking among 
separate adenine nucleotide pools.
Figure 2. Com prom ised ce llu la r energetics in MAK== skeletal m uscle A. Reduced CK 
phosphotransfer in MAK=/= skeletal muscle. Percentage of CrP-phosphoryl oxygens replaced with 18O 
reflecting CK-catalyzed phosphotransfer, in wild-type (n=6) and MAK=/= (n=6) GPS muscle. B. 
Dramatically reduced AK phosphotransfer in MAK=/= skeletal muscle. Percentage of p-ATP-phosphoryl 
oxygens replaced with 18O, as an indicator of AK-catalyzed phosphotransfer, in wild-type (n=6) and 
MAK=/= (n=6) GPS muscle. C. CrP levels in resting and contracting wild-type and MAK=/= skeletal 
muscle. CrP levels were measured in wild-type (n=6) and MAK=/= (n=6) GPS muscles, incubated for 3 
min in 18O-water, at rest or paced at 2 Hz. D. Reduced capacity to maintain Pi levels in contracting 
MAK=/= skeletal muscle. Pi was measured in wild-type (n=6) and MAK=/= (n=6) GPS muscle incubated 
for 3 min in 18O-water, at rest or paced at 2 Hz. Star indicates significant difference between groups.
Upon initiation of contraction, CrP levels in wild-type muscles decreased from 62.2 ±
2.6 nmol CrP-mg protein-1 in the resting state to 31.5 ± 3.0 nmol CrP-mg protein-1 in the active 
state, a reduction of 49%. In double mutants a reduction only by 21% was observed (from 
57.4 ± 1.4 nmol CrP-mg protein-1 in muscle at rest to 45.5 ± 3.4 nmol CrP-mg protein-1 in 
active muscle, p<0.05, n=6; Fig. 2C). This indicates that the total CrP level does not correlate 
with muscle genotype when measured at rest, but is differentially affected by the absence of 
M-CK/AK1 under conditions of higher metabolic demand.
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Intracellular levels of inorganic phosphate (Pi), resulting from hydrolytic cleavage of 
ATP, were similar in wild-type and MAK= = muscles at rest (39.0 ± 1.8 vs. 39.5 ± 0.6 nmol 
Pi-mg protein-1). Upon functional load, however, the level of Pi increased by 20% in MAK==, 
but was still significantly lower compared with the 44% increase of Pi in wild-type muscle 
(46.8 ± 2.2 vs. 56.7 ± 2.7 nmol Pi-mg protein-1 in MAK = = vs. wild-type, p<0.05, n=6; Fig. 
2D). Accordingly, the CrP/Pi ratio, an index of the cellular energetic status, was significantly 
higher in the contracting MAK= = muscle (1.0 ± 0.1 vs. 0.6 ± 0.1; p<0.05, n=6) compared with 
wild-type controls (n=6). In non-contracting muscle this ratio was maintained at similar levels
1.6 ± 0.1 vs. 1.5 ± 0.1 in wild-type and MAK ==, respectively (p>0.05, n=6). These results 
indicate that, in the absence of M-CK and AK1, the dynamics of CK (i.e. mitochondrial CK- 
driven) catalysis and Pi utilizing and/or producing reactions are sufficient to maintain cellular 
metabolite levels at rest, but become inadequate with increased metabolic demand.
Loss of AK- and CK-supported contraction in MAK=/_ actomyosin
In skeletal muscle, M-CK is clustered at the M-line and I-band of myofibers where it 
regenerates ATP to sustain myosin ATPase activity (13, 24). AK1 also localizes on the 
myofibrillar I-band where it may work as an ATP-regenerator to support muscle contraction 
(13, 21, 47). To determine whether this cellular AK1 and M-CK partitioning has functional 
significance we compared the contractile properties of actomyosin complexes isolated from 
wild-type and MAK = = muscles. Using wild-type actomyosin complexes, in the presence of 
0.2 mM ADP, AK1-supported induction of contraction was observed (Fig. 3A). Similar 
contractile characteristics were seen in the presence of 2 mM CrP, based on the M-CK activity 
that remained in the actomyosin complex after isolation. However, the AK1- and M-CK- 
supported contractions were abolished in actomyosin complexes isolated from MAK = = 
muscles (Fig. 3A). Lack of contraction in wild-type actomyosin complexes in the presence of 
ADP was also observed with pharmacological inhibition of the AK-circuit by diadenosine 
pentaphosphate, Ap5A, (not shown). Addition of 0.2 mM exogenous ATP, as a “direct” 
substrate, caused wild-type actomyosin complex to contract with a maximum amplitude of 
0.51 ± 0.02 absorbance units-min-1-mg protein-1 (n=3; Fig. 3B). The onset of contraction was, 
however, delayed in comparison when ATP was delivered via AK1 and M-CK enzymes that 
co-purified with the actomyosin complex (Fig. 3A and 3B). On average, in wild-type, the 
times to onset of contraction after addition of 0.2 mM ADP and 2.0 mM CrP (plus 0.2 mM 
ADP) were tcontr, a d p =  28 ± 14 s (n=3) and tcontr, crp= 15 ± 4 s (n=3), respectively, while after 
direct addition of 0.2 mM ATP a significantly longer tcontr, ATP= 334 ± 13 s (n=3; p<0.01) was 
required to initiate contraction. These results suggest that the actomyosin-associated M-CK 
and AK1 enzymes serve to channel ATP molecules, and thereby provide the myosin ATPase 
microenvironment with preferential access to metabolic energy.
Although lack of cytosolic M-CK and AK1 phosphotransfer blunted CrP- and ADP- 
supported actomyosin contraction, activation of pyruvate kinase (PK) catalyzed ATP 
production by the glycolytic substrate phosphoenolpyruvate (PEP) secured contraction in both
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wild-type and MAK== actomyosin complexes (Fig. 3C). PEP, at 2.0 mM, produced 
contraction in MAK= = actomyosin at approximately similar rates as in wild-type, i.e. 0.064 ± 
0.008 (n=3) in wild-type and 0.05 ± 0.01 (n=2) absorbance units-min-1-mg protein-1 in mutant 
actomyosin (Fig. 3C). Thus, the ability of actomyosin to contract using ATP delivered 
through the glycolytic pathway was not affected in the MAK == muscle, suggesting that 
alternative safeguarding routes for high-energy phosphoryl transfer are operational in the 
absence of M-CK and AK1.
A B
actomyosin contraction
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Figure 3. Impaired contractile  properties in MAK=/= skeletal m uscle actom yosin  rescued by 
pyruvate kinase activ ity. A. Loss of AK- and CK-mediated contraction in MAK=/= actomyosin. 
Contractile recordings (n=3; preparation from 2 animals per sample), in the presence of 0.2 mM ADP 
and 2.0 mM CrP, of wild-type (open circles) and MAK=/= (closed circles) skeletal muscle actomyosin. 
B. Effects of ATP from different sources on initiation of wild-type actomyosin contraction. Time to onset 
of contraction measured (n=3) in the presence of exogenous ATP (closed squares) and ATP 
generated by AK/CK-mediated catalysis (open squares). C. Pyruvate kinase-mediated contraction in 
wild-type and MAK=/= actomyosin. Contractile recordings (n=3), in the presence of 2 mM ADP and 2 
mM PEP, of wild-type (open squares) and MAK=/= (closed squares) skeletal muscle actomyosin. 
Representative recordings are shown in A and C.
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Glycolytic and guanylate metabolism in MAK=/_ muscle
Studies in AK1 or M -C K  single-mutant mice and cell model systems suggest a 
compensatory interchange between the AK/CK circuits and the glycolytic machinery for 
energy production (4, 6, 16, 33, 39, 48). We determined here that 18O metabolic labeling of 
glucose-6-phosphate (G-6-P) by hexokinase, the initial step in the glycolytic cascade, was 
significantly increased from 8.1 ± 0.9% (n=6) in the wild-type to 18.9 ± 0.9% (n=6) in 
MAK= = muscle (p<0.05), at a labeling rate of 1.0 ± 0.1 and 3.6 ± 0.5 nmol-min-1-mg protein-1 
(p<0.05, n=6; Fig. 4A), respectively. In line with this finding, the total G-6-P content in 
MAK= = muscle contracting at 2 Hz was higher than in wild-type (12.9 ± 1.3 vs. 5.9 ± 0.3 
nmol G-6-P-mg protein-1, respectively, p<0.05, n=6). These results implicate elevated 
glycolytic phosphotransfer activity that could compensate for lack of metabolic flux through 
the AK1- and M-CK-mediated reactions. Lactate levels, however, remained unchanged in the 
contracting MAK = = muscle (50 ± 2 vs. 47 ± 2 nmol lactate-mg protein-1 in mutant vs. wild­
type muscles; n=6), suggesting a coordinated elevation of pyruvate oxidation, i.e. 
mitochondrial Krebs cycle activity in conjunction with accelerated aerobic glycolysis.
Remodeling of intracellular high-energy phosphoryl fluxes through guanylate 
phosphotransfer circuits may provide additional compensation for deficits in the cellular 
phosphotransfer network (6, 18). Guanine and adenine nucleotide metabolism is intertwined 
through nucleoside diphosphate kinase (NDPK), guanylate kinase (GK), and succinate 
thiokinase catalysed reactions (42, 49-51). Notably, the percentage of y-GTP 18O-labeling was 
significantly higher in MAK = = muscle, 22 ± 2% in MAK = = vs. 13 ± 1% in wild-type, 
respectively (p<0.05, n=6; Fig. 4B), indicating an increased flux through GTP metabolizing 
enzymes such as succinyl-CoA synthase in the Krebs cycle and/or NDPK. Moreover, in 
support of enhanced guanylate phosphotransfer, an increased turnover of P-phosphoryls in 
GTP and GDP was observed in MAK=/= muscle. The percentage of combined P-GTP/GDP 
18O-labeling was 2.8 ± 0.1 (n=3) and 4.5 ± 0.3 (n=3) in wild-type and MAK ;= skeletal 
muscle, respectively (p<0.05; Fig. 4C), indicating increased GK-catalyzed phosphotransfer in 
the MAK = = muscle. Consequently, the increased guanine nucleotide contribution to cellular 
energetics resulted in a 2-fold reduction in the ATP/GTP ratio in mutant muscle (41 ± 3 vs. 78 
± 3  in MAK == and wild-type muscle, respectively; p<0.05, n=6). Thus, in response to 
combined AK1/M-CK deficiency, mutant muscles demonstrate elevated glycolytic and 
guanine nucleotide phosphotransfer metabolism.
Disrupted intracellular energetic communication in MAK=/_ muscles
Efficient removal of ADP and Pi, released in the hydrolysis of ATP, is a prerequisite 
for optimal muscle function (52, 53). Pi produced by cellular ATPase activity in one 
compartment must be captured by ATP supplying pathways to regenerate ATP in another 
compartment. The 18O-phosphoryl labeling technique permits assessment of metabolite 
exchange between different cellular sites (54). The [18O]Pi/[18O]y-ATP ratio, an index for 
intracellular phosphotransfer communication, was significantly reduced in MAK=/= muscles
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Figure 4. Increased hexokinase-catalyzed G-6-P turnover and guanine nucleotide m etabolism  in 
MAK=/= skeletal muscle. A. Percentage of G-6-P phosphoryl oxygens replaced with 18O, as an 
indicator of glycolytic flux rate, measured in wild-type (n=6) and MAK=/= (n=6) GPS muscle paced for 3 
min at 2 Hz. B. Increased y-GTP phosphate turnover in MAK=/= skeletal muscle. Percentage of y-GTP 
phosphoryl oxygens replaced with 18O, as an indicator of enzyme activity catalyzing GTP production, 
measured in wild-type (n=6) and MAK=/= (n=6) GPS muscle paced for 3 min at 2 Hz. C. Increased p- 
GTP/GDP phosphate turnover in MAK=/= skeletal muscle. Percentage of p-GTP/GDP phosphoryl 
oxygens replaced with 18O, as an indicator of guanylate kinase-catalyzed phosphotransfer, measured 
in wild-type (n=6) and MAK=/= (n=6) GPS muscle paced for 3 min at 2 Hz.
(0.45 ± 0.03 vs. 0.66 ± 0.03; p<0.05, n=6), i.e., by 32% compared with the wild-type (Fig. 
5A). Although other factors could contribute to the observed changes, reduction of the 
[18O]Pi/[18O]y-ATP ratio is in line with the compromised ability of mutant muscle to maintain 
metabolite levels and ratios. In this regard, the lower [18O]Pi/[18O]y-ATP ratio in contracting 
MAK== muscle was accompanied by increased 18O labeling of y-ATP (22.2 ± 0.8% in 
MAK== vs. 17.9 ± 0.6% in wild-type, p<0.05, n=6; Fig. 5B). These results suggest an 
increased ATP supply capacity (apparently mitochondrial), yet perturbed energetic
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communication between cellular locales of ATP production and consumption in MAK = 
muscles.
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Figure 5. D isrupted in tracellu lar com m unication between sites o f ATP production and 
consum ption  in MAK=/= skeletal muscle. A. [180 ]P /[180]y-ATP ratio as an indicator of the P, 
exchange rate between cellular ATP-producing and ATP-hydrolyzing sites. [180]P, and [180]y-ATP 
measured in wild-type (n=6) and MAK=/= (n=6) GPS muscle paced for 3 min at 2 Hz. B. Increased y- 
ATP phosphate turnover in MAK=/= skeletal muscle. Percentage of y-ATP phosphoryl oxygens replaced 
with 18O, as an indicator of the cellular ATP synthesis capacity, in wild-type (n=6) and MAK“/_ (n=6) 
GPS muscle.
Phosphotransfer dynamics in MAK_/_ muscle
Metabolic demand and/or stress may cause redistribution of fluxes through 
phosphotransfer pathways (6, 16, 18, 19, 42, 54, 55). Therefore, we measured the relative 
contribution of AK- and CK- and alternative phosphotransfer reactions to total cellular 
phosphotransfer under resting and working conditions. Absence of both AK1 and M-CK did 
not affect total ATP turnover in wild-type or MAK= = resting muscle, which were 11.4 ± 0.2 
vs. 11.5 ± 0.5 nmol ATP-min-1-mg protein-1, respectively (p>0.05, n=6, Fig. 6A). However, in 
the active contracting state, total cellular ATP turnover increased by 114% in wild-type but 
only by 70% in MAK = = muscle, suggesting a lower energetic capacity of AK1 and M-CK 
deficient myocytes. Indeed, in contracting MAK= = muscle total ATP turnover was lowered by 
20% compared with wild-type, i.e., 19.5 ± 1.4 and 24.3 ± 0.7 nmol ATP-min-1-mg protein-1 
(n=6, p<0.05; Fig. 6C), respectively. In wild-type muscle, the estimated AK-flux increased 
from 1.9 ± 0.1 nmol-min-1-mg protein-1 in resting muscle to 5.6 ± 0.4 nmol-min-1-mg protein-1 
in contracting muscle (n=6, p<0.05), an increase of 194%, that could account for 17 and 23% 
of total cellular ATP turnover, respectively (Fig. 6B and D). Although the estimated CK-flux 
was increased by 42%, from 9.4 ± 0.3 (n=6) to 13.3 ± 0.9 (n=6) nmol-min-1-mg protein-1 in 
resting and contracting wild-type muscle, respectively (p<0.05; Fig. 6), the contribution of 
CK-mediated phosphotransfer to total cellular ATP turnover decreased from 83 to 55% in 
response to muscle workload. In the MAK= = knockout muscle, the residual AK flux was 0.48
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± 0.05 in the resting and 0.80 ± 0.08 nmol-min"1-mg protein"1 in the contracting state. Under 
both conditions, AK catalyzed phosphotransfer activity could account for 4% of total ATP 
turnover, indicating that a very limited AK capacity remained in MAK = = muscles (Fig. 6A 
and C). Indeed, residual AK activity in double mutant muscles was 44 ± 9 nmol ATP-min"1 
•mg protein"1 (n=5), which is ~1-2% of total AK activity in the wild-type. In mutant muscle, 
CK flux increased from 5.1± 0.2 at rest to 6.0 ± 0.4 nmol-min-1-mg protein-1 upon activation 
of contractions, and accounted for 45% and 31% of cellular ATP turnover, respectively (Fig.
6). Thus, ablation of AK1 translated into a 75% decline in the contribution of AK catalysis to 
cellular ATP processing, a contribution further reduced, by 82%, under increased workload. 
Absence of M-CK translated into a 46% and 44% reduction in the contribution of CK 
catalysis to cellular ATP processing in resting and contracting muscle, respectively. 
Therefore, in the active state, the combined AK and CK contribution to cellular high-energy 
phosphoryl transfer was reduced from 78% in the wild-type to 35% in MAK= = muscle. This 
phosphotransfer deficit was partially compensated by glycolytic, hexokinase-catalyzed, and 
guanine nucleotide-dependent phosphoryl exchange mechanisms (Fig. 4). Contribution of 
such mechanisms increased from 9% in wild-type to 39% in MAK==, leaving about 25-30% 
of the total metabolically active ATP unexplained. This could be accounted for by the 
remaining phosphotransfer systems, such as the glyceraldehyde 3-phosphate 
dehydrogenase/phosphoglycerate kinase enzyme couple (19, 33, 39, 56), pyruvate kinase (39) 
or by diffusional type of ATP replenishment due to cytoarchitectural rearrangements (57).
DISCUSSION
AK- and CK-catalyzed phosphotransfer reactions have been considered as essential 
mediators in cellular energetic and metabolic signaling processes (3-5, 18, 22). Skeletal 
muscles carrying a null mutation in either AK1 or M -C K  genes demonstrate energetic 
abnormalities coupled with developmental adaptations and metabolic rearrangements within 
the cellular phosphotransfer pathways (6, 18, 24). Absence of AK1 causes an increased flux 
through the CK-catalyzed phosphotransfer (6), whereas absence of M-CK leads to increased 
AK-catalyzed phosphotransfer activity (18, 36). Here, metabolic consequences of combined 
disruption of the M -C K  and AK1 gene in skeletal muscle as well as adaptive rearrangements 
were defined using 18O metabolic labeling to monitor intracellular phosphotransfer dynamics. 
Skeletal muscle devoid of M-CK and AK1 showed a severe decline in total muscle AK and 
CK activities, which translated into a 54% and 85% reduction in CrP and ATP P-phosphoryl 
turnover, respectively. The remaining CK activity can be attributed to the ScCKmit isoform 
still present in mitochondria of MAK==. The reduction in P-phosphoryl turnover is apparently 
less severe in MAK= = compared to the single AK1 knockout muscle, where a 99% reduction 
in P-phosphoryl turnover was observed (6), suggesting that MAK == muscles are more 
proficient in recruiting a functional reserve of the P-phosphoryl transfer capacity. Increased 
flux capacity through the AK3-catalyzed GTP:AMP phosphotransfer
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Figure 6. D ifferentia l dynam ics o f phosphotransfer pathways in w ild -type  and M A K "  muscles.
A. Maintained total ATP turnover in resting MAK“/_ GPS muscle. Total ATP turnover, obtained from 
18O incorporation into cellular high-energy phosphoryls, measured in wild-type (n=6) and MAK=/= (n=6) 
GPS muscle at rest. B. Contribution of AK- and CK-catalyzed phosphotransfer to total cellular ATP 
turnover in resting wild-type and MAK=/= GPS muscle. AK- and CK-catalyzed phosphotransfer 
expressed as the percentage of total ATP turnover, in wild-type (n=6) and MAK=/= (n=6) GPS muscle 
at rest. C. Reduced total ATP turnover in contracting MAK=/= GPS muscle. Total ATP turnover, 
obtained from 18O incorporation into cellular high-energy phosphoryls, measured in wild-type (n=6) and 
MAK“/_ (n=6) GPS muscle paced for 3 min at 2 Hz. D. Contribution of AK- and CK-catalyzed 
phosphotransfer to total cellular ATP turnover in the working wild-type and MAK“/_ GPS muscle. AK- 
and CK-catalyzed phosphotransfer expressed as the percentage of total ATP turnover, in wild-type 
(n=6) and MAK=/= (n=6) GPS muscle paced for 3 min at 2 Hz.
reaction could underlie this phenomenon as the high-energy phosphate from GTP is 
transferred to AMP, followed by conversion to ATP by oxidative phosphorylation in the 
mitochondrial matrix (9), in line with the increased y-GTP turnover in MAK= = muscles.
The presence of cytosolic CK and AK within local microenvironments of actomyosin 
ATPases facilitates transfer of high-energy phosphoryls to regenerate ATP, thus supporting 
the kinetic and thermodynamic efficiency of muscle contraction (5, 47). Indeed, resting and 
contracting MAK == knockout muscles, displayed overall lower ATP/ADP and higher 
ADP/AMP ratios compared to wild-type. This suggests that AK1 and/or M-CK are not only 
necessary for local ATP regeneration, but also for equilibrating adenine nucleotide gradients
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throughout the entire cytosolic pool. Inefficient local and global communication in MAK = = 
muscle is manifested in a decreased overall cellular ATP turnover and lower Pi levels in 
response to increased workload. This may result from insufficient delivery of ATP to cellular 
ATPase sites despite an increased ATP synthesis capacity as indicated from increased 18O 
labeling of y-ATP.
The interaction between AK, CK, and glycolytic phosphotransfer systems is critical for 
energy supply and local ATP regeneration in different cell types (4, 6, 16, 33, 39, 48, 53). In 
muscles deficient in both AK1 and M-CK, glycolysis is likely the only remaining major 
cytosolic phosphotransfer circuit. Glycolytic metabolism could safeguard maintenance of 
appropriate ATP/ADP ratios in the myosin ATPase microenvironment, required for efficient 
contractile cycles (58, 59). Indeed, the overall concentration and turnover-rate of the first 
glycolytic intermediate, G-6-P, was more than doubled in MAK = = mice. Contribution of 
glycolytic, hexokinase-catalyzed phosphotransfer increased from 8% in wild-type to 37% in 
MAK_/_ muscles, while combined activities of guanylate phosphotransfer enzymes, such as 
succinate thiokinase, NDPK and GK, could account for only 0.6 and 1.8% of total cellular 
ATP turnover in wild-type and MAK_/_ muscle, respectively. Therefore, enhanced ATP 
production and distribution by glycolytic enzymes may have a general compensatory role in 
sustaining physiological relevant ATPase activity in MAK= = muscle.
Localization of glycolytic enzymes within myofibrils at the I- and M-bands, as well as 
their binding to mitochondrial outer membrane, provides a network capacity for transferring 
and distributing high-energy phosphoryls (13, 60, 61). This global glycolytic function 
integrating mitochondrial ATP production with cytosolic sites of ATP consumption, may 
underlie increased coupling between high-energy phosphoryl flux through glycolytic 
metabolism and muscle contraction in MAK == mice. Indeed, the apparently increased 
glycolytic flux in MAK= = skeletal muscle was paralleled by the increased ATP synthesis rate 
and enhanced metabolic labeling of y-GTP. This result can be explained by elevated Krebs 
cycle activity (42), coupled to increased oxidative phosphorylation activity. The finding of a 
significant increase in volume of intermyofibrillar mitochondria in MAK_/_ muscles (E.J.; 
unpublished observation) similar to that seen in AK1  and M -C K  single mutants (6, 24), and in 
other muscles with compromised energy metabolism (62-64), supports this conclusion. Thus, 
it is conceivable that MAK = = muscles combine the advantages of increased glycolytic flux 
and improved mitochondrial potential for aerobic ATP production to compensate for the loss 
of M-CK and AK1 supported high-energy phosphoryl transfer activities.
Measurements in isolated actomyosin showed that the onset of contraction was 
approximately 12-20-fold faster if ATP was provided via AK1 or M-CK, rather than by direct 
ATP supply through diffusional nucleotide exchange. In this regard, previous functional 
studies on fast-twitch muscles of mice lacking M-CK have demonstrated lack of burst activity 
(24) and compromised ability to sustain contraction force (43), in line with loss of preferential 
access to ATP via the CK reaction. Similarly, AK1 activity facilitates muscle relaxation, 
indicating that removal of contraction-produced ADP by AK1 and its phosphorylation to ATP
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takes place much faster than diffusional exchange of ADP to ATP (47). As ultra-fast local and 
global ATP regeneration is required to sustain contractile activity in fast-twitch muscle (24, 
52), this would underscore the particular importance of the CK- and AK-catalyzed 
phosphotransfer in these muscle types. Moreover, mice carrying a single mutation in the AK1 
or M -C K  gene show more pronounced adaptations at the molecular and architectural level in 
their fast rather than slow-twitch fibers (24, 37-39). Thus, tight coordination between cellular 
sites of ATP consumption and ATP generation by the complete set of high-energy phosphoryl 
transfer pathways would not only be essential for safeguarding cellular energetic economy (6, 
33, 54, 65) but also for preserving the differential physiological contractile characteristics of 
slow and fast twitch muscles. Studies in vivo, with measurement of physiological performance 
of intact muscle will be eventually necessary to reveal further details.
In summary, this study demonstrates that lack of the M-CK and AK1 catalytic capacity 
abolished CK- and AK-mediated efficient high-energy phosphoryl delivery to skeletal muscle 
actomyosin ATPase accompanied with compromised ability to sustain ATP turnover and to 
maintain nucleotide ratios in response to functional load. An apparent compensatory 
redistribution of high-energy phosphoryl flux through glycolytic and guanylate 
phosphotransfer pathways lessened the genetic stress-induced energetic burden. The results 
provide reverse genetics-based evidence for the physiological significance of an integrated 
cellular phosphotransfer and energy-homeostasis network composed of complementary 
enzymatic pathways.
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ABSTRACT
Adenylate kinases (AK, EC 2.7.4.3) have been considered important enzymes for 
energy homeostasis and metabolic signaling. To gain a better understanding of their cell- 
specific significance we studied the structural and functional aspects of products of one 
adenylate kinase gene, AK1, in mouse tissues. By combined computer database comparison 
and Northern analysis of mRNAs, we identified transcripts of 0.7 and 2.0 kilobases with 
different 5’ and 3’ non-coding regions which result from alternative use of promoters and 
polyadenylation sites. These mRNAs specify two distinct proteins, AK1 and a membrane- 
bound AK1 isoform (AK1P), which differ in their N-terminal end and are co-expressed in 
several tissues with high-energy demand, including the brain. Immunohistochemical analysis 
of brain tissue and primary neurons and astrocytes in culture demonstrated that AK1 isoforms 
are expressed predominantly in neurons. AK1P, when tested in transfected COS-1 and N2a 
neuroblastoma cells, located at the cellular membrane and was able to catalyze 
phosphorylation of ADP in vitro. In addition, AK1P mediated AMP-induced activation of 
recombinant ATP-sensitive potassium channels in the presence of ATP. Thus, two structurally 
distinct AK1 isoforms co-exist in the mouse brain within distinct cellular locations. These 
enzymes may function in promoting energy homeostasis in the compartmentalized cytosol and 
in translating cellular energetic signals to membrane metabolic sensors.
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INTRODUCTION
Metabolic signaling and cooperation between different subcellular compartments is of 
pivotal importance for the maintenance of cellular energy homeostasis (1-5). This implies the 
presence of a control network that adjusts the rate of energy conversion to the amount of work 
needed in order to attain a steady state.
Phosphotransfer reactions are believed to play a critical role in the transduction o f 
metabolic signals to different intracellular locales. Specifically, the adenylate kinase (AK)- 
mediated phosphotransfer reactions facilitate metabolic communication between intracellular 
ATP-production and -utilization sites and have been shown to efficiently relay energetic 
signals to metabolic membrane sensors, in particular the ATP sensitive potassium (KATP) 
channels (6-11). In this way, the membrane electrical activity is coupled to the cellular 
metabolic status (12, 13).
Adenylate kinases (AK, EC 2.7.4.3) are evolutionarily strongly conserved enzymes 
that catalyze the reaction ATP + AMP o  2 ADP. Several isoforms exist that each have their 
own tissue specific distribution and distinct subcellular localization (14). Studies to unravel 
the biological significance of adenylate kinases have mainly focused on the role of AK1, the 
major AK isoform, in heart and skeletal muscle (5, 7, 15-18). The role of AKs in brain, where 
three o f the five known AK isoforms are expressed, is less well described although recent 
studies indicate that they may contribute to neuronal maturation and regeneration (19-22).
Here, we aim to clarify the physiological role of AK1 gene products in the mouse 
brain. The main product of the AK1 gene is cytosolic AK1. However, recently, the existence 
of another gene product, p53-inducible membrane-bound AK1P, has been reported and 
implicated in p53-dependent cell-cycle arrest (23). Earlier, we have shown that genetic 
ablation of the AK1 gene, and hence both the AK1 and AK1P proteins, compromises cellular 
energetic economy but is still compatible with overtly normal development (5). By studying 
their cell-type expression, intracellular distribution and accessory role in energy transfer and 
signaling we have here obtained evidence that AK1 and AK1P may fulfill spatially distinct 
and location-dependent roles in brain energy homeostasis.
MATERIALS AND METHODS 
Stable and transient transfection assay
Mouse AK1 and AK1P were expressed from the eukaryotic expression vector pSG5
(24), which was modified to create multiple cloning sites. For transfection of COS-1 cells 
(ATCC #CRL-1650) supercoiled plasmid DNA was transfected using DEAE-dextran. Briefly, 
1-4 ^g plasmid DNA was mixed with 100 ^g chloroquine (Sigma) and 50 ^g DEAE-dextran 
(Sigma) in a total volume of 1 ml OPTIMEM (Gibco). Prior to addition of the DNA solution, 
cells were washed with OPTIMEM. The DNA solution was added to the cells and incubated 
for 2 hours at 37°C and 7.5% CO2. Cells were shocked with 10% DMSO in PBS for two min
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and fresh Dulbecco’s Modified Eagle Medium (DMEM, Gibco) medium containing 10% 
Fetal Calf Serum (FCS, PAA Laboratories) was added to the cells. Incubation was continued 
for 24-48 hours at 37°C and 7.5% CO2, after which the cells were used for experiments. For 
stable transfection of the murine neuroblastoma cell line N2a (ATCC #CCL-131) AK1 and 
A K lß cDNA inserts were cloned downstream of the SV40 promoter and enhancer elements in 
a modified pSG5 expression plasmid (24), carrying a selectable puromycine resistance gene. 
The eukaryotic expression vectors encoding Kir6.2 (pcDNA3.1/ZEO; Invitrogen) and SUR2A 
(pcDNA3.1; Invitrogen), carrying respectively a zeocin and neomycin selectable cassette, 
were used to reconstitute recombinant KATP channels (8). N2a cells were transfected with 5-10 
^g linearized plasmid DNA upon lipofectamine treatment according to the manufacturers 
instructions (Life Technologies). Twenty-four hours after transfection, cells were given 
DMEM, containing 10% FCS and the desired antibiotic. G418 (Gibco), zeocin (Invitrogen), 
and puromycin (Clontech) were used at concentrations of 400, 350, and 12 ^g/ml, 
respectively. Resistant colonies were isolated after 12-14 days and analyzed for stable DNA 
integration and protein production by means of Southern (5) or Western blot analysis.
Primary hippocampal neuron and astrocyte co-culture
Primary cultures of astrocytes and hippocampal neurons were prepared as described
(25). Briefly, brains were isolated from 16.5 dpc fetuses or 1-day old mouse pups from AK1 
knockout (5) and wild-type control animals, having a 50%-50% C57BL/6x129/Ola mixed 
inbred background. Meninges were removed and hippocampi were separated from the 
hemispheres. Both hippocampi and hemispheres were incubated for 20 min at 37°C in Hank's 
Balanced Saline Solution (HBSS, Gibco), containing 0.05 % trypsin, 1 mM EDTA, and 20 
mM HEPES (pH 7.35). To obtain astrocytes, cerebral hemispheres were dissociated by 
repeated pipetting (10 times) with a Pasteur pipette, seeded in T165 tissue culture flasks 
(Corning) and cultured in DMEM, supplemented with 10% FCS and 0.05 mg/ml gentamycin 
(Gibco). Neurons were isolated by dissociating hippocampi by repeated pipetting, after which 
the cells were seeded on 24 mm coverslips (Menzel Gläser) that were coated overnight with 1 
mg/ml poly-L-lysine (Sigma) in borate buffer (3.1 g/l boric acid, 4.75 g/l borax, pH 8.5). Cells 
were allowed to attach for 3-4 hours in DMEM, containing 10% FCS and 0.05 mg/ml 
gentamycin. Finally, coverslips with attached neurons were inverted onto a 30-50 % confluent 
layer of astrocytes. The co-culture was maintained for up to 2 weeks in Neurobasal Medium 
(Gibco), containing B27 supplement (Gibco), 0.5 mM glutamine, and 0.05 mg/ml gentamycin 
at 37°C and 5% CO2 .
Immunohistochemical analysis
Mice were deeply anesthetized with a mix containing Hypnorm® (fentanyl citrate 
0.315 mg/ml and fluanisone 10 mg/ml; Janssen Pharmaceutica), Dormicum® (midazolam 5 
mg/ml; Roche) and distilled water in a 1:1:2 dilution (0.20 ml/mouse i.p. or 0.07 ml/10 gram 
body weight) and transcardially perfused with 15 ml 0.1 M phosphate buffered saline (PBS;
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pH 7.4) followed by perfusion of 30 ml freshly prepared solution of 0.1 M phosphate buffer 
containing 4% paraformaldehyde. Brains were dissected and stored overnight at room 
temperature in 0.1 M phosphate buffer (pH 7.4) containing 1% paraformaldehyde. Brains 
were embedded in paraffin and cut into 5 ^m slices using a microtome. Subsequently, brain 
sections were dewaxed and dehydrated with ethanol and incubated for 30 min in 
methanol/0.375% H2O2 at room temperature. Sections were rinsed in water and PBS and prior 
to primary antibody staining sections were incubated in PBS containing 1% bovine serum 
albumine (BSA) fraction V (Sigma), 2% normal donkey serum, and 0.15% glycine to block 
non-specific binding sites. Polyclonal anti-AK1 serum (see below) was used in a 1:10000 
dilution and incubated overnight at 4°C in PBS containing 1% BSA, 2% normal donkey 
serum, and 0.15% glycine. Sections were washed (3x10 min) in PBS containing 1% BSA and 
subsequently incubated for 1 hour with biotin-sp-conjugated donkey anti-mouse or biotin-sp- 
conjugated donkey anti-rabbit (Jackson ImmunoResearch Laboratories) in a 1:100 dilution. 
Sections were washed (3x5 min) in PBS containing 0.05% tween, subjected to the avidin- 
biotin horseradish peroxidase system (Vector laboratories) according to the manufactures 
instructions and stained in 0.03% H2O2 and 2.5 mM diaminobenzidine tetrachloride (DAB). 
Finally, sections were counterstained with hematoxylin, taken to ethanol and xylene, and 
mounted in Eukitt (Kindler) for microscopic analysis (Leitz, Dialux 22).
Immunofluorescence
Cells grown on coverslips were fixed for 5 min in 2% paraformaldehyde in PHEM 
buffer (60 mM Pipes; 25 mM Hepes, pH 6.9; 10 mM EGTA; 2mM MgCl2) at room 
temperature. N2a cells were rinsed once with PBS and permeabilized with 0.2% Triton X-100 
(Amersham) in PBS for 5 min. COS-1 cells were treated identically but permeabilized with 
PBS containing 0.1% saponin for 15 min. To block non-specific binding sites cells were 
preincubated for 30 min in PBS containing 4% BSA. Primary antibody was incubated in PBS 
containing 4% BSA for 1 hour at room temparature. Polyclonal anti-AK1 serum was used in a 
1:5000 dilution. The monoclonal antibody directed against GFAP was prepared according to 
the manufacturers instructions (Neural Cell Typing Set, Boehringer Mannheim) and used in a 
1:10 dilution. The monoclonal P3-tubulin antibody (Promega) was used in a 1:200 dilution. 
Cells were washed (3x5 min) in PBS containing 4% BSA and incubated for 1 hour with 
fluorescein-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories) in a 
1:100 dilution. For nuclei staining, 10 ^g/ml propidium iodide (Sigma) was simultaneously 
incubated with the secondary antibody and RNase (10 ^g/ml). Finally, sections were washed 
(3x5 min) with PBS, embedded in Mowiol (Sigma), and analyzed using a fluorescence 
confocal laser-scanning microscope (MRC1024, Bio-Rad).
RT-PCR
Total RNA from freshly isolated skeletal gastrocnemius muscles and brains were 
extracted using the lithium chlori de-urea method (26). AK1, AK1P and AK2 cDNAs were
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generated by RT-PCR. To this end, 1 ^g RNA extracted from brain or 2 ^g RNA extracted 
from skeletal muscle was reverse-transcribed for 1 hour at 42°C in the presence of 10 ng/^l 
oligo(dT), 1 mM dNTPs, 5 mM dithiothreitol, 40 U RNase inhibitor (RNaseOut; Gibco), 200 
U reverse transcriptase (SuperScript II; Gibco) in a final volume of 20 ^l. PCR amplification 
was performed on RT-product in 5-15 ^l reaction mixture. Primer was derived from the 
nucleotide sequences of human AK1 cDNA, accession no. J04809 (AK1: sense primer, 5’- 
T AT AGAATT CAT GGAAGAGAAGCT GAAGAAGGC C-3 ’; antisense primer, 5’- 
TATACTCGAGTTACTTCAGGGAGTCAAGATAGG-3’) and AK1P cDNA, accession no. 
AJ010109 (AK1P: sense primer, 5’-TATAGAATTCATGGGCTGCTGTGTGTCTAGTG-3’; 
antisense primer, 5 ’ -T AT ACTCGAGTT ACTTCAGGGAGTCAAGAT AGG-3 ’). Mouse AK2 
cDNA (exon 2-6) was amplified using primers derived from the nucleotide sequence o f rat 
AK2 cDNA, accession no. D13061 (AK2: sense primer, 5’-ACCCAGGCACCCAA-3’; 
antisense primer, 5’-GGTCTGGGACGCATC-3’). PCR reactions were carried out in 50 ^l 
containing 0.25 mM dNTPs, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.1% 
Triton x-100, 100 ng of each primer of the appropriate primer-combination and 2 U Taq 
polymerase, using thirty successive cycles, at 96°C for 1 minute, at 55°C for 1 minute, and 
72°C for 1 minute. The amplified AK1 or AK1P cDNA was purified by agarose gel 
electrophoresis and, for expression studies in COS-1 cells, subcloned between the EcoR  I and 
Xho I sites in the pSG5-vector (24).
Northern blot analysis
RNA blots were hybridized with 32P-labeled cDNA probes. For detection o f AK1 
transcripts mouse AK1 cDNAs (spanning exon 2-7) or rat AK1 cDNAs (spanning exon 5-7; 
kindly provided by T. Tanabe (14)) were used, whereas mouse AK2 cDNA (exon 2-6) was 
used as probe to determine AK2 mRNA levels. Hybridization was carried out overnight at 
68°C in 0,5 M NaPO4-buffer pH 7.2, 7% (w/v) SDS, 1 mM EDTA, and blots were washed to 
a final stringency of 0.1xSSC/1% (w/v) SDS at 68°C when using the AK1 cDNA exon 2-7 or 
0.3xSSC/1% (w/v) SDS at 65°C when using AK1 cDNA exon 5-7 and AK2 cDNA as a 
probe. Blots were exposed to Kodak X-Omat films.
Generation of AK1 antibody
Full-length AK1 cDNA, spanning exon 2 to 7, was cloned into a suitable prokaryotic 
expression vector, pGEX-3X (Pharmacia). AK1-glutathion S-transferase (GST) fusion 
proteins were expressed in large quantities in E.coli and isolated using column-immobilized 
glutathion, according to the manufacturers instructions. Rabbits were subcutaneously 
immunized with 500 ^l PBS containing 500 ^g AK1-GST fusion protein in Freunds adjuvant 
and boosted twice with 500 ^l PBS containing respectively 500 and 200 ^g AK1-GST fusion 
protein. Blood was collected and the antibody directed against AK1-GST fusion protein was 
used in Western blot and immunohistochemical assays in a 1:10000 dilution.
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Western blot analysis
Transiently or stably transfected cells were lysed and extracted in a buffer containing 
100 mM KCl, 25 mM Tris-HCl (pH 8.0), 0.05% NP-40, 1 mM, 5 mM MgCh, 5 mM PMSF 
and complete protease inhibitor cocktail (PIC; Boehringer Mannheim). The lysate was 
centrifuged (10 min, 8000 g, 4°C) and supernatant and pellet fractions each were diluted in 
sample buffer containing 100 mM Tric-HCl (pH 6.8), 200 mM dithiothreitol, 20% glycerol, 
4% SDS, and 0.2% bromophenol blue. Proteins were separated on 10-15% SDS- 
polyacrylamide gels, and electrophoretically transferred onto nitrocellulose membranes. AK1 
and AK1P proteins were detected using the anti AK1-GST antibodies described above. 
Immune complexes were visualized by chemiluminescence using goat anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories) coupled to horse raddish peroxidase as a secondary 
antibody, followed by exposure to Kodak X-omat AR film.
Membrane isolation
Cell lysates were prepared by Dounce homogenization. Briefly, cells were washed and 
harvested in PBS containing 1 mM EGTA and complete protease inhibitor cocktail (PIC; 
Boehringer Mannheim) and centrifuged (10 min, 2000 g, 4°C). The pellet was resolved in a 
buffer containing 10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 0.5 mM EDTA, 4 mM 
dithiothreitol, and PIC in a final volume of 3 ml, incubated for 10 min on ice, and subjected to 
40 strokes of a tight fitting pestle. Subsequently, 3 ml buffer containing 10 mM Tris-HCl (pH 
7.5), 4 mM dithiothreitol, 0.5 M sucrose, 0.3 M KCl and PIC was added to the homogenate 
and subjected to another 20 strokes. After centrifugation (20 min, 1500 g, 4°C) the 
supernatant was ultracentrifuged (40 min, 40000 g, 4°C) and the pellet, containing the 
membranes, homogenized in 10 mM Tris-HCl (pH 7.5), 2 mM dithiothreitol, 0.25 M sucrose, 
0.15 M KCl and PIC using a teflon homogenizer.
AK activity assay
Transiently or stably transfected cells were lysed by Dounce homogenization and 
enzyme activities measured using coupled enzyme assays with a Beckman DU 7400 
spectrophotometer at 340 nm. The activity of AK was measured in 100 mM potassium 
acetate, 10 mM HEPES (pH 7.5), 20 mM glucose, 4 mM MgCh, 2 mM NADP+, 2 mM ADP, 
2 mM EDTA, 2 mM dithiothreitol, 4.5 U/ml hexokinase, and 2 U/ml glucose-6-phosphate 
dehydrogenase.
Electrophysiology
Patch-clamp recordings were performed in excised patches from transfected 
neuroblastoma N2a cells using the inside-out configuration. Pipettes (~7-10 MQ) were filled 
with (in mM) KCl 140, CaCl2 1, MgCl2 1, HEPES-KOH 5 (pH 7.3), and cells superfused with 
(in mM): KCl 140, MgCl2 1, EGTA 5, HEPES-KOH 5 (pH 7.3). Experiments were performed 
at 30±1oC using a temperature controller (TC2bip; Cell MicroControls). Channel activity was
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analyzed and presented as NPo, where N is the number o f channels and Po the open channel 
probability (27).
Computer analysis
Promoter and poly(A)+ addition signals were predicted by using the computer
programs BDGP Neuronal Network Promoter Prediction (URL:
http://www.fruitfly.org/seq_tools/promoter.html) and HCpolya (URL:
http://l25.itba.mi.cnr.it/~webgene/wwwHC_polya.html). Exon-intron boundaries were
predicted with BDGP, Splice Site Prediction by Neuronal Network (URL: 
http://www.fruitfly.org/seq_tools/splice.html).
Statistics
Data are presented as mean ± S.E. Student’s t test for unpaired samples was used for 
statistical analysis, and P<0.05 was considered significant.
RESULTS
Characterization of the mouse AK1 gene
Screening o f a mouse Genomic Database with part o f the mouse AK1 intron 3 
sequence (5) revealed the presence of a DNA sequence (Acc AC021446) that contained the 
entire AK1 gene. To identify exons and exon-intron boundaries, the genomic EST clone 
AC021446 was aligned with mouse (Acc AJ010108), rat (Acc D13376), and our own 
subcloned mouse AK1 cDNA sequences (see below) or determined in silico using the Splice 
Site Prediction program (URL: http://www.fruitfly.org/seq_tools/splice.html). As shown in 
Fig. 1A the mouse AK1 gene contains 7 exons and 6 introns, distributed over 9567 base pairs 
(bp). Next, we analyzed the sequence with a Time-Delay Neural Network (TDNN) program 
for the prediction o f transcription-initiation sites (URL: 
http://www.fruitfly.org/seq_tools/promoter.html). The transcription-initiation site was located 
82 bp upstream of the ATG startcodon in the AK1 transcript and referred to as position +1 of 
the AK1 gene. A TATAA sequence was present at position -29 to -24 and very likely 
represents the functional TATA box of the AK1 promoter (Fig. 1A). Strikingly, we found the 
mouse -44 to -10 sequence to be completely identical to the -56 to -22 sequence (with the 
TATAA at position -41 to -36) in the promoter of the human AK1 gene (28), indicating a 
high degree of evolutionary conservation of the upstream regulatory regions in the AK1 gene 
area.
Previous studies in murine cells had indicated that another transcript, designated AK1P 
mRNA, can be produced upon induction of the tumor suppressor protein p53 (23). In this 
transcript an alternative exon 2 (exon 2P) segment is present, which we located between 
positions +3996 to +4130 in the mouse AK1 gene (Fig. 1A). Interestingly, TDNN-program
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prediction revealed presence of an alternative promoter initiation region (+3957 to +4007) 
including a TATA box (+3970 to +3974) upstream of exon 2P, supporting the assertion that 
the expression of AK1P is the result of alternative promoter usage rather than alternative 
splicing o f exon 1.
F igu re  1. M ouse adeny la te  k inase  1 gene  and g e n e -p ro d u c t s tru c tu re . A. Structural organization 
o f the mouse AK1 gene. Top, partial restriction map of the AK1 gene. Bottom, AK1 gene structure. 
Exons: black or shaded. Introns or extragenic regions: horizontal lines. Numbers above the exons 
indicate the size in basepairs (bp). Numbers below the exons indicate exon order and intron size in bp. 
Positions of in silico predicted transcription-initiation regions are double underlined: A and B indicate 
the putative initiation sites of AK1 and AK1P transcripts, respectively. Vertical black lines (I, II, and III) 
indicate possible poly(A)+ addition signals. B. Structure of mRNA and protein products of the mouse 
AK1 gene. Exon derived segments in mRNAs are given as boxes (open is translated, shaded is 
untranslated). The AK1 translation startcodon is located in exon 2, the startcodon for AK1P is in exon 
2P. The translation stop codon is situated in exon 7. Arrows indicate non-translated mRNA regions in 
bp. C. Schematic representation of the 0.75 and 2.0 kb AK1 transcripts. Two polyadenylation signals 
were identified in the long transcript.
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Tissue distribution and isoform profiles of AK1 mRNAs.
In order to examine the tissue-specific expression o f AK1 we isolated the full-length 
AK1 cDNA, spanning exon 2 to 7, and used this as probe in Northern blot analysis (Fig. 2). 
High expression of AK1 was found in skeletal muscle, brain, and heart. AK1 was moderately 
expressed in kidney, whereas expression was low or below detection level in lung, stomach, 
spleen and liver. Altogether three types o f transcripts with molecular weights of 
approximately 2.0, 1.5 and 0.7 kb were detected in skeletal muscle, heart, and brain o f wild 
type mice. The production o f these transcripts is likely to be tissue-type dependent, as the 
relative abundance of the 0.7 kb transcript in heart was 5- and 2-fold higher than in skeletal 
muscle and brain, respectively. Identical tissues from AK1-/- mice lacked signals for all three 
mRNAs (Fig. 2A; 5), confirming that they are products from a single gene.
The presence o f AK1 mRNA species that differ in length may be the result of 
differential use of poly(A)+ addition signals (28). Computer analysis (URL: 
http://l25.itba.mi.cnr.it/~webgene/wwwHC_polya.html) of the last exon of the mouse AK1 
gene predicted three polyadenylation signals at positions 8356 (acactaaaga sequence), 9545 
(aaaataaata sequence), and 9549 (taaataaatg sequence), respectively (Fig. 1A). EST/cDNA 
searches indeed confirmed the occurrence of short (accession number AI853614 and 
AI326047) and long (accession number AJ010108) AK1 3’ non-coding sequences in 
individual cDNA clones in different databases. Sequence alignment with the genomic AK1 
clone positioned the acactaaaga and taaataaatg/taaataaatg signals at 22 and 17/21 bp before the 
actual start of the poly(A) tails (Fig. 1C), providing strong support for their functional role in 
the production of the 2.0 and 0.7 kb AK1 mRNA species. Due to lack of data for full-length 
AK1P cDNA(s) in the EST database we were not able to demonstrate the existence of 
multiple AK1P mRNA species with poly(A) tails at different positions. We surmise, however, 
that the processing of primary AK1P mRNA transcripts follows the same route as AK1 
mRNA transcripts, and hence, that both mRNAs bear similar 3’ non-coding ends. The origin 
of the 1.5 kb AK1 transcript was not investigated further, and we therefore currently do not 
know whether this mRNA also results from alternative splicing and/or alternative 
polyadenylation.
To test whether the 2.0 and 0.7 kb bands each represented heterogeneous mixtures of 
co-expressed AK1P and AK1 mRNAs RT-PCR was performed, taking advantage of the 
unique exon 2P sequences in the AK1P cDNA sequence (23). DNA products with sequences 
corresponding to AK1 P cDNA were produced on both brain and gastrocnemius skeletal 
muscle mRNA templates (data not shown), suggesting that AK1P is expressed together with 
AK1 in these tissues. Whether this implies full congruence of AK1 and AK1P mRNA 
expression in all cell types remains subject for further study.
To test whether co-expression of cytosolic (i.e. AK1/AK1P) and mitochondrial AKs 
was also genetically programmed we analyzed the tissue distribution o f the mRNA for AK2, 
the only adenylate-specific mitochondrial AK isoform (14). High levels o f expression o f AK2 
mRNA were found in heart, liver, and kidney (Fig. 2B). In fact, expression of mRNAs for
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AK1 (+ AK1P, presumably) and AK2 appeared mutually exclusive in all tissues analyzed, 
with the exception of the heart (Fig. 2B). Two different AK2 mRNAs with lengths of 
approximately 0.9 and 1.7 kb were detected. Earlier it has been reported that bovine AK2 
transcripts are alternatively spliced, resulting in short AK2A (0.9 kb) and long AK2B (1.7 kb) 
mature mRNAs (29). Our results suggest that the ability of AK2 transcripts to undergo 
alternative splicing has been evolutionarily conserved between species. Apparently, this 
splicing is cell-type dependent as mouse heart muscle expressed only the shorter AK2A 
transcript (Fig. 2B, middle panel).
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F igu re  2 . T issu e -sp e c if ic  e xp re ss io n  o f AK1. A. Northern blot analysis of RNAs from wild-type (+/+) 
and AK1 knockout (-/-) tissues. Lanes were loaded with equivalent amounts of total RNA (10 |jg) from 
various tissues, and the resulting blot was probed with 32P-labeled mouse AK1 cDNA probe (exon 2­
7). Note the high expression of AK1 mRNA in skeletal (sk) muscle, heart, and brain of wild type 
animals and absence of signal in homozygous mutants. B. Tissue distribution of AK1 and AK2 
mRNAs. Northern blot of RNAs from various tissues probed with rat AK1 (exon 5-7) and mouse AK2 
(exon 2-6) cDNA show mutually exclusive expression profiles for AK1 and AK2 (except for heart). The 
GAPDH mRNA signal was used as a control for loading. As an indicator of transcript size, the 18 S 
RNA position is marked.
AK1 expression in brain
To assess cell type-dependence of AK1 expression in the brain we performed 
immunohistological analyses of paraffin-embedded adult brain sections from forebrain, 
midbrain, and cortex. Fig. 3A shows AK1 immunoreactive neurons in the suprachiasmatic 
nucleus of the mouse midbrain. In fact, in all brain sections examined, AK1 expression was 
uniquely confined to neurons, including Purkinje cells in the cerebellum (not illustrated). The
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F igu re  3 . C e ll-type  de p e n d e n t e xp re ss io n  o f AK1 in th e  bra in . A. Immunohistochemical 
localization of AK1 in a coronal section of the suprachiasm atic nucleus, showing a high level of AK1 
immunoreactivity in neurons. As a control, sections were stained with preimmune serum. Nuclei were 
counterstained with hematoxylin. B and C . Fluorescent images of primary neurons and astrocytes of
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specificity of the antibody was confirmed with control incubations with pre-immune serum 
under identical conditions (Fig. 3A). These results support a role in the brain for AK1 in 
neurons only. We next examined whether the cell-type dependent expression of AK1 was also 
maintained in primary neurons and astrocytes in culture. As shown in Fig. 3B, strong AK1 
expression was only seen in neurons. Astrocytes from wild type and AK1 knockout mice 
showed only marginal staining or no staining at all with the AK1 antiserum used (Fig. 3C), 
confirming the in vivo findings. AK1 reactive staining in neurons was dispersed throughout 
the cell body, and also included the axons, dendrites and the nucleus (Fig. 3B). Primary 
neurons from AK1 knockout mice gave no immuno-reactive signal. From our findings in cells 
in tissue and in culture we conclude that AK1 has its main role in neurons, and may be less 
important for energy metabolism in astrocytes.
Distinct subcellular localization of AK1 isoforms
To evaluate functional enzymatic properties of AK1 and AK1P their cDNAs were 
cloned in a mammalian expression vector and transiently expressed in COS-1 cells. Our 
polyclonal antibody directed against bacterially produced AK1-GST fusion protein recognized 
both products equally well and revealed the anticipated subcellular distribution, with AK1 
located mainly in the cytosol and AK1P mainly cell membrane bound (23) (Fig. 4A). 
Additionally, we observed strong immunofluorescence signals at the nuclear envelope in 
many, but not all, AK1P transfected cells, suggesting that the AK1P protein is not only 
anchored in the cell membrane but also associated with the nuclear envelope (Fig. 4A), in line 
with recent reports on the role o f AK in regulating nuclear membrane function (30).
Conspicously, we identified the presence of doublet immune-reactive bands of AK1 
and AK1P proteins in transiently transfected COS-1 cells. Besides a 22 kDa AK1 protein an 
additional protein with an molecular mass of approximately 44 kDa was detected in the pellet 
fraction of transfected cells (Fig. 4B). Similarly, in the supernatant fraction of cells expressing 
the membrane-bound AK1P two proteins were detected, at 23 and 46 kDa (Fig. 4B). The 
slightly decreased mobility on SDS-PAGE of AK1P compared with AK1, must be due to its 
altered N-terminus and presence of the myristoylation moiety which anchors the protein into 
the cell membrane (23). In the pellet fraction of COS cells that expressed the AK1P protein, a 
smear o f immuno-reactive products was detected, probably caused by incomplete SDS- 
solubilization of the lipid bilayers in which the AK1P protein resides. The identification of 
additional bands, migrating at roughly twice the apparent molecular weight o f monomer 
proteins, allows the conclusion that mouse AK1 and AK1P may occur as dimeric structures,
wild type (a-c) and AK1 knockout mice (d-f) in in vitro culture. p3-tubulin stained cells are neurons, 
GFAP stained cells are astrocytes. Note the high expression of AK1 in neurons but marginal 
expression in astrocytes. As a control, AK1 deficient primary cultured neurons and astrocytes were 
stained.
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which are not completely broken up by detergent treatment prior to and during gel 
electrophoresis. The existence o f dimeric and trimeric adenylate kinase structures has been 
reported for E.coli and Archaea bacteria earlier (31, 32).
F igu re  4 . S u b ce llu la r lo ca liza tio n  o f AK1 and 
AK1P. A. COS-1 cells were transiently transfected 
with AK1 and AK1P cDNAs, immunostained for 
AK1 and analyzed by confocal laser scanning 
microscopy. Note the cytosolic distribution of AK1, 
and cell and nuclear membrane localization of 
AK1P. B. W estern blot images for empty vector, 
AK1, and AK1P. COS-1 cells were transiently 
expressed with empty vector, and AK1 and AK1P 
expression vectors, respectively. The cell lysate 
was fractionated into supernatant (S) and pellet 
(P) and proteins present in both fractions were 
subjected to SDS-PAGE and W estern blot 
analysis. Presence of AK1 reactive protein was 
revealed by staining with antiserum against 
bacterially expressed AK1-GST fusion protein.
The enzymatic properties and location of both AK1 gene products in a neuronal cell­
like context were examined in stably transfected neuroblastoma (N2a) cell lines with 
eukaryotic expression vectors carrying either AK1 or AK1P cDNAs. N2a cells were chosen as 
recipient cells as they appeared naturally devoid of AK1 (data not shown). 
Immunohistochemical analysis and biochemical fractionation of extracts from populations of 
cells from several transfected and puromycin selected (see Materials and Methods) N2a cell 
clone populations confirmed the distinct subcellular partitioning o f cytosolic and membrane- 
bound AK1 in N2a cells (Fig. 5A). As anticipated from our COS cell experiments, AK1 
occurred predominantly in the cytosolic fraction, while AK1P was particularly enriched in the 
membrane fraction (Inset, Fig. 5B and 5C). It is of note here that we observed again additional 
immunoreactive proteins with a molecular weight twice of that of the AK1P protein (not 
shown). As the stably transfected N2a cell lines, unlike COS cells, produce “near natural” 
levels of AK gene products, we consider this a strong indication for the existence of AK1(P) 
dimers in eukaryotic tissues (data not shown).
In order to measure the phosphotransfer activity of AK1 and AK1P we compared 
homogenate and membrane fractions of our N2a cell clones. In the cytosolic protein fraction 
from cells expressing AK1 the phosphotransfer activity was 998 ± 8 nmol ATP minute-1 mg
AK1P is a functional adenylate kinase
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protein-1, but only 141 ± 3 nmol ATP minute-1 mg protein-1 for cells expressing AK1P. In 
cytosolic extract from mock-transfected controls cells this activity was 56 ± 4 nmol 
ATP minute-1 mg protein-1. In contrast, the adenine nucleotide-dependent AK activity 
determined in the membrane fractions of cells expressing AK1P and AK1 was 730 ± 38 and 
63 ± 3 nmol ATP minute-1 mg protein-1, respectively, and only 7.7 ± 0.4 nmol ATPminute-1 
mg protein-1 for control cells (Fig. 5B and 5C). Almost complete pharmacological inhibition 
of AK1 was achieved with the specific inhibitor diadenosine pentaphosphate (Ap5A) (33), as 
shown in Fig. 5D. The enzymatic activity in the membrane fraction of AK1P expressing cells 
was equally sensitive, and reduced to 94% in the presence of Ap5A (Fig. 5E). Thus, these 
results demonstrate that AK1P occupies its own membranous intracellular niche, but is 
otherwise a fully functional adenylate kinase.
AK1P mediates AMP-induced activation of KATP channels in the presence of ATP
Adenylate kinases may serve in local communication o f energetic signals and 
compartmentalized regulation o f ATP-sensitive protein systems, such as KATP channels (8­
11). In order to evaluate the function of AK1P we focused on its specific effect on KATp 
channel regulation in neuroblastoma N2a cells stably transfected with eukaryotic-expression 
vectors bearing cDNA inserts for full-length channel components Kir6.2 and SUR2A. N2a 
cells were first co-transfected with Kir6.2 and SUR2A producing vectors, and neomycine and 
zeocin resistant clones with stable integrations of complete cDNAs for both channel subunits 
were selected after Southern blot analysis (see Materials and Methods for details). Next, the 
resulting cell line, referred to as A10, with properly integrated SUR2A and KIR6.2 cDNAs, 
was used for transfection-complementation with AK1P or AK1 vectors, respectively. 
Subclones with additional puromycin resistance were selected and Western blot and 
immunohistochemical analyses were used to confirm production of either AK1 or AK1P in 
the recombinant Kir6.2/SUR2A background (Fig. 6A and 6B). Isolated membranes from AK1 
and mock transfected A10 control cells were completely devoid o f AK activity (data not 
shown).
Electrophysiological measurements o f KATP channel activity, in excised membrane­
patches from neuroblastoma cells expressing Kir6.2/SUR2A, showed that channel inhibition 
by 50 ^M ATP was unaffected by AMP (Fig. 6C). However, following co-transfection with 
AK1P ATP-inhibited KATP channels were activated by 50 ^M AMP (Fig. 6D). On average, in 
the presence of ATP and AMP, KATP channel activity, measured as NP0, was 0.05 ± 0.001, in 
Kir6.2/SUR2A transfected cells (n=3), and 0.26 ± 0.06, in Kir6.2/SUR2A + AK1P transfected 
cells (n=3), i.e. an increase of ~30% (p<0.05; Fig. 6E). Thus, the dynamics of AK1P 
catalyzed phosphotransfer provides a mechanism for translation o f cellular energetic signals to 
membrane metabolic sensors.
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F igu re  5 . A K1p is a fu n c tio n a l adeny la te  k inase. A. N2a cells stably transfected with empty vector 
(a and d) or AK1 (b and e) and A K ip  cDNA expression vectors (c and f). Cells were immunostained 
for AK1 and analyzed by confocal laser scanning microscopy. Nuclei were identified by propidium 
iodide staining. The inset in picture c shows an A K ip  expressing N2a cell during mitosis. B and C . 
Adenylate kinase-catalyzed phosphotransfer activity in homogenate (B) and isolated membrane 
fraction (C) of AK1 and A K ip  expressing cells determ ined by enzyme-coupled spectrophotometric 
analysis (expressed as absorbance at 340 nm). Insets show W estern blot images stained for AK1- 
reactive protein in extracts used in the enzyme assay. D and E. Adenylate kinase-catalyzed 
phosphotransfer activity in homogenate (D) and isolated membrane fraction (E) of AK1 and AK1p 
expressing N2a cells in presence or absence of 50 |j M Ap5a, a specific inhibitor of adenylate kinase. 
Note the high sensitivity of AK1p to Ap5a (E).
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F igu re  6 . A K1p m ed ia tes A M P -induced  a c tiva tio n  o f KATP ch a n n e ls  in th e  p resence  o f ATP. A.
W estern blot image for AK1-reactive protein in homogenate and membrane protein extracts from N2a 
cells stably expressing K ir6.2/SUR2A (A10) and AK1, AK1p or empty vector. B. Confocal fluorescent 
image localizing AK1 in N2a cells stably transfected with Kir6.2/SUR2A and AK1p. Nuclei were stained 
with propidium iodide. C. KATP channel record from membrane patch of cells expressing Kir6.2/SUR2A 
before and after the addition of 50 j M  ATP, following application of 50 j M  AMP. D. AMP (50 j M )  
increased the inhibited KATP channel activity in the presence of ATP (50 j M )  in membrane patches of 
N2a cells expressing both Kir6.2/SUR2A and AK1p. E. Average KATP channel activity (mean ± S.E.) in 
COS-1 cells expressing recombinant KATP channels (Kir6.2/SUR2A; black) and recombinant KATP 
channels plus AK1p (striped), in the presence of 50 j M  ATP, following addition of 50 j M  AMP.
DISCUSSION
In the present study we have analyzed the tissue- and cell-type distribution and 
intracellular location of AK1 gene products, mRNAs and proteins, with special emphasis on 
mouse brain.
Based on previous reports (5, 23, 28) and our data shown here we propose that alternative 
promoter and alternative polyadenylation use are both involved in the production of mature 
AK1 mRNAs, in humans and mice. Alternative promoters represent a mechanism to generate 
protein isoform diversity and to tightly regulate differential expression (34-36). Our computer
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analysis of the genomic sequence of the AK1 gene predicted two regions with putative 
promoter activity (including functional TATA-motifs) preceding the transcription-initiation 
start sites for the AK1 and AK1P transcripts. For future studies it will be of major interest to 
see whether both promoters are functionally active in the same cell type(s), or differentially 
regulated. Based on our RT-PCR analysis of total RNA preparations from brain and muscle 
we can already conclude that AK1 and AK1P are co-expressed at the tissue level. Moreover, 
Nothern blot analysis indicated that expression of the ensemble of AK1/AK1P mRNAs is 
indeed confined to a rather limited number of tissues. This suggests a certain degree of 
overlap in the cell type specificity of the AK1 and AK1P promoters. Based on literature 
reports we know that myogenin, MyoD and NeuroD (important determinants in muscle and 
brain cell differentiation), may be involved in AK1 promoter activity regulation (22). The 
tumor supressor p53 is specifically involved in the regulation of AK1P production (23). It is 
therefore tempting to speculate that AK1-AK1P promoter switches might occur during tissue 
differentiation, or under the influence of genotoxic stress. Whether cis-activated exclusion, or 
rather functional interdependence, is involved in such regulation is a question which can not 
be answered until we are able to distinguish both transcripts and monitor their production 
dynamics at the single cell level (37).
Another factor in AK1/AK1P expression level regulation may be the positioning of the 
poly(A) tail. Ultimately, this determines the length and sequence content of the 3’ non-coding 
region, a region which plays an important role in regulating mRNA transport, stability and 
efficiency of translation (38-41). Here, we reported the existence of at least two different 
mRNAs (0.7 and 2.0 kb) with 3’ non-coding regions which differ by 1189 nucleotides in 
length. Interestingly, also the human AK1 gene produces two transcripts with similar different 
3’ termini (42), but from the chicken AK1 gene only one AK1 transcript has been reported 
(28). However, no correlation with function has been made with species differences.
For a full understanding of the AK system insight in both the quantitative and 
qualitative aspects of intracellular partitioning of isoforms is important. It has been proposed 
that cooperation of cytosolic and mitochondrial adenylate kinases might be essential to 
maintain a high-energy phosphoryl shuttle mechanism between the cytosolic ATP 
consumption and mitochondrial production sites, similar to what has been established for the 
creatine kinase/creatine phosphate (CK/CrP) system (6, 15, 43-45). However, here we 
demonstrate that co-expression of AK1 and the mitochondrial intermembrane-specific AK2 
isoform is restricted to heart only, and does not occur in brain and muscle. If the 
mitochondrial matrix enzyme AK3, which is more widely expressed (and is the only other 
known mitochondrial AK (14)), cannot substitute for this lack of AK2 then phosphoryl 
shuttling between mitochondria and cytosol is not a main role for the AK system in brain or 
skeletal muscle. Recently, two brain specific adenylate kinases, named AK4 and AK5, were 
reported (19, 20). While the AK4 mRNA is expressed in neuronal cells in several regions of 
the central nervous system, the cell-specific (cytosolic) expression of AK5 in the brain has not 
been determined. When we performed enzymatic staining for AK isoforms in the cerebrum
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and cerebellum of wildtype and AK1 deficient mice we only found high enzymatic activity 
staining for the AK1 isoform (E. J., personal observation). Therefore, we conclude that AK1, 
and possibly A K ip must be the major p-phosphoryl ATP-energy transfer enzymes (5) in the 
mouse brain. Earlier we demonstrated that AK1/AKip enzymes are responsible for 98-99% of 
total p-phosphoryl conversion activity in muscle.
A particular striking finding of this study was that AK1, and most likely also AKip, 
expression is almost exclusively confined to neurons and not, or only marginally, present in 
astrocytes. Other ~P transfer systems like the creatine kinases and the glycolytic transfer 
pathway enzymes occur most prominently in astrocytes, but are present in neurons as well. 
This was an unanticipated observation as both cell types have a high-energy demand, with 
energy needed for neurotransmitter shuttling, exocytosis, glutamate-glutamine cycling, 
electrogenic activity involved in the maintenance of membrane potential (neurons) and Na+, 
Ca2+ homeostasis, and dynamic vesicle transport.
Our transfection studies in COS and N2a neuroblastoma cells have provided evidence 
that AK1 p is almost entirely coupled to the plasma membrane and (in a fraction of cells) can 
also be found in the nuclear membrane. Existence of synaptic plasma membrane associated 
adenylate kinase activity has been reported earlier for rat and human brain (46, 47). Moreover, 
adenylate kinase was found closely associated with the heart sarcolemmal membrane (10), 
and in skeletal muscle A Kip is expressed next to AK1. It is therefore reasonable to assume 
that in neurons and myocytes there is co-occurrence and fairly complete partitioning of A Kip 
and AK1 into the plasma membrane and cytosolic compartments, respectively.
What could be the functional significance of this distribution? AK1 and A Kip may 
both serve in the channeled distribution of high-energy phosphoryl groups from cytosolic 
locales to spatially distinct compartments at or in the cell membrane. We show here by 
transfection complementation in N2a neuroblastoma cells that A Kip activity, in the presence 
of appropriate levels of ATP and AMP, is able to evoke opening of the KATP channel. This 
channel adjusts plasma membrane potential according to the metabolic state of the cell (i2, 
i3). In neurons, opening of KATP channels reduces the frequency of action potentials, thereby 
serving a protective function (48). The mechanism by which the KATP channel protects may 
represent a common pathway of ischemic preconditioning as has been established for the 
myocardium (49). This view is supported by KATP channel involvement in neuroprotection of 
hippocampal slices achieved by anoxic preconditioning in the brain (50). Moreover, in 
glucose responsive neurons KATP channels are believed to fulfill a role in glucose sensing and 
control of glucose homeostasis as in pancreatic p-cells (5i, 52). Proper regulation of the KATP 
channel, and other aspects of ATP homeostasis in which A K ip and AKi may play a role is 
therefore critically important in brain and must be adequate to enable neurons to sustain 
varying activity-dependent energy demands (53).
Sub-local ATP and ADP are the primary regulators of KATP channel behavior (48), yet 
until recently it was not understood how channels can operate in a cytoplasmic environment 
where the overall ATP concentration is maintained above the channel inhibition constant (54,
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55). In line with our previous demonstration of AKi-dependent KATP channel regulation (8), 
we here hypothesize that A K ip could physically approach the Kir6.2-SUR multimer by 
lateral drift in the plane of the membrane. Ultimately this may facilitate exchange of adenine 
nucleotides within the KATP channel microenvironment. This privileged access to local ADP 
from the AKi(p) catalyzed reactions, may couple channel gating to glycolytic and oxidative 
ATP (and ADP) production. In fact, we have shown that AK can physically associate with the 
cardiac KATP channel (8), while others have demonstrated that also AK3 (a mitochondrial AK 
isoform) and creatine kinase (CK) can engage in binding interactions with the channel 
complex ( i i ,  56). The stoichiometry of the proposed KATP-AKi(p)-CK protein complex, and 
its possible regulation through complementary actions of AKs and CKs as producers and 
scavengers of local ADP remains to be established. Future work should therefore be 
concentrated on the study of AKi and AKip  protein distribution dynamics across the 
cytosolic and membranous fractions of the neuronal cell body and in the axonal and dendritric 
projections.
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Summarizing discussion
SUMMARIZING DISCUSSION
Maintenance of energy (i.e. ATP) homeostasis is one of the most important tasks of a living 
cell. Tight control of this process allows cellular reactions to run at the lowest metabolic costs 
and is also a crucial factor in growth, motility and life-death decisions of cells during 
development and ageing. Phosphotransfer reactions, besides ATP production and utilization 
reactions, are therefore of pivotal importance. As is indicated throughout the different 
chapters in this thesis, the AK-catalyzed phosphotransfer is one of the main and “evolutionary 
oldest” reactions, coupling cellular sites of ATP-production with those for ATP-utilization. 
Several AK-isoforms exist and have specific subcellular localizations. The key enzyme of this 
study, AK1, is found highly expressed in tissues with a high-energy turnover, including 
skeletal muscle, heart and brain and has classically been considered as an enzyme important 
for the equilibration of intracellular adenine nucleotide concentrations under situations when 
cellular energy metabolism is compromised. At the time when my Ph.D. study started 
evidence was beginning to accumulate in support of an integrated intracellular high-energy 
phosphoryl transfer network comprised of AK, CK and glycolytic phosphotransfer enzymes. 
As direct evidence for the physiological role of intracellular AK1 catalysis was lacking we 
decided to generate knockout mice in order to define its biological and physiological 
significance at the metabolic and molecular level in the context of the entire animal. In the 
different chapters of this thesis we describe the generation of AK1 deficient mice and the 
phenotypic consequences of the gene knockout, providing information about the role and 
function of AK1 in maintenance of skeletal muscle and myocardial energetics and in the 
translation of cellular energetic signals to metabolic sensors in the cellular membrane.
As a prerequisite for targeted disruption of the AK1 locus in embryonic stem cells the 
AK1 gene was isolated from a genomic phage library, which was enabled by the use of an 
AK1-specific cDNA as probe. The genomic organization of the AK1 gene was analyzed and 
compared to that of AK1 genes in other organisms (chapter 2). A more detailed description of 
the coding capacity and gene products of the AK1 gene is given in chapter 6. Based on this 
knowledge a targeting vector suitable for targeted mutagenesis was constructed (chapter 2) 
and used to generate embryonic stem (ES) cells with one mutated allele. Three of the mutant 
clones selected were used for injection into recipient blastocysts to generate chimeric mutant 
animals. Male chimeras from one clone transmitted the introduced mutation to their offspring, 
and interbreeding of heterozygous AK1 mutant offspring ultimately gave homozygous AK1 
mutant mice, which appeared viable and fertile.
In the strategy chosen, targeted disruption of the exon 3-5 region in the gene was 
designed to delete the ATP binding site of the AK1 protein, rendering the predicted 
(remaining) mutant protein product catalytically fully inactive. In contrast to our expectation, 
however, we observed that the introduced gene mutation already resulted into undetectable 
levels of AK1 transcripts and, as a consequence, complete absence of AK1 protein and 
enzymatic activity in skeletal muscle, heart and brain was seen (chapter 2 and 3). When
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mutant skeletal muscles were subjected to fatiguing exercise protocols, mutant muscle did not 
develop abnormalities in contractile behavior; rather the energetic costs of muscle contraction 
appeared to be elevated in muscle lacking AK1, as demonstrated by means of 18O metabolic 
labeling (chapter 2). Moreover, AK1 deficient muscles were unable to maintain normal 
ATP/ADP/AMP ratios, underscoring the role of AK1 in adenine nucleotide metabolism. 
Finally, also the activity of AMP-deaminase in a related metabolic circuit was decreased in 
AK1 deficient gastrocnemius muscle. This result suggested that with absence of AK1 the need 
for AMP deamination is essentially limited. Strikingly, GTP and GDP levels were increased 
in mutant muscle, which may be attributed to increased activities of GTP/GDP producing 
enzymes in associated metabolic circuits (chapter 2). Alternatively, the energy provided by 
GTP for the re-amination of IMP to AMP could have been spared by a reduction in the 
accumulation of AK1-produced AMP. From the 18O-metabolic labeling studies described in 
chapter 2, it was concluded that presence of AK1 is important for maintaining a high energetic 
efficiency during muscle activity, enabling muscle cells to perform at the lowest metabolic 
costs.
In the heart of AK1 knockout mice the lack of AK1 produced a 94% reduction in total 
AK activity, but surprisingly only a 36% reduction in P-phosphoryl energetics was observed. 
Although AK1 was predicted to be the major catalyst in the transfer of P-phosphoryls among 
adenine nucleotides in the mouse heart, other remaining AK-isoforms are apparently capable 
of compensating the AK1 deficit (chapter 3). Loss of AK1 was also accompanied by a 1.5- 
fold increase in activity of the glycolytic enzyme phosphoglycerate kinase (PGK), apparently 
as an adaptation to facilitate ATP regeneration via glycolytic phosphotransfer systems. 
Comparison of the results of Chapters 2 and 3 clearly demonstrates that lack of AK1 produces 
aberrant energy metabolism in skeletal muscle (chapter 2), whereas lack of AK1 in the heart 
can obviously be compensated in the absence of metabolic stress (chapter 3). Yet, under 
conditions of metabolic insult, such as chemical hypoxia, the adaptive response in the 
myocardium is not able to meet the energetic deficit produced by AK1 absence (chapter 3). 
This result implies that the threshold of sensitivity, and thus the “relative” importance of AK1 
catalysis, is correlated with the type of metabolism occurring in specific cells of muscle, and 
thus with cell type. Apparently, muscle cells that are characterized by high ATP-turnover and 
glycolytic rates rely relatively more on the regenerative ATP capacity via the AK circuit, 
while this capacity is less important for muscles with a high oxidative metabolism (including 
the heart). This view is supported by the finding that also AK1 gene expression and AK1 
activity are highly correlated with the type of muscle metabolism; fast-twitch gastrocnemius 
muscle contain relatively higher levels of AK1 transcript and enzymatic activity than slow- 
twitch soleus muscle (chapter 4).
Our 18O-metabolic labeling data were indicative for remodeling of high-energy 
phosphoryl fluxes through glycolytic, guanylate and creatine kinase phosphotransfer 
pathways. Evidence for the fact that glycolytic activity in skeletal muscle was upregulated in 
response to AK1 deficiency came also from increased levels of intracellular glucose-6-
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phosphate and lactate (chapter 2). Moreover, ischemic AK1 deficient GPS muscle showed an 
increased level of glycolytic phosphomonoesters as was demonstrated by in vivo 31P-NMR 
measurements (chapter 2). To determine if, how, and to what extent, molecular events could 
underlie the phosphotransfer rewiring in AK1 knockout muscle gastrocnemius (fast-twitch) 
and soleus (slow-twitch) muscle were studied at the molecular level. cDNA-array analysis 
revealed that AK1 deficiency induces fiber-type specific transcript variation in groups of 
genes involved in glycolysis and mitochondrial metabolism and gene products related to 
structural and myogenic events and were found most pronounced in fast-twitch fibers (chapter 
4). Ultrastructural and enzymatic analysis revealed that fast-twitch fibers overcome the lack of 
AK1 by increasing their intermyofibrilar mitochondrial volume, accompanied by increased 
ADP:ATP activities of the glycolytic enzymes phosphoglycerate kinase (PGK) and pyruvate 
kinase (PK). In fact, upregulation of PGK-activity in AK1 deficient muscle is in line with 
upregulation of PGK-activity in the AK1 knockout heart and points to adaptive ATP 
generation via glycolytic phosphotransfer systems. The fact that AK1 deficiency re-programs 
many glycolytic gene transcripts for long-term compensation, but does so mainly in fast- 
twitch muscle, again suggest that inter-connection of the AK-catalyzed phosphotransfer and 
glycolytic metabolism is most tight in this type of muscle. How is this intertwining between 
pathways and the consecutive steps within pathways regulated? We have found evidence for 
regulation at the transcriptional as well as the translational level. Both concordance and 
discordance between changes in mRNA and protein levels were observed. For example, when 
comparing the change in transcript level with corresponding protein levels (chapter 4) we 
observed that an almost 2-fold increase in GAPDH mRNA was not translated into increased 
levels of GAPDH protein or activity. Conversely, increased levels of the mitochondrial 
marker proteins, ScCKmit and ANT, did not result from an increase in gene expression of the 
respective ScCKmit and ANT genes (chapter 4). Therefore, we have to assume that the 
adaptive response must include regulation at the rate of protein translation or turnover, 
whereby shifts in isoenzyme composition, phosphorylation status or protein complex 
formation ability should also be taken into account.
Because AK- and CK-catalyzed phosphotransfer reactions have been implicated as 
essential mediators in cellular energetics and metabolic signaling processes we next studied 
the metabolic consequences in skeletal muscle carrying a null mutation in both the AK1 and 
CK-M gene (chapter 5). Double knockout MAK=/= muscle displayed aberrant adenine 
nucleotide ratios in both the resting and working state. In the resting state, the MAK=/= double 
mutant is able to maintain total ATP turnover but, under conditions of increased workload, the 
total ATP turnover was severely compromised. This phenomenon very likely represents a 
reduced capacity of the MAK=/= muscle to deliver high-energy phosphoryls to ATP utilizing 
sites as was evidenced by the lack of CK- and AK-mediated high-energy delivery to the 
actomyosin ATPase (chapter 5). Increased fluxes through glycolytic and guanylate pathways 
tended to diminish the energetic deficit caused by the combined AK1 and M-CK deficiency. 
Thus, it was concluded that phosphotransfer reactions have a mandatory role in maintaining
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optimal cellular energetics and, that in particular, the AK and CK-catalyzed phosphotransfer 
have a role in this process.
To elucidate the biological function of AK1 also in non-muscle tissues (other than 
muscle and heart) we next aimed to shed light on the physiological role of AK1 gene products 
in the mouse brain. AK1 transcripts of 0.7 and 2.0 kb were identified by Northern analysis, 
which are the result of alternative polyadenylation. Evidence for this latter process was 
provided by computer database analysis. In silico gene analysis was used to identify an 
alternative transcription initiation site in the mouse AK1 gene, which is believed to transcribe 
the p53-inducible membrane-bound AK1p. Both the AK1 and AK1P transcripts appeared in 
brain. Immuno-histochemical and immuno-fluorescence analysis demonstrated expression of 
AK1 in neurons in brain, as well as in primary cell culture. Expression of AK1 in primary 
cultured astrocytes was only marginal. Our findings suggest that during evolution AK 
catalysis has got embroiled in neuronal associated functions, probably mainly to support the 
complex energy requirements of neurons. We also showed, by demonstrating in vitro AK1P- 
mediated phosphorylation of ADP and by patch clamp analysis, that AK1P is a functional 
adenylate kinase and has the capacity to activate ATP inhibited KATP channels in the presence 
of AMP (chapter 6). Based on these findings it was concluded that AK1 and AK1P might 
serve in communicating energetic or metabolic signals from cytosolic locales to spatially 
distinct compartments at or in the cell membrane.
When taken combined all our results suggest that altered expression of metabolic 
genes, along with the capacity to rewire alternate phosphotransfer pathways, forms part of the 
normal physiological repertoire for biochemical adaptation. High plasticity in this repertoire 
enables the muscle to maintain its cellular and energetic integrity even under extremely 
variable situations, brought in via extrinsic or intrinsic conditions. An intriguing question that 
is directly connected to this observation is how cells that are energetically challenged by AK1 
ablation are able to sense the induced energetic deficit and transmit the signals for activation 
of compensatory mechanisms that counteract this energetic deficit. Since MYF 5 and MyoD 
have both been implicated in the regulation of fiber-type determination, including 
maintenance of fast-twitch characteristics of skeletal muscle, the increase in transcript level of 
MYF 5 (and MyoD), as demonstrated in chapter 4, might represent one of these signals. In 
fact, an increase in MYF5 mRNA levels is known to be dependent on the activity of 
calcineurin and NFAT and, therefore, involvement of the calcineurin-NFAT signaling 
pathway is very well possible. Normally, we would expect the AMP molecule itself to form a 
direct signal that, through AMPK-mediated pathways, could induce ultrastructural and 
biochemical adaptations. As a result of AK1 absence, however, the intracellular AMP 
concentration and subsequent ATP/AMP ratio do not extremely fluctuate in our AK1 deficient 
mice. Thus, AMPK-directed activation of compensatory mechanisms is not likely to be the 
key signal in the adaptive response in our AK1 deficient animals. Alternatively, also the role 
of the AK1 protein as a building block of the sarcomere may be considered. Since assembly 
and integrity of the sarcomere is controlled by the elastic filament system (composed of the
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protein titin) lack of the AK1 protein from this distinct region of the sarcomere (i.e. I-band), 
multi-enzyme complex or cluster, may transmit a signal for activation of compensatory 
mechanisms. This possibility is put forward since subcellular targeting of AK, CK, and 
phosphofructokinase to titin is believed mediated by the LIM domain protein, DRAL/FHL-2, 
which in general are proteins that play an important role in linking myofibrils to the 
surrounding cytoskeleton. Unfortunately, not much is known about such a signaling role for 
metabolic-structural enzymes. Therefore, tackling the signals that could be responsible for the 
metabolic remodelling response in our AK1 mice remains one of the main challenges for 
future research. Transcriptomic and proteomic approaches may help in this endeavour.
In conclusion, the studies described in this thesis address the metabolic importance of 
AK1 in safeguarding cellular energy homeostasis. By making the energy available stored in 
the pool of P-phosphoryls the AK1-mediated metabolic circuit allows cellular energy 
metabolism to occur in a highly efficient mode. By regulating subcellular pools of ATP and 
ADP in the ATPase microenvironment or at ATP/ADP sensing-sites the AK1-catalyzed 
phosphotransfer conducts metabolic signals, which ultimately may lead to new cellular 
responses. Whether the existence of strategically located AK1 isoforms may enhance and 
fine-tune this mediation of energetic signals is still an open question.
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Hoofdstuk 7
SAMENVATTING EN DISCUSSIE
Een van de belangrijkste taken van een levende cel is het bewaken van zijn 
energiehuishouding (ATP-homeostase). Strakke controle van dit (biologisch) proces betekent 
dat cellulaire reacties kunnen verlopen tegen de kleinst mogelijke “metabole kosten” en is 
eveneens een cruciale factor in groei, beweging en leven/dood beslissingen gedurende 
ontwikkeling. Fosfotransfer reacties zijn, naast ATP producerende en consumerende reacties, 
daarom van essentieel belang. Zoals aangegeven in de verschillende hoofdstukken van dit 
proefschrift is de AK gekatalyseerde fosfotransfer een van de “evolutionair” oudste reacties, 
welke cellulaire plaatsen van ATP-productie en ATP-consumptie met elkaar verbinden. Er 
bestaan verschillende isovormen van AK, elk voorkomend op specifieke plaatsen in de cel. 
Het onderwerp van deze studie, AK1, wordt sterk tot expressie gebracht in weefsels met een 
hoog energieverbruik, inclusief skeletspier, hart, en brein, en wordt van oudsher beschouwd 
als een enzym dat belangrijk is voor het instellen van een evenwicht tussen adenine nuclotide 
concentraties in de cel. Voor aanvang van deze studie waren er aanwijzingen voor een 
integraal netwerk, bestaande uit AK, CK en glycolytische fosfotransfer reacties. Echter, direct 
bewijs voor de fysiologische rol van AK1-katalyse in de cel ontbrak. Daarom besloten we een 
“knockout” muizenmodel te creëren, teneinde de biologische en fysiologische functie van 
AK1 te definiëren op metabool en moleculair niveau in de context van het gehele dier. In de 
hoofdstukken van dit proefschrift beschrijven we de ontwikkeling van AK1 deficiënte muizen 
en de fenotypische consequenties van de AK1 deletie, welke informatie verschaffen over de 
rol van AK1 in het bewaken van de energiehuishouding in skeletspier en hart én in de 
vertaling van energetische signalen naar metabole sensors in het celmembraan.
Om het AK1 gen te kunnen muteren in embryonale stam cellen was het van belang om 
het AK1 gen te isoleren uit een genomische faagbank. Dit werd bewerkstelligd door gebruik 
te maken van AK1 cDNA als AK1 specifieke probe. De genomische structuur van het AK1 
gen werd geanalyseerd en vergeleken met dat van AK1 genen in andere organismen 
(hoofdstuk 2). Een meer uitvoerige beschrijving van het AK1 gen en AK1 gen producten 
wordt gegeven in hoofdstuk 6. Op basis van de verkregen kennis werd een “targeting vector” 
gemaakt, geschikt voor homologe recombinatie experimenten in embryonale stam (ES) cellen, 
en vervolgens gebruikt om ES cellen te genereren met een gemuteerd allel. Drie van de 
gemuteerde ES cellijnen werden geselecteerd en gebruikt voor injectie in blastocysten en 
generatie van chimere muizen. Chimere mannetjes muizen afkomstig van één kloon gaven de 
mutatie door aan hun nageslacht. Deze heterozygote AK1 mutanten werden onderling 
gekruist, wat resulteerde in levensvatbare en vruchtbare homozygote AK1 deficiënte 
nakomelingen.
De strategie voor de gerichte manipulatie van het AK1 gen werd zodanig gekozen dat 
de exon 3-5 regio van het gen werd vervangen. Naar verwachting zou dit resulteren in een 
katalytisch inactief eiwit. Echter, in tegenstelling tot onze verwachting resulteerde de 
geïntroduceerde mutatie reeds in niet detecteerbare AK1 transcripten en als gevolg hiervan,
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afwezigheid van AK1 eiwit en enzymatische activiteit in skeletspier, hart en brein (hoofdstuk 
2 en 3). Gemuteerde spieren vertoonden geen abnormaliteiten in contractiele parameters, 
wanneer deze getest werden in uitputtingsexperimenten. Echter, de energetische kosten van 
spiercontractie bleken toegenomen in spieren zonder AK1, zoals werd aangetoond met behulp 
van 18O metabole labeling. Bovendien bleken AK1 deficiënte spieren niet goed in staat om 
normale ATP/ADP/AMP ratios te handhaven, wat de rol van AK1 in adenine nucleotide 
metabolisme benadrukt. Ook de activiteit van AMP deaminase in een gerelateerd metabool 
circuit was afgenomen in AK1 deficiënte gastrocnemius spieren. Dit resultaat suggereert dat 
door afwezigheid van AK1 de behoefte tot AMP deaminering is gelimiteerd. Opmerkelijk was 
dat GTP en GDP niveaus bleken te zijn toegenomen in gemuteerde spieren, wat 
toegeschreven kan worden aan een toegenomen activiteit van GTP/GDP producerende 
enzymen in verwante metabole circuits (hoofdstuk 2). Een andere mogelijkheid is dat de 
energie afkomstig van GTP voor de re-aminering van IMP naar AMP wordt gespaard 
vanwege een reductie in de accumulatie van AK1 geproduceerd AMP. Tenslotte werd uit data 
verkregen met 18O metabole labeling geconcludeerd dat aanwezigheid van AK1 belangrijk is 
voor het handhaven van een hoog energetische efficiëntie tijdens spierarbeid, zodat spieren 
kunnen functioneren met zo min mogelijk metabole kosten (hoofdstuk 2).
Afwezigheid van AK1 in het muizenhart veroorzaakte een reductie van 94% in totale 
AK activiteit, terwijl verrassend genoeg slechts een reductie van 36% in P-fosforyl energie 
metabolisme werd waargenomen. Hoewel AK1 wordt gezien als de belangrijkste katalysator 
in de transfer van P-fosforyls tussen adenine nucleotiden in het muizenhart, zijn andere AK 
isovormen klaarblijkelijk in staat om het AK1 tekort te compenseren (hoofdstuk 3). 
Afwezigheid van AK1 werd ook geassocieerd met een 1.5-voudige toename in activiteit van 
het glycolytisch enzym phosphoglycerate kinase (PGK) en dit is klaarblijkelijk een aanpassing 
om ATP regeneratie te bewerkstelligen via glycolytische fosfotransfer systemen. Vergelijking 
van de resultaten beschreven in hoofdstuk 2 en 3 maakt duidelijk dat afwezigheid van AK1 in 
skeletspier resulteert in afwijkend energie metabolisme (hoofdstuk 2), terwijl deficiëntie van 
AK1 in hart kan worden gecompenseerd in afwezigheid van metabole stress (hoofdstuk 3). 
Echter, onder metabole stress condities, zoals chemische hypoxia, is het adaptief vermogen 
van het hart ontoereikend om het energetisch tekort, geproduceerd door de afwezigheid van 
AK1, te compenseren (hoofdstuk 3). Dit resultaat suggereert dat de gevoeligheidsdrempel en 
hiermee het “relatieve” belang van AK1-katalyse, correleert met het type metabolisme dat 
plaatsvindt in de specifieke cel van de spier, en dus met het type cellen. Klaarblijkelijk zijn 
spiercellen die gekarakteriseerd worden door een hoge ATP-omzetting en glycolytische flux 
meer afhankelijk van het regeneratief ATP vermogen via het AK1 circuit dan spieren met een 
hoog oxidatief metabolisme (inclusief hart). Deze stelling wordt onderbouwd door de 
bevinding dat ook AK1 genexpressie en AK1 activiteit sterk afhankelijk zijn van het type 
spiermetabolisme: de snelle gastrocnemius spier bevat relatief meer AK1 transcripten en 
enzym activiteit dan de langzamere soleus spier (hoofdstuk 4).
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Data verkregen met behulp van 18O metabole labeling leverden het bewijs voor 
remodellering van een hoog energetische fosfaat flux door glycolytische, guanylaat en 
creatine kinase fosfotransfer reacties. Bewijs voor het feit dat glycolytische activiteit was 
opgereguleerd als gevolg van AK1 deficiëntie werd ook geleverd door de verhoging van 
intracellulaire glucose-6-fosfaat en lactaat concentraties (hoofdstuk 2). Bovendien vertoonden 
ischemische AK1 deficiënte GPS spieren een verhoogd niveau aan glycolytische 
fosfomonoesters, gemeten met behulp van in vivo 31P-NMR (hoofdstuk 2). Teneinde de 
moleculaire gebeurtenissen te bepalen, die verantwoordelijk zouden kunnen zijn voor de 
fosfotransfer remodellering in AK1 deficiënte spieren, werden de gastrocnemius (snelle 
contractie) en soleus (langzame contractie) spier bestudeerd op moleculair niveau. Via cDNA- 
array analyse werd aangetoond dat afwezigheid van AK1 resulteert in vezeltype specifieke 
variatie in groepen van genen die betrokken zijn bij glycolytisch en mitochondrieel 
metabolisme en structurele en myogene processen. Deze variatie in specifieke transcripten 
werd voornamelijk gevonden in snelle spiervezels (hoofdstuk 4). Via ultrastructurele en 
enzymatische analyse werd aangetoond dat snelle spiervezels AK1 deficiëntie compenseren 
door hun mitochondriële volume te verhogen in combinatie met een toename in de ADP:ATP 
activiteit van de glycolytische enzymen fosfoglyceraat kinase (PGK) en pyruvaat kinase (PK). 
Feitelijk is de verhoging van PGK-activiteit in de AK1 deficiënte spier overeenkomstig met 
de verhoging van PGK-activiteit in het AK1 deficiënte hart en vormt een aanwijzing voor 
adaptieve ATP regeneratie via glycolytische fosfotransfer systemen. Het feit dat AK1 
deficiëntie de herprogrammering van verschillende glycolytische gentranscripten induceert, 
maar met name in snelle spieren, suggereert opnieuw dat de AK gekatalyseerde fosfotransfer 
gekoppeld is aan glycolytisch metabolism in dit type spieren. Hoe is de koppeling tussen deze 
systemen en de achtereenvolgende stappen in deze cascade(s) gereguleerd? We hebben bewijs 
gevonden van regulatie op zowel transcriptioneel als translationeel niveau met zowel 
overeenkomstige als afwijkende verschillen tussen mRNA en eiwit. Wanneer de verandering 
in transcript niveau met het corresponderende eiwit niveau werd vergeleken (hoofdstuk 4) dan 
bleek bijvoorbeeld de bijna 2-voudige toename in GAPDH mRNA niet te worden vertaald in 
een toegenomen hoeveelheid GAPDH eiwit of activiteit. Aan de andere kant bleek de 
toegenomen hoeveelheid aan mitochondriële markereiwitten, ScCKmit en ANT, niet het 
resultaat van een toename in genexpressie van de respectievelijke ScCKmit en ANT genen 
(hoofdstuk 4). Daarom nemen we aan dat de aanpassing plaatsvindt op het niveau van 
regulatie van eiwit aanmaak of afbraak, waarbij we ook rekening moeten houden met 
veranderingen in isovorm samenstelling, fosforyleringsstatus of eiwit-complex formatie.
Omdat AK en CK gekatalyseerde fosfotransfer reacties worden beschouwd als 
essentiële factoren in cellulaire energie metabolisme en metabole signalering werden 
vervolgens de metabole consequenties bestudeerd in skeletspier, waarin zowel het AK1 gen 
als het M-CK gen waren gemuteerd (hoofdstuk 5). Dubbel gemuteerde MAK== spieren 
vertoonden afwijkende adenine nucleotide ratios tijdens spierarbeid, maar ook in staat van 
rust. Hoewel de MAK== dubbel mutante spier in staat was zijn totale ATP-omzetting te
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handhaven in staat van rust, bleek dit bij een toename in spierarbeid niet meer mogelijk. Dit 
fenomeen weerspiegelt waarschijnlijk een gereduceerde capaciteit van de MAK=/= spier om 
hoog energetische fosfaten af te leveren op plaatsen van energiebehoefte, zoals ook werd 
aangetoond voor de afwezigheid van de hoog energetisch fosfaat afgifte aan actomyosine 
ATPase, indien AK1 en M-CK afwezig zijn (hoofdstuk 5). Een toename in flux door 
glycolytische en guanylaat metabole circuits verminderde het energetisch tekort als gevolg 
van de gecombineerde AK1 en M-CK deficiëntie. Aldus werd geconcludeerd dat fosfotransfer 
reacties een belangrijke rol hebben in het handhaven van optimale cellulaire energie 
metabolisme en dat de AK en CK gekatalyseerde fosfotransfer een speciale rol spelen in dit 
proces.
Om de biologische functie van AK1 in ander weefsel dan spier en hart op te helderen 
trachtten we vervolgens de fysiologische rol van AK1 genproducten te belichten in het brein 
van de muis. AK1 transcripten van 0.7 en 2.0 kb werden geïdentificeerd, welke het gevolg 
zijn van alternatieve polyadenylering. Bewijs voor dit laatste werd geleverd aan de hand van 
computer database-analyses. In silico gen-analyse werd gebruikt om een alternatief 
transcriptie-initiatiesignaal te identificeren in het AK1 muizengen, welke waarschijnlijk 
gebruikt wordt voor transcriptie van p53-induceerbaar membraan gebonden AK1p. Zowel 
AK1 als AK1P transcripten bleken voor te komen in muizenbrein. Met immuno- 
histochemische en immunofluorescente technieken werd de expressie van AK1 in neuronen in 
brein aangetoond, alsmede in primaire celkweken hiervan. Expressie van AK1 in gekweekte 
primaire astrocyten bleek echter marginaal klein te zijn. Deze bevinding suggereert dat, 
gedurende de evolutie, AK1-katalyse nauw verbonden is geraakt met neuronaal geassocieerde 
functies, waarschijnlijk om de complexe energievraag van neuronen te ondersteunen. 
Vervolgens werd met AK1P gekatalyseerde in vitro fosforylering van ADP en 
elektrofysiologische technieken aangetoond dat AK1P een functioneel adenylate kinase is en 
de capaciteit heeft om KATP-kanalen, die geblokkeerd zijn met ATP, in aanwezigheid van 
AMP te activeren (hoofdstuk 6). Op basis van deze bevindingen werd geconcludeerd dat AK1 
en AKP een functionele rol kunnen hebben in de communicatie van energetische of metabole 
signalen van cytosolische compartimenten naar andere compartimenten bij of in het 
celmembraan.
De combinatie van alle resultaten tezamen wekt de suggestie dat aangepaste expressie 
van metabole genen, gecombineerd met de capaciteit om fosfotransfer reacties te 
reorganiseren, een aanpassing is welke behoort tot het normale fysiologische repertoire voor 
biochemische adaptatie. Een hoge plasticiteit in dit repertoire maakt het de spier mogelijk om 
zijn cellulaire en energetische integriteit te bewaren, zelfs onder extreem variabele situaties 
veroorzaakt door extrinsieke of intrinsieke condities. Een intrigerende vraag die direct 
gekoppeld is aan deze observatie is hoe cellen de gevolgen van AK1 deficiëntie kunnen 
voelen en de signalen voor activering van compensatoire mechanismen kunnen doorgeven, 
zodat het geïntroduceerde energetisch defect kan worden gecompenseerd. Omdat MYF5 en 
MyoD beide worden verondersteld betrokken te zijn in de regulatie van het type spiervezel,
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inclusief het handhaven van snelle spierkarakteristieken, zou de toename in de hoeveelheid 
MYF5 (en MyoD) transcript een mogelijk regelsignaal kunnen zijn (hoofdstuk 4). Feitelijk 
blijkt een toename in MYF5 mRNA niveaus afhankelijk te zijn van de activiteit van 
calcineurin en NFAT. Daarom is betrokkenheid van de calcineurin-NFAT signalerings 
cascade zeer wel mogelijk. Normaal gesproken zou worden verwacht dat ook het AMP 
molecuul zelf een signaalfunctie bezit die, via AMPK gereguleerde reactie cascades, 
ultrastructurele en biochemische adaptaties zou kunnen induceren. Echter, de intracellulaire 
AMP concentratie en ATP/AMP ratio fluctueren niet extreem in onze AK1 deficiënte muizen, 
als gevolg van afwezigheid van AK1. AMPK gereguleerde activering van compensatoire 
mechanismen is daarom niet erg waarschijnlijk in de adaptieve reactie in AK1 deficiënte 
muizen. Als alternatief zou ook de rol van AK1 als bouwsteen van het sarcomeer hierbij in 
overweging moeten worden genomen. Omdat assemblage en integriteit van het sarcomeer 
worden gecontroleerd door het elastische filament systeem, gevormd door het eiwit titin, zou 
afwezigheid van AK1 in een bepaalde regio van het sarcomeer (d.w.z. de I-band), multi­
enzym complex of cluster, een signaal kunnen zijn voor activering van compensatoire 
mechanismen. Deze mogelijkheid wordt geopperd, omdat het “loodsen” van AK, CK, en 
fosfofructokinase naar specifieke plaatsen in de cel wordt verondersteld te gebeuren door het 
LIM domein eiwit, DRAL/FHL-2. LIM domein eiwitten zijn eiwitten die een belangrijke rol 
vervullen in de koppeling van myofibrillen aan het omringende cytoskelet. Helaas is er tot op 
heden weinig bekend over een dergelijke rol voor metabool-structurele eiwitten in signalering. 
Daarom is het ophelderen van de signalen, die verantwoordelijk zouden kunnen zijn voor de 
metabole herstructurering in AK1 deficiënte muizen, een van de belangrijkste uitdagingen 
voor toekomstig onderzoek. Transcriptome en proteome analyses zouden hierbij van nut 
kunnen zijn.
Aan de hand van de studies beschreven in dit proefschrift concludeer ik dat AK1 van 
metabool belang is voor het handhaven van cellulaire energiehomeostase. Door het 
beschikbaar maken van energie die is opgeslagen in de vorm van p-fosforylgroepen is het 
AK1 gereguleerde metabole circuit verantwoordelijk voor een zeer efficiënte manier van 
cellulaire energiehomeostase. Door het reguleren van ATP en ADP microcompartimenten in 
de naaste omgeving van een ATPase of ATP/ADP gevoelige locatie in de cel is de AK1 
gekatalyseerde fosfotransfer in staat om een metabool signaal door te geven. Dit kan 
uiteindelijk leiden tot nieuwe cellulaire acties. Of het bestaan van AK1 isovormen op 
strategische plaatsen in de cel deze beoogde functie in de regulering van metabole signalen 
zou kunnen versterken of verbeteren is tot op heden een open vraag.
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ABBREVIATIONS
A.U. arbitrary units
ADP adenosine 5'diphosphate
AK adenylate kinase
AMP adenosine 5'monophosphate
AMPD AMP deaminase
AMPK AMP-activated protein kinase
AMPKK AMP-activated protein kinase kinase
ANT adenine nucleotide translocator
ATP adenosine 5'triphosphate
B-CK cytosolic brain creatine kinase
bHLH basic helix-loop-helix
BSA bovine serum albumine
CaMK calcium-calmodulin-dependent protein kinase
CK creatine kinase
COX cytochrome c oxidase
cpm counts per minute
Cr creatine
CrP creatine phosphate
DMEM Dulbecco's modified Eagle's medium
DMSO dimethylsulfoxide
DTT dithiothreitol
EDTA ethylenediaminetetraacetate
ES embryonic stem
EST expressed sequence tag
ETC electron transport chain
f a d h 2 flavin adenine dinucleotide hydrogen
FCS fetal calf serum
FIAU 1-(2 deoxy, fluoro-p-D-arabinofuranosyl)-5 iodouracil
Fitch fluorescence isothiocyanate
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GDH glutamate dehydrogenase
GLUT glucose transporter
Glut. Synt glutamine synthetase
GPDH glycerol phosphate dehydrogenase
GPS gastrocnemius-plantaris-soleus complex
HSV-tk herpes simplex virus thymidine kinase
Hygro(B) hygromycine B phosphotransferase
IMP inositol monophosphate
Katp channel ATP sensitive potassium channel
Kir inwardly rectifying potassium channel subunit
LDH lactate dehydrogenase
MAK=/= M-CK'a plus AK1 'a double knockout mouse
M-CK cytosolic muscle creatine kinase
M-CK-/" M-CK knockout mouse
MEF myocyte enhancing factor
MHC myosin heavy chain
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MLC-1s/v essential myosin light chain 1 slow/ventricular
MLC2 myosin light chain
MLC-2s MLC-2 slow
MRS magnetic resonance spectroscopy
N2a neuroblastoma 2a
NAD+ nicotinamide adenine dinucleotide
NADH nicotinamide adenine dinucleotide hydrogen
NDPK nucleoside diphosphate kinase/nm23
Neo neomycin phosphotransferase
NFAT nuclear factor of activated T cells
NMR nuclear magnetic resonance
NTP/NDP/NMP nucleoside tri/di/mono-phoshate
OXPHOS oxidative phosphorylation
~P high-energy phosphoryl
PBS phosphate buffered saline
PFK phosphofructokinase
PGC-1 a peroxisome-proliferator-activated receptor-y coactivator-1
PGK phosphoglycerate kinase
Pi inorganic phosphate
PIC protease inhibitor cocktail
PiC inorganic phosphate carrier
PK pyruvate kinase
PK-M muscle type pyruvate kinase
PME phosphomonoesters
RLU relative light units
ScCKmit sarcomeric mitochondrial creatine kinase
ScCKmit'/_ ScCKmit knockout mouse
SDS sodium dodecyl sulphate
SEM standard error of the mean
SERCA2 SR/ER Ca2+ ATPase
SUR2A sulfonyl urea receptor
TCA cycle tricarboxic acid cycle (citric acid cycle)
Tfam mitochondrial transcription factor A (mtTFA)
Tris tris(hydroxy-methyl)aminomethane
UbCKmit ubiquitous mitochondrial creatine kinase
UbCKmit'/_ UbCKmit knockout mouse
VDAC voltage dependent anion channel (porin)
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En dan gaan je gedachten terug naar hoe en wanneer het werken als promovendus 
allemaal is begonnen. Na een onrustige periode als analist bij de afdeling Celbiologie (wil ik 
die cursus?; welk project start ik nu?) kwam voor mij de ‘verlossing’: het aanbod om een 
proefschrift te schrijven over de rol en functie van Adenylate kinase 1 aan de hand van het 
AK1 knockout muizenmodel. Dit was voor mij een nieuwe uitdaging, waaraan ik met 
hartelust en grote vrijheid heb kunnen werken. Mijn dank gaat daarom allereerst uit naar mijn 
promotor Prof. Dr. Bé Wieringa. Beste Bé, ik weet niet of je mijn onrust toentertijd hebt 
aangevoeld, maar ik wil je bedanken voor de gegeven kans en het vertrouwen. Onder jouw 
vleugels heb ik de opleiding als zeer plezierig en leerzaam ervaren.
Onontbeerlijk waren natuurlijk de collega’s van het eerste en tweede uur die, samen 
met de nodige studenten, zorgdroegen voor een prima werksfeer. Daarom wil ik alle mensen 
van de afdeling Celbiologie en de (ex-)leden van de ‘CK-groep’ in het bijzonder bedanken 
voor hun hulp en plezierige samenwerking, op welke wijze dan ook. Zonder iemand te kort te 
doen wil ik Carolina Jost, Ad de Groof en Jan Kuiper apart noemen en bedanken voor hun 
gezelligheid, de bereidheid om te helpen indien dit nodig was, maar bovenal voor de ‘wilde’ 
discussies die we gevoerd hebben. Het spuien van nieuwe ideeën werd hierdoor meestal een 
stuk makkelijker! Ad en Jan, het doet mij plezier dat jullie mij willen bij staan als paranimf. 
Frank Oerlemans, dank voor het in stand houden van de diverse (AK1 gerelateerde) 
muizenlijnen. De spierisolaties waren altijd reden tot openhartige, soms diepzinnige 
gesprekken. Ik zal ze missen!
Hoewel het AK-onderzoek zich in beginsel op een eiland bevond heeft de overzeese 
samenwerking letterlijk een brug geslagen tussen de specialismen moleculaire biologie en 
fysiologie. Mijn werkbezoeken aan de Mayo Clinic zijn daarom van onschatbare waarde 
geweest in de totstandkoming van dit proefschrift. In this regard, I would like to thank all the 
people from the Cardiovascular Research Laboratory (Mayo Clinic, USA) for their help and 
contribution related to the work described in this thesis. I would like to thank a few people in 
particular: Prof. Dr. Andre Terzic; Dear Andre, the way you bring people together and make 
them feel comfortable is special. Combined with your scientific input and your approach to 
present results you have been one of my scientific mainstays. Indeed, Mayo feels as a second 
home! Many thanks. Dr. Petras Dzeja; Dear Petras, you have been my main teacher in 
learning how to speak the difficult language of the land of energetics. Thank you very much, 
not only for your help, advice, and the many discussions we had, but also for the warmth and 
hospitality of you and your family. Dr. Martin Bienengraeber; Dear Martin, your presence in 
the lab completed the fantastic time at Mayo. It was a real pleasure to work next to you.
En dan was daar die andere baan. Commercial Break, zeven jaar lang als een kindje 
van me. Wat begon als een muzikaal avontuur mondde uit in een goedlopende onderneming. 
Toch hebben we in het laatste jaar van mijn carrière als muzikant ook moeilijke tijden gekend. 
Wat is muziek toch hartstochtelijk mooi als je juist dan de juiste toon weet te zetten! Patrick,
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Remco, Martin, Priscilla en Belinda: dank voor jullie flexibiliteit en aanpassingsvermogen als 
het ‘andere werk’ weer eens voorging en voor de fijne tijd die we samen gehad hebben. Er 
wordt wel gezegd: ”keuzes maken in het leven is soms moeilijk”. Geloof me dat dit er één van 
was. Commercials(!), het ga jullie goed.
Han, Emile, Arjan en Marie-Jose. In jullie heb ik een nieuwe muzikale sparringpartner 
gevonden. Jullie welgemeende interesses naar de voortgang van mijn onderzoek en de 
luchtige gesprekken(!) die we hieromtrent gehad hebben waardeer ik enorm.
En dan zijn er de mensen in mijn directe omgeving die ik graag wil bedanken. Mijn 
familie en vrienden die, hoewel ik de laatste jaren soms weinig tijd voor ze had, altijd begrip 
en interesse hebben getoond. Nu ook deze klus geklaard is zal ik de frequentie opvoeren; 
jullie zullen nog spijt krijgen!
Pap en mam, dit is nu waar het allemaal om te doen is geweest. Hoewel ik weet dat 
jullie sommige dingen ‘vanzelfsprekend’ vinden, wil ik jullie enorm bedanken voor de altijd 
onvoorwaardelijke steun die ik (lees we) van jullie heb gekregen, als het figuurlijke hooi weer 
eens van de vork viel.
Christel, mijn rots in de branding. Je hebt altijd gezegd: ”Je hoeft mij niet te bedanken 
in je dankwoord”. Inderdaad, iemand die achter de schermen regisseert en de zaken draaiende 
houdt verdient veel meer. Mijn respect voor jouw manier van aanpak is onbegrensd. Met Sam 
en Noor gaan we samen een fantastische tijd tegemoet!
Nijmegen, juni 2003
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Edwin Janssen werd geboren op 25 januari 1971 te Nijmegen. Na het behalen van het 
eindexamen MAVO in 1987 te Druten vervolgde hij zijn studie aan de Middelbare 
Laboratorium Opleiding te Oss. In 1991 werd het diploma MLO Biochemie behaald, waarna 
hij aansluitend aan de Hogeschool Gelderland te Nijmegen de Hogere Laboratorium 
Opleiding met differentiatie Biochemie volgde en hier in 1995 afstudeerde. Tijdens deze 
opleidingen werd stage gelopen op de afdelingen Moleculaire Biologie (KUN) onder leiding 
van Dr. G. Zaman en Prof. Dr. Konings en Celbiologie (KUN) onder leiding van Dr. P. 
Groenen en Prof. Dr. B. Wieringa. Vanaf juli 1995 tot 1998 was hij als analist werkzaam op 
laatstgenoemde afdeling, alwaar hij per juli 1998 werd aangesteld als promovendus. Onder 
begeleiding van Prof. Dr. B. Wieringa verrichtte hij het onderzoek dat is beschreven in dit 
proefschrift.
Tijdens de promotietijd werd driemaal een werkbezoek gebracht aan de 
Cardiovascular Research Laboratory (May o Clinic, USA) onder leiding van Prof. Dr. A. 
Terzic en werd tweemaal deelgenomen aan het European Muscle Conference of the European 
Society for Muscle Research (2001 en 2002), waar hij de resultaten van zijn 
promotieonderzoek presenteerde.
Sinds Oktober 2002 is hij als postdoc werkzaam binnen de groep van Prof. Dr. B. 
Wieringa, afdeling Celbiologie, NCMLS, Universiteit van Nijmegen, waar hij onderzoek 
verricht naar de rol van fosfotransfer enzymen tijdens celmigratie en metastasis.
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